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Introduction
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The path towards an established medical anticancer treatment is a long and winding road. 
After thorough pre-clinical studies, novel drugs or combinations of drugs enter clinical 
development usually in a so-called phase I dose-finding study. These studies primarily aim 
to determine the dose that can safely be administered and is recommended for further 
studies. Subsequently, in phase II studies patients with a specific tumor entity are enrolled 
to screen whether in that specific population the drug or combination of interest exerts anti-
tumor activity considered worthwhile enough for further studies and to gather additional 
information on the tolerability. Lastly, the decision whether or not the novel regimen should 
be implemented in clinical practice is generated from a phase III trial in which the novel 
regimen is compared to standard care in the population of interest. 
 Early cancer drug development refers to phase I studies and to a lesser extent to phase 
II studies. Although the development of a specific agent towards the phase III trial seems 
pretty straight forward, there are many important factors relevant to the dose and dosing 
strategy of the anticancer drug entering phase III. These include initial choices regarding 
dose-escalation steps as well as the determination of the maximally tolerated dose (MTD; 
the maximum dose that can be tolerated by patients) versus the biological optimal dose, 
the dose at which drug-mediated effects important for anti-tumor activity are exerted.
Combining agents
The number of issues that need to be addressed in combining drugs is multiplied if 
compared to single agents. Most important challenges in studying combinations in early 
cancer-drug development, include the following:
1. Choice of the drugs
2. Determining the dose-limiting toxicity (DLT) observation time window
3. Dose escalation steps
4. Sequence versus combination
Choice of the drugs
Which drugs to pair is a critical first step. In the last decade the majority of anticancer 
drugs gaining marketing approval are targeted agents such as monoclonal antibodies and 
tyrosine kinase inhibitors (TKIs). The introduction of these agents with a mechanism of action 
different to conventional chemotherapy also triggered trials combining these agents with 
conventional cytotoxic agents. In selecting two drugs, frequently encountered criteria are 
non-overlapping toxicity of the drugs involved, potential synergism in anti-tumor activity, a 
patient-population in whom the combination may be worthwhile, and an absent or limited 
potential for drug-drug interaction augmenting toxicity or attenuating anti-tumor effects.
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Determining the DLT observation time window
Early drug development studies on traditional cytotoxic agents, which in general are only 
applied for a limited period of time, for example for 4 or 6 cycles, hardly covered chronic 
toxicity. This was deemed acceptable since the majority of severe adverse events induced 
by traditional cytotoxic drugs determining the recommended dose for further studies are 
transient, do not cumulate, and resolve before the administration of the subsequent cycle. 
As a result, toxicity from such agents observed during the first cycle in general adequately 
reflects the toxicity profile of the drug during the whole, relatively short time of treatment. 
However, most targeted agents induce tumor growth stasis and therefore need to be 
administered for prolonged periods of time. Due to this longer exposure to targeted agents 
the margins of tolerability might be crossed in a completely different fashion and will thus 
have to be assessed from a different perspective. Importantly, while short lasting severe 
side-effects may still be considered tolerable, less severe side-effects experienced for 
prolonged periods may not. For example, grade 3 nausea for a few days due to a cytotoxic 
agent may be better tolerable than daily grade 2 nausea for a few weeks. As a consequence 
we may have to change our definitions of DLT for chronic dosing as well as the methodology 
of determining DLT in a phase I study, or may have to lean more on the safety evaluation in 
subsequent phase II trials. 
Dose escalation steps
One of the other challenges in phase I studies on drug combinations is the dose-escalation 
schedule. In contrast to single agent studies, in which the consequence of exceeding the 
MTD is pretty clear, the decision rules in combination phase I studies can be applied in 
several ways, rendering other doses to be tested. And even in the steps towards the MTD, 
choices in dose escalation can greatly impact the final MTD as illustrated in figure 1. This 
figure illustrates the stepwise increase in dose-level, starting at dose-level 1 for both drugs. 
Subsequently one of the drugs is escalated at each following dose-level. The predefined 
dose-escalation steps in itself already determine which dose of a drug might become an 
MTD (Figure 1).
 Usually there is a fair amount of prior data on the single drug toxicity profiles of the 
separate agents once explored in combination. Exploring a drug with a high incidence of 
severe toxicities as one of the components in a combination-study poses a challenge to 
the investigator. The dose-finding study should be defined in such a way that potentiating 
effects from the other drug on the toxicity is easily detected. In other words, the “back-
ground noise” should be identified. Additionally, recognition of a relevant drug-drug-
interaction rendering a lower or higher drug-exposure should be detected at an early stage. 
Furthermore, during the design-process, decision rules should be considered that allow 
the investigator to anticipate for unexpected events. If adequately constituted, these rules 
ideally can result in the detection of the upper boundary of safe dosing based on safety, 
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pharmacokinetic and pharmacodynamics parameters. Ideally, this boundary is not just a 
single MTD, but multiple MTDs.
 Specific challenges are posed when adding an agent with a novel mechanism to an 
established cytotoxic drug. Usually, the dose of the established cytotoxic therapy is defined 
on the basis of the occurrence of adverse events at MTD. Adding a new drug easily tilts 
the combination above the tolerated border rendering coincidence to have a large impact 
on dose-escalation possibility. For example, if an established therapy has an incidence of 
severe toxicity at or close to the MTD and a novel drug is added at zero milligram (placebo 
level) to this treatment in the first two patients and they both experience severe adverse 
events, than even the addition of “nothing” inadvertently creates the conclusion that this 
dose is above the MTD.
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Figure 1 | Four maximally tolerated doses (MTDs) determined with two drugs, solely depending on 
escalation steps. (Numbers are dose-levels. Grey blocks are the dose-levels exceeding the MTD). 
(Hamberg et al. Eur J Cancer 2010: 2870-2878).
Sequence versus combination
If MTDs of the drugs in combination are defined then subsequent studies will have to 
evaluate the combination on hints for efficacy as well as provide more robust information 
on tolerance. Yet, the optimum schedule still needs refinement also in later phase studies. 
For example, a combination of two drugs might be tolerable, but a key-question in the 
end is whether the combination is better than the sequence of both single agents. Phase II 
trials can also be helpful in “picking a winner”, the combination or the sequence of the both 
drugs, that should proceed to phase III.
 This thesis focuses on combining anticancer drugs in early clinical trials and addresses 
several of the challenges mentioned above. The combinations described in this thesis all 
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involve so-called targeted agents, agents designed to inhibit a specific factor or receptor, 
combined with conventional cytotoxic drugs.
 Chapter 2 provides an overview of cytotoxic agents in combination with inhibitors 
of the vascular endothelial growth factor – vascular endothelial growth factor receptors 
(VEGFR) pathway. The third chapter introduces novel models to improve dose-finding 
anticancer drug combination studies in general. The fourth chapter describes a study that 
aims to determine the MTD of the targeted agent sunitinib, a TKI targeting, amongst others, 
the VEGFR, combined with two different schedules of ifosfamide. The fifth chapter reviews 
the properties of pazopanib, another oral TKI inhibiting VEGFRs. In the subsequent sixth and 
seventh chapter, pazopanib is combined with two schedules of ifosfamide and docetaxel, 
respectively. The eighth chapter describes a phase II study comparing a combination of 
two drugs to both drugs given sequentially. Finally, a summary, discussion, and future 
perspectives are provided in chapter 9.

2C h a p t e r 
It takes two to tango: combinations of 
conventional cytotoxics with compounds 
targeting the vascular endothelial growth 
factor-vascular endothelial growth factor 
receptor pathway in patients with solid 
malignancies
IA Boere
P Hamberg
S Sleijfer
Cancer Science 2010; 101: 7-15
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AbSTrACT
Through advances in molecular biology, insight into the mechanisms driving malignancies 
has improved immensely and as a result, various factors playing an essential role in the 
biology of numerous tumor types have been revealed. By using compounds that 
specifically block the function of a single factor being crucial for tumor pathogenesis, 
it was hoped to exert antitumor activity while avoiding toxicities characteristic 
for conventional chemotherapy. One of the processes of crucial importance in the 
development of cancer, and consequently an attractive target, is angiogenesis. In 
recent years, several key factors for angiogenesis have been identified, including 
ligands, receptors, and transduction signaling factors. Of these, the vascular endothelial 
growth factor (VEGF) pathway has been found to be activated in numerous tumor 
types and considered one of the main drivers of angiogenesis. Roughly, VEGF-mediated 
angiogenesis can be inhibited by two approaches: either by monoclonal antibodies 
directed towards VEGF or its corresponding receptors, or by kinase inhibitors targeting 
the signal transduction of the VEGF receptors. As monotherapy, several kinase inhibitors 
exert antitumor activity in tumor types such as renal cell carcinoma. However, in most 
tumor types, the antitumor activity of compounds targeting the VEGF pathway is 
limited. In recent years, evidence is mounting that the paradigm of one single factor that 
drives malignant behavior applies rarely and is an oversimplification for most tumors in 
which there are multiple driving pathways. Consequently, multitargeting rather than 
single-targeting approaches are required. One of the means is by combining targeted 
agents with conventional cytotoxics. As the VEGF pathway also affects the sensitivity 
of tumor cells to chemotherapeutics, combinations of compounds targeting this 
pathway and conventional cytotoxics have been explored. This review addresses such 
combinations. 
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INTrODuCTION
Recently, anticancer therapy has focused on cancer cell specific therapy, often referred to 
as targeted therapy. Mainly through improved molecular techniques, numerous factors 
involved in tumor pathogenesis have been identified. Such factors are frequently expressed 
both in tumor cells, and in adjacent normal cells, supporting tumor growth. Examples of 
tumor-driving factors include ligands (e.g. VEGF, and hepatocyte growth factor), receptors 
(e.g. c-KIT, VEGFR, EGFR, and human EGFR-2), and factors involved in signal transduction 
pathways. Initially, it was hoped that one or only a few factors would drive malignant 
behavior of solid tumors, and that inhibiting these factors would exert antitumor activity.
 Indeed, the concept of a single pathway driving malignant behavior is illustrated by the 
example of gastro-intestinal stromal tumor (GIST). GIST is driven by activating mutations 
in the c-KIT gene.1 The introduction of imatinib, a TKI targeting c-KIT, dramatically improved 
the out- comes of advanced GIST patients.2,3 However, in contrast to GIST, in most tumors 
multiple pathways are active in parallel, therefore targeting one or a few pathways 
will frequently not yield significant antitumor activity. Multiple driving pathways require 
multi-targeting approaches, which can be achieved by several means; cancer cell-specific 
drugs are designed to have a broader range of activity, cancer cell-specific drugs can be 
combined, and targeted therapy may be combined with conventional chemotherapy. The 
present review addresses the rationale and currently available data on combinations of 
conventional chemotherapy and cancer cell-specific therapies directed towards the VEGF 
pathway.
Vascular endothelial growth factor-driven angiogenesis as a target for therapy 
in solid tumors
Angiogenesis is crucial for tumor growth and dissemination and therefore forms an 
attractive pathway to target. In this process, the VEGF family plays a central role. VEGF-A 
is the major pro-angiogeneic factor, usually referred to as VEGF. Other family members 
include VEGF-B, VEGF-C, VEGF-D, and placental growth factor. In addition to tumor cells, 
VEGF is produced by a number of cells, such as platelets, stromal, and muscle cells. 
Although VEGFR is sometimes expressed by tumor cells, VEGF’s predominant site of 
action is at endothelial cells. Binding of VEGF to VEGFR-1 and VEGFR-2 initiates a cascade 
of downstream intracellular signal transduction pathways resulting in endothelial cell 
proliferation and migration, vascular permeability, and subsequently to the formation 
of new blood vessels.4
 VEGF is overexpressed in many solid tumor types as a consequence of several 
underlying mechanisms. VEGF can be induced by a number of genetic and epigenetic 
alterations, by cytokines, growth factors, hormones, and hypoxia. One of the best 
examples elucidated thus far is in clear-cell renal cell carcinoma (RCC) , in which the 
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activity of the VHL gene is disrupted due to mutations or methylation. Normally, 
VHL binds to and inactivates the transcription factor hypoxia inducible factor 1-α. Due 
to the disrupted VHL function in RCC, however, hypoxia inducible factor 1-α levels are 
elevated, inducing transcription of many factors including VEGF.5 In many cancer types, 
increased VEGF expression is associated with poor outcome, irrespective of tumor 
stage or grade.6 A higher potency to disseminate and chemoresistance account for 
this, thus rendering the VEGF pathway one of the most attractive targets for anticancer 
therapy.
Clinical studies on single agents targeting the VEGF pathway
Currently, the VEGF pathway can be blocked by mAb or kinase inhibitors. Concerning mAb, 
only bevacizumab has been extensively explored in the clinic. Bevacizumab is directed 
towards VEGF, thereby hindering its attachment to receptors. As bevacizumab does not 
bind factors other than VEGF, bevacizumab is regarded as a truly single factor-targeting 
treatment. In contrast, kinase inhibitors targeting VEGFR often abrogate the function 
of other factors as well, therefore being less specific. Recently, compounds targeting the 
VEGF pathway have been widely explored. One of the first issues that had to be solved 
in the context of these studies was how to reliably assess their activity in clinical studies. 
Historically, the RR was used for this purpose, but data are accumulating that for many 
antitumor agents, in particular those targeting the VEGF pathway, antitumor activity is not 
adequately reflected by changes in size but more relevantly by parameters reflecting tumor 
stabilization, such as the ratio of tumor progression before and after starting the agent of 
interest, the progression free survival (PFS), and progression-free rate at a certain time point.
Bevacizumab
The first proof of the efficacy of an anti-angiogenesis treatment in human malignancy 
was established in advanced RCC. Monotherapy bevacizumab induced a low RR (10%), 
but PFS almost doubled compared to placebo.7 However, apart from RCC, monotherapy 
bevacizumab has been explored only in a few other tumor types and only in non-randomized 
settings. In cervical cancer and castrate refractory prostate cancer, no antitumor activity 
was observed (Table 1).
 In hepatocellular carcinoma (HCC), bevacizumab induced a 6-months progression-free 
rate of 65% compared with 40% in historical controls, although fair comparison remains 
difficult without a randomized control arm.8 For ovarian cancer, two non-randomized phase 
II studies in heavily pretreated patients have been published, both showing interesting 
PFS and overall survival (OS)9,10 compared to historical controls.11 It was concluded 
that bevacizumab has activity against ovarian cancer, albeit this conclusion is based on 
non-randomized studies. Furthermore, bevacizumab has recently been Food and Drug 
Administration (FDA)-approved based on data of two non-randomized studies in patients 
with previously treated glioblastoma (AVF3708g and NCI 06-C-0064E), both not published 
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as full papers yet. Another non-randomized phase II study confirmed bevacizumab’s activity 
in pretreated glioblastoma.12
Table 1 | Trials with monotherapy bevacizumab
Indication Study 
phase
Patients 
(n) 
Agent End points reference
Metastatic clear-cell  
RCC 2nd line
II 116 Bevacizumab 3 
and 10 mg/kg q2w 
or placebo
PFS bevacizumab  
10 mg/kg 4.8 m;  
3 mg/kg 3.0 m; placebo  
2.5 m OS ns RR 10% 
bevacizumab 10 mg/kg
[7]
Metastatic castrate 
refractory prostate 
carcinoma
II 15 Bevacizumab  
10 mg/kg q2w 
non-randomized
No objective response [73]
Platinum resistant 
epithelial ovarian/ 
peritoneal serous 
cancer 3rd/4th line
II 44 Bevacizumab  
15 mg/kg q3w  
non-randomized
PFS 4.4, OS 10.7 m, PR 15.9%, 
perforation 11%, 3 deaths 
(historical PFS 2.3–3.4 m, 
OS 8–10.3 m)
[10]
Epithelial ovarian/  
primary peritoneal 
cancer 2nd/3rd line
II 62 Bevacizumab  
15 mg/kg q3w 
non-randomized
PFS 4.7 m, OS 17 m RR 21% [9)]
Recurrent cervical 
cancer 2nd/3rd line
II 46 Bevacizumab  
15 mg/kg q3w 
non-randomized
PFS 3.4 m, OS 7.3 m, PR 10.9%  
(historically OS 4–6.6 m)
[74]
Non-metastatic 
unresectable HCC
II 46 Bevacizumab  
5 or 10 mg/kg q2w 
non-randomized
PFS 6.9 m, PFS rate 65%  
at 6 m, OS not available
[8]
Recurrent 
glioblastoma 
II 48 Bevacizumab  
10 mg/kq q2w 
non-randomized
PFS 16 w, OS 31 w,  
RR 35% (MacDonald criteria)/ 
71% (Levin criteria)
[12]
HCC, hepatocellular carcinoma; OS, overall survival; PFS, progression-free survival; PR, partial response; RCC, renal 
cell carcinoma; RR, response rate; w, weeks; m, months.
Tyrosine kinase inhibitors
The first two TKI targeting VEGFR that were widely explored in solid tumors are sunitinib 
and sorafenib. In addition to VEGFR-2, sunitinib also inhibits c-KIT, FMS-like tyrosine kinase 
3, PDGF-α, and PDGF-β. Sorafenib is a potent Raf kinase inhibitor that directly suppresses 
tumor cell proliferation, and also targets VEGFR-2, VEGFR-3, and PDGFR-β. Sunitinib 
improves PFS and RR compared with IFN-α as first-line therapy for advanced clear-cell 
RCC. PFS and RR were 11 months and 47% in the sunitinib group, compared with 
5 months and 12% in the IFN-α group respectively.13 A trend to better OS in the 
sunitinib group was observed (26.4 vs 21.8 months [P=0.051]). Within the IFN-α group, 
however, the majority of patients received active post-study antitumor treatment, 
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obscuring the true impact of sunitinib on OS. In the subgroups not receiving post-
study therapy, sunitinib doubled the OS compared with IFN-α (28.1 vs 14.1 months, 
respectively),14 strongly supporting sunitinib’s activity in RCC. Furthermore, sunitinib 
is active in patients with advanced GIST failing to imatinib.15
 Sorafenib improved PFS in patients with advanced clear-cell RCC pretreated 
with cytokine-containing therapy in a placebo- controlled phase III trial (median PFS 
5.5 vs 2.8 months). Subsequently, the trial was stopped early and patients receiving 
placebo were allowed to cross over to sorafenib.16 Although an intent-to-treat analysis 
demonstrated no OS benefit (17.8 vs 15.2 months, respectively), censoring placebo 
patients indicated a better OS for those receiving sorafenib (17.8 vs 14.3 months), 
suggesting an important cross-over effect.17 Surprisingly, given the effects of sorafenib 
in second-line treatment, sorafenib and IFN-α had equivalent activity as first-line 
treatment of metastatic RCC.18 In HCC, sorafenib yielded a 2% RR, but signifcantly 
improved PFS and OS over placebo. PFS was 5.5 versus 2.8 months, and OS was 10.7 
versus 7.9 months, respectively.19 This study clearly shows that antitumor activity of 
VEGF-targeting agents is frequently not appropriately reflected in RR. Furthermore, 
sunitinib and sorafenib have been studied in a wide range of other tumor types (Table 
2).
 In addition to sunitinib and sorafenib, the number of TKI targeting the VEGFR is rapidly 
increasing, as is the number of tumor types in which they are assessed. Recently, the 
results of a randomized placebo-controlled phase III trial of pazopanib as first- or second-line 
treatment in clear-cell RCC were presented. Compared to placebo, pazopanib improved RR 
and PFS.20 Although the outcomes of many of the studies exploring pazopanib and other 
novel VEGFR TKI are promising, the lack of results from randomized studies is insufficient 
to give an exact definition of their role in this process. However, it is not unrealistic that 
besides a few exceptions, the activity of these agents as monotherapy is at best modest for 
most tumor types.
Rationale to combine compounds inhibiting the VEGF-pathway with conventional 
chemotherapy
There are several potential reasons rendering VEGF pathway-inhibiting drugs attractive to 
combine with conventional chemotherapeutic drugs. Besides promoting angiogenesis, 
VEGF expression can confer resistance against chemotherapy, potentially contributing to 
the generally worse outcome for patients with VEGF-overexpressing tumors. In xenografts, 
VEGF-producing tumor cell lines formed highly vascular tumors with accelerated growth 
compared to the parental cell lines, and exhibited less sensitivity to doxorubicin. Adding 
an anti-VEGF mAb reinforced the antitumor effects of doxorubicin.21 Several mechanisms 
explaining how VEGF may confer chemoresistance, and why combinations of conventional 
chemotherapy with VEGF pathway-inhibiting agents may yield synergistic interaction have 
been revealed.
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Table 2 | Trials with monotherapy tyrosine kinase inhibitors
Indication Study 
phase
Patients 
(n) 
Agent End points reference
Metastatic clear-cell  
RCC 1st line 
III 750 Sunitinib 50 mg  
4 weeks q6w, or IFNα 
9 MU 3/week 
PFS sunitinib 11 m vs IFNα  
5 m OS 26.4 vs 21.8 m,  
RR 42% vs 12%
[14]
Metastatic clear-cell  
RCC 1st line
II 189 Sorafenib 400 mg  
bid or IFNα 9 MU  
3/week.  
Cross-over to 
sorafenib 600 mg bid 
or sorafenib  
400 mg bid
PFS sorafenib 5.7 m vs IFNα  
5.6 m, PR 5 vs 7%  
Cross-over: PFS sorafenib  
600 mg 3.6 m; 400 mg 5.3 m
[18]
Metastatic clear-cell  
RCC 2nd line
III 903 Sorafenib 400 mg  
bid or placebo 
Interim analysis: PFS sorafenib 
5.5 m vs placebo 2.8 m.  
Cross-over: OS sorafenib 17.8 
m vs placebo 15.2 m (ns) OS 
(placebo censored) sorafenib  
17.8 m vs placebo 14.3 m 
[6,17]
Metastatic clear-cell  
RCC 1st/2nd line
III 434 Pazopanib 800 mg  
or placebo 
PFS pazopanib  
9.2 m vs placebo 4.2 m,  
OS awaited, RR 30% vs 3%
[20]
Metastatic castrate 
refractory prostate 
cancer 1st line
II 55 Sorafenib 400 mg  
bid non-randomized
PFS 8 w, PFS rate 1 y 13%,  
OS not reached
[75]
Metastatic soft tissue 
sarcoma 2nd line
II 142 Pazopanib 800 mg 
non-randomized
PFS rate 12 w 36–49% 
(leiomyosarcoma, synovial);  
PFS rate 1 y 14%,  
OS rate 1 y 34%
[76]
Advanced  
HCC 1st/2nd line 
II 34 Sunitinib  
37.5 mg/d 4w q6w 
non-randomized
PFS 3.9 m, OS 9.8 m RR 2.9%, 
50% stable disease
[28]
Advanced HCC 1st line III 271 Sorafenib 400 mg  
bid or placebo 
PFS sorafenib  
2.8 m vs placebo 1.4 m,  
OS 6.5 m vs 4.2 m
[77]
Advanced HCC 1st line III  602 Sorafenib 400 mg  
bid or placebo 
PFS sorafenib  
5.5 m vs placebo 2.8 m,  
OS 10.7 m vs 7.9 m
[19]
Glioblastoma 1st/2nd 
line 
II 16 Cediranib 45 mg/d 
non-randomized
PFS 3.7 m, OS 7 m [29]
HCC, hepatocellular carcinoma; OS, overall survival; PFS, progression-free survival; PR, partial response; RCC, renal cell 
carcinoma; RR, response rate; w, weeks; m, months; y, years; ns, non-significant.
Increased VEGF expression can protect tumor endothelial cells from apoptosis, through 
increased levels of Bcl-2 and surviving, two anti-apoptotic factors.22,23 Furthermore, VEGF 
over-expression may account for chemoresistance through increased interstitial fluid pressure 
(IFP) in tumors. Tumor vasculature is more fragile and leaky than normal vasculature, leading 
to elevated IFP, which hinders the delivery of drugs from the circulation into tumors.24 
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Abnormal tumor vasculature also leads to reduced blood flow and perfusion, thereby 
further impairing delivery of anticancer drugs. Normalization of tumor vasculature by anti-
angiogenic drugs can transiently reverse these abnormalities, and enhance the effects of 
chemotherapy (or radiotherapy), provided that it is administered during the ‘‘normalization 
window’’.25,26 In a small series of six patients with locally advanced colorectal carcinoma 
(CRC), bevacizumab decreased tumor perfusion, vascular volume, microvascular density, 
and IFP, all being signs of tumor vasculature normalization.27 Furthermore, there was no 
change in FDG-PET uptake, despite less blood flow, indicating increased efficiency of blood 
vessels.27 Consistently, in HCC patients treated with sunitinib, and in glioblastoma patients 
treated with cediranib, signs of reduced vascular permeability corresponding with vascular 
normalization were seen.28,29 A third VEGF-mediated mechanism that may contribute 
to tumor growth and tumor cell repopulation after chemotherapy is the VEGF-mediated 
mobilization of circulating endothelial progenitor cells (EPC) after cytotoxic therapy. It is 
hypothesized that EPC are mobilized from the bone marrow and transported through the 
circulation to become incorporated into the walls of growing blood vessels,30-32 thereby 
contributing to blood vessel formation and tumor regrowth after chemotherapy-induced 
cytotoxic effects. Both clinical and preclinical data showed substantial increases in viability 
and mobilization of EPC post-chemotherapy.33-35 Notably, EPC induction by cytotoxic drugs 
seems to be drug-dependent. Paclitaxel, 5-fluorouracil (5-FU), and docetaxel cause acute 
elevations in viable EPC levels, unlike other cytotoxic agents (e.g. gemcitabine, cisplatin, 
and doxorubicin).34 VEGF’s role has been demonstrated as the rapid induction of EPC was 
blocked when an anti-VEGFR mAb was added prior to paclitaxel-containing chemotherapy. 
Furthermore, combining the anti-VEGFR mAb with paclitaxel yielded synergistic antitumor 
effects that could not be observed with gemcitabine.34 However, debate is still ongoing 
concerning the identity and relative contribution to tumor angiogenesis of EPC, as 
extreme variability in the contribution of EPC to tumor vasculature were reported. 
Altogether, several ways may yield synergy between conventional chemotherapy and VEGF 
pathway-targeting drugs.
Combinations of bevacizumab and chemotherapy
Bevacizumab has been combined with various chemotherapeutic regimens in a wide range 
of tumor types. In general, combining bevacizumab with chemotherapy is safe, although 
exceptions exist; combining bevacizumab with doxorubicin in soft tissue sarcoma yielded a 
greater than expected cardiotoxicity.36 Given the great number of studies on bevacizumab-
containing regimens, only those combinations for which randomized data are available, 
and which have been published as full papers, will be addressed here.
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Colorectal cancer
The first hint of bevacizumab’s activity in metastatic CRC was observed in a phase III trial, 
comparing irinotecan, 5-FU, and leucovorin with or without bevacizumab. The addition of 
bevacizumab improved OS and PFS significantly. OS was 20.3 months in the combination 
arm, compared with 15.6 months for irinotecan, 5-FU, and leucovorin, whereas PFS was 
10.6 and 6.2 months respectively. Furthermore, RR increased from 34.8% to 44.8%.37 
More recently, bevacizumab was explored in combination with two nowadays more widely 
used first-line treatment schedules for metastatic CRC; capecitabine plus oxaliplatin and 
FOLFOX-4. Again, PFS was improved in the combination arm, but only slightly (9.4 vs 
8.0 months), while OS and RR were comparable.38 In addition to combination regimens 
such as capecitabine plus oxaliplatin, monotherapy 5-FU or capecitabine is frequently 
used in patients considered unfit for combinations. The added value of bevacizumab to 
capecitabine, or capecitabine plus mitomycin C was investigated as first-line therapy for 
metastatic CRC. RR and PFS were significantly improved in the bevacizumab-containing 
regimens, but OS was unchanged.39 Recently, the value of bevacizumab was assessed 
in stage II and III CRC, in which patients were treated with adjuvant FOLFOX-6 with or 
without bevacizumab. After a median follow up of 36 months, disease-free survival was 
comparable in both treatment arms.40 In contrast to the findings in first-line and adjuvant 
settings, bevacizumab added to FOLFOX-4 significantly improved RR, PFS, and OS when 
given as second-line treatment for metastatic CRC.41 In conclusion, bevacizumab added 
to conventional chemotherapy in CRC may enhance antitumor effects, but the extent to 
which this occurs is not fully elucidated, and seems to be dependent on regimen and 
setting.
Breast cancer
The first randomized study in metastatic breast cancer (MBC) compared capecitabine 
with capecitabine plus bevacizumab as second- and third-line treatment of MBC. The 
combination regimen improved RR, but there was no PFS or OS benefit.42 However, 
bevacizumab added to paclitaxel as first-line treatment of MBC did show a benefit in PFS. 
In this trial, bevacizumab combined with weekly paclitaxel significantly improved the RR 
from 21.2% to 36.9% and PFS from 5.9 to 11.8 months.43 Although less striking, preliminary 
data showed that bevacizumab improves RR and PFS when added to docetaxel.44 So also 
in MBC, the effects of bevacizumab seem regimen dependent.
Non-small cell lung cancer
Two randomized phase III studies explored bevacizumab with first-line chemotherapy in 
NSCLC. Bevacizumab with carboplatin and paclitaxel significantly improved both OS and 
PFS with 8 and 6 weeks respectively; however, this was at the cost of significant side 
effects in terms of bleeding, hypertension, and grade 4 neutropenia. Even though patients 
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with squamous cell tumors were excluded, lethal pulmonary hemorrhage occurred in 
1.2%.45 In the second study (AVAiL), two dose levels of bevacizumab were combined with 
gemcitabine and cisplatin in advanced NSCLC. PFS was 6.1 months in the chemotherapy 
alone arm, compared with 6.7 and 6.5 months for the bevacizumab low and high dose, 
respectively. RR was 20.1% in the chemotherapy alone group, compared with 34.1% and 
30.4% in the chemotherapy plus bevacizumab low and high dose groups, respectively. 
The incidence of serious adverse events and pulmonary hemorrhages were comparable 
in all groups.46 So, bevacizumab modestly enhanced the outcomes of platinum-based 
chemotherapy, but at the expense of increased toxicity. Particularly in older patients, 
toxicity seems to outbalance antitumor activity47 and as most NSCLC patients are of older 
age with comorbidity, only a minority of patients may benefit from bevacizumab added 
to chemotherapy.
Pancreatic cancer
Many approaches to improve the outcomes of the current standard in advanced pancreatic 
cancer (gemcitabine) have failed, including the addition of bevacizumab. In a large phase 
III trial, adding bevacizumab to gemcitabine failed to improve RR, PFS, and OS.48 Data of 
bevacizumab added to gemcitabine ⁄ erlotinib were recently published. Median OS was 
equivalent in both groups, while adding bevacizumab significantly improved PFS (4.6 vs 
3.6 months).49
Combinations of receptor TKI and chemotherapy
As previously mentioned, TKI harbor a broader range of activity than mAb. Consequently, 
TKIs may be more effective than antibodies, but at the cost of more toxic effects. Accordingly, 
combinations of chemotherapy with VEGFR TKI seem less feasible than combinations of 
chemotherapy with bevacizumab. Unfortunately, data of randomized trials on VEGFR-
targeting TKI-containing regimens are currently scarce. In addition to the few randomized 
trials, combinations explored in phase I, including toxicity and interaction issues that 
arise from these studies, are discussed. As the outcomes of single-arm efficacy studies on 
combinations without a control arm are hard to interpret, these will not be addressed.
Combinations of Sorafenib and Chemotherapy
Phase I on sorafenib-containing combinations
Numerous chemotherapeutic drugs have been combined with sorafenib and evaluated 
for toxicity, and pharmacokinetic interactions (Table 3). In the majority of these trials 
the toxicity profiles encountered were deemed acceptable and similar to the expected 
toxicity from each agent when given as monotherapy. Sorafenib (from day 4 at 100, 200, or 
400 mg twice a day) in combination with doxorubicin (60 mg ⁄ m2, every 3 weeks) has been 
explored in a dose escalation (n=34), and an extension part (n=18), the latter enrolling only 
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advanced HCC patients.50,51 The most frequent grade 3–4 drug-related adverse events were 
neutropenia (56%), lymphopenia (18%), fatigue (12%), and hand-foot-skin reaction (HFSR) 
(12%). The frequency of cardiotoxicity was not higher than expected from monotherapy 
doxorubicin. In HCC patients, a high incidence of hepatic toxicity (change >2 grades from 
baseline) was observed: bilirubin (62%), albumin (24%), and alkaline phosphatase (17%). 
Furthermore, grade 3 diarrhea was observed (18%), and two patients withdrew from 
treatment due to adverse events (renal failure grade 4 and hepatic encephalopathy). DLT 
were experienced by eight patients (20%), mainly HFSR and diarrhea. The MTD was not 
reached. Sorafenib increased doxorubicin exposure, with an increase in AUC of 21% and 
Cmax of 33%. The pharmacokinetics of sorafenib and one of doxorubicin’s active metabolites, 
doxorubicinol, were not affected.51
Table 3 | Phase I trials combining sorafenib with chemotherapy
Study population Patients 
(n) 
Agent End points reference
Refractory solid tumors 
(n=15) and metastatic 
melanoma (n=24)
39 Sorafenib (100, 200, 400 mg 
bid) Carboplatin (AUC6) and 
paclitaxel (225 mg/m2)
DLT: 6 rash, 1 hypertension 
Melanoma: 1 CR, 9 PR,  
PFS 10.2 m, RR 26%
[54]
Refractory solid tumors 
(n=27) and CRC (n=10)
37 Sorafenib (200, 400 mg bid) 
Oxaliplatin (130 mg/m2)
MTD not reached  
DLT: 2 diarrhea gr 3  
2 PR (6%), SD>10 w  
43% solid tumors, 78% CRC
[53]
Refractory solid tumors 
(n=19) and pancreatic 
cancer (n=23)
42 Sorafenib (100, 200, 400 mg bid)  
Gemcitabine (1000 mg/m2)
MTD not reached  
DLT: 1 fatigue gr 3  
2 PR (11%), 25 SD
[52]
Refractory solid tumors 
(n=34) and advanced  
HCC (n=18)
52 Sorafenib (100, 200, 400 mg bid)  
Doxorubicin (60 mg/m2) 
MTD not reached  
DLT: 7 HFSR 1 gr 3 diarrhea  
Solid tumor: 1 PR, 15 SD 
(48%) HCC: 1 PR (6%),  
10 SD (63%)
[50,51]
Refractory solid tumors 
(n=20) and CRC (n=14)
34 Sorafenib (100, 200, 400 mg bid)  
Irinotecan (125 mg/m2 or  
140 mg)
MTD not reached  
DLT: 1 hemorrhage, 2 HFSR  
22 SD (67%), 1 PR
[55]
CR, complete response; CRC, colorectal carcinoma; DLT, dose-limiting toxicity; HCC, hepatocellular carcinoma; HFRS, hand–
foot skin reaction; MTD, maximum tolerated dose; PFS, progression-free survival; PR, partial response; RR, response rate; SD, 
stable disease.
Sorafenib continuously (100, 200, or 400 mg bid) has been combined with gemcitabine 
(1000 mg ⁄ m2; day 1, 8, 15; every 4 weeks).52 The most frequent adverse events were 
constitutional (fatigue 78.6%), gastrointestinal symptoms, dermatological, and bone 
marrow toxicities. Common grade 3–4 adverse events were thrombocytopenia (28.6%), 
lymphopenia (21.4%), lipase elevation (19%), neutropenia (16.7%), fatigue (14.3%), 
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thrombosis (11.9%), and hypertension (7.1%). Grade 3–4 elevations in hepatic transaminases 
or bilirubin occurred in 5–10%. One DLT, grade 3 fatigue, was observed in the cohort with 
400 mg bid sorafenib. Therapeutic dosages of gemcitabine and sorafenib (400 mg bid) 
could be administrated without reaching the MTD. No clinically relevant pharmacokinetic 
interaction between sorafenib and gemcitabine was observed.52
 Sorafenib (200 or 400 mg continuously from day 4) was combined with oxaliplatin 
(130 mg/m2) in 27 patients with refractory solid tumors, and 10 patients with refractory CRC 
in the extension part. Adverse events were generally mild to moderate. Common adverse 
events were diarrhea (43%), neuropathy (37%), and dermatological toxicities (51%). Two 
DLT were reported (grade 3 diarrhea), and the MTD was not reached. No pharmacokinetic 
interaction between sorafenib and oxaliplatin was found.53
 The combination of sorafenib (100, 200, or 400 mg bid days 2–19) combined with 
paclitaxel (225 mg/m2 every 3 weeks) and carboplatin (AUC6) showed promising results in 
39 patients with advanced cancer, of which 24 were melanoma.54 All patients experienced 
treatment-related adverse events, mostly hematological (95%), dermatological (85%), 
fatigue (59%), sensory neuropathy (59%), nausea (56%), and arthralgia (26%). Grade 
4 neutropenia occurred in 62%, and HFSR grade 3 was reported in 23%. Seven patients 
experienced a DLT, grade 3 rash / HFSR in six patients, and hypertension in one patient. 
There was no clear dose-dependent relationship in treatment-related adverse events. The 
recommended phase II dose was sorafenib 400 mg bid, carboplatin AUC6, and paclitaxel 225 
mg/m2. Although clearance of paclitaxel is dependent on the cytochrome P450 enzymes, 
sorafenib had no apparent effect on the pharmacokinetics of paclitaxel. One complete 
response and nine partial responses were observed, all among patients with melanoma.54
 Sorafenib (100, 200, and 400 mg bid) was combined with irinotecan (125 mg/m2 on days 
1, 8, 15, and 22 of each 6-week cycle) in patients with advanced solid tumors, and in an 
extended cohort in CRC patients, receiving fixed-dose irinotecan (140 mg weekly). Three 
DLT related to sorafenib were found, with sorafenib 400 mg bid, one cerebellar hemorrhage, 
and two HFSR. Frequent drug-related toxicities were gastrointestinal, dermatological, 
constitutional, and metabolic, mostly grade 1–2. Grade 3–4 adverse events were diarrhea 
(40%), infection / neutropenic fever (35%), leukopenia (10%), and neutropenia (5%). The 
MTD was not reached. Irinotecan had no impact on sorafenib’s pharmacokinetics. In 
contrast, sorafenib doses higher than 200 mg bid significantly increased irinotecan and 
SN38 exposure; however, this was not associated with increased toxicity.55
randomized trials on sorafenib-containing combinations
Melanoma
The promising results of sorafenib combined with paclitaxel and carboplatin in the 
abovementioned phase I trial prompted further studies in melanoma patients. Recently, 
a phase III study was published in which 270 patients with advanced melanoma received 
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second-line therapy with carboplatin (AUC6) and paclitaxel (225 mg/m2, every 3 weeks) 
with sorafenib (400 mg bid) or placebo. Disappointingly, no difference was observed in any 
of the end points of the study. Dermatological events (91% vs 73%), and fatigue (75% vs 
57%) were more common in patients treated with chemotherapy plus sorafenib.56 Another 
study with a comparable design is expected to complete accrual in 2010.
 Based on a phase I study, published as an abstract, it was shown that sorafenib (400 mg 
bid) can be safely combined with dacarbazine (1000 mg/m2, every 3 weeks). This combination 
was compared with dacarbazine alone as first-line treatment in advanced melanoma 
patients (n=101). A trend for improved PFS was observed for the sorafenib group (21.1 vs 
11.7 months) without any difference in OS. The combination of sorafenib with dacarbazine 
in therapeutic dosage was well tolerated and had a manageable toxicity profile. Grade 3–4 
adverse events were reported in 50% of patients in the control arm, and in 69% of patients 
in the sorafenib plus dacarbazine arm, 51% of the sorafenib-treated patients had grade 3–4 
hematological toxicity.57
Combinations of Sunitinib and Chemotherapy
Phase I on sunitinib-containing combinations
Currently, several combinations of conventional chemotherapy and sunitinib are being 
studied in phase I / II settings, including combinations with ifosfamide, capecitabine, 
carboplatin plus paclitaxel, gemcitabine, irinotecan, gemcitabine plus cisplatin, and 
5-FU plus irinotecan. Most combinations of sunitinib plus conventional chemotherapy 
seem feasible, but at the expense of increased hematological toxicity. The severity and 
frequency of neutropenia is probably determined by the dose and schedule of sunitinib, 
and on the toxicity profile of the cytotoxic agent used. For example, sunitinib combined 
with capecitabine resulted in grade 4 neutropenia in <10% of patients, whereas sunitinib in 
combination with irinotecan or carboplatin / paclitaxel resulted in grade 3–4 neutropenia 
in 30–60% of patients. Furthermore, sunitinib in combination with ifosfamide was not 
feasible without growth factor support.58 However, none of these studies have thus far 
been published as full papers, and therefore will not be discussed in further detail. The same 
applies to randomized trials exploring sunitinib-containing combinations. Many such trials 
are ongoing but have not been published yet.
Other TKI
Phase I trials on vandetanib-containing combinations
Vandetanib is an orally administered TKI of VEGFR2, VEGFR3, and epithelial growth factor 
receptor (EGFR). As monotherapy, it is well tolerated dosed at 300 mg per day.59 In a 
phase I study, 21 patients with advanced NSCLC received vandetanib (100 or 300 mg) with 
pemetrexed (500 mg/m2, every 3 weeks) as second-line therapy. Both dose levels were 
well tolerated. Two DLT were reported, asymptomatic QTc prolongation and interstitial 
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lung disease, which resolved after steroid therapy. Most common adverse events were 
rash, anorexia, fatigue, and diarrhea (all approximately 50%), and most were grade 1–2. No 
pharmacokinetic interactions were found.60
 The safety and tolerance of vandetanib plus FOLFOX-6 was recently investigated in 
patients with advanced CRC as first- or second-line chemotherapy. Seventeen patients 
received 14-day treatment cycles of mFOLFOX-6 plus vandetanib (100 or 300 mg). Both dose 
levels were tolerable, but a DLT (diarrhea) occurred in each cohort. Overall, the most common 
adverse events were diarrhea, nausea, lethargy (all 65%), neutropenia, and neuropathy (both 
59%). There was no pharmacokinetic interaction. At steady-state exposure to vandetanib, 
there was an increase in exposure to oxaliplatin, but time-dependent increases have also 
been observed previously with oxaliplatin as monotherapy.61
Phase II randomized trials on vandetanib-containing combinations
Vandetanib has been studied with docetaxel in advanced NSCLC patients as second-line 
treatment in a randomized phase II study. Advanced NSCLC patients (n=127) were treated 
with docetaxel (75 mg/m2, every 3 weeks) combined with either placebo or vandetanib 
(100 or 300 mg). Diarrhea and rash were most frequent and severe in patients receiving 
vandetanib 300 mg. Patients in both vandetanib groups showed a modest increase in blood 
pressure at 6 weeks. Asymptomatic QTc prolongation was only observed in the vandetanib-
treated patients. Though not adequately powered to detect small differences, RR and PFS 
were significantly improved in the vandetanib 100 mg group, compared with the other two 
groups. Combined use did not cause detectable changes in the pharmacokinetic profile 
of either drug.62 Currently, a randomized phase III trial of docetaxel with vandetanib or 
placebo as second-line therapy for advanced NSCLC is ongoing.
 In another randomized phase II study, the combination carboplatin / paclitaxel was 
compared with vandetanib monotherapy, and with carboplatin / paclitaxel combined with 
vandetanib in advanced NSCLC patients as first-line therapy. The vandetanib monotherapy 
arm was stopped early after an interim analysis. Treatment was tolerable in all three groups, 
but more patients receiving vandetanib plus carboplatin / paclitaxel experienced insomnia, 
anorexia, depression, grade 3–4 diarrhea, asymptomatic QTc prolongation, skin disorders, 
and hypertension. Neutropenia was the most frequently reported grade 3 adverse event, 
equally distributed among the chemotherapy-containing arms. A statistically significant 
improvement in PFS of only 1 week was observed in the group treated with vandetanib 
and chemotherapy, compared with chemotherapy alone. OS and RR were not significantly 
different. No detectable changes in pharmacokinetic exposure to vandetanib with the 
addition of carboplatin ⁄ paclitaxel were observed.63
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Phase I trial on cediranib-containing combinations 
The TKI cediranib targets VEGFR, PDGFRb, and c-kit. In a phase I study, cediranib (daily 30 or 
45 mg) was combined with carboplatin (AUC6) and paclitaxel (200 mg/m2, every 3 weeks) in 
patients with advanced NSCLC as first-line therapy. Toxicity was manageable, and common 
side effects were fatigue, diarrhea, anorexia, and neutropenia. No DLT were reported. 
Steady-state levels of cediranib were comparable to those seen in single-agent therapy. 
Carboplatin clearance was unchanged, but paclitaxel clearance was decreased in cycle 2, 
which was reflected in the nadir of the platelet counts.64 
 In another phase I trial, cediranib (30 or 45 mg daily) was added to mFOLFOX-6 
(every 14 days) in 16 metastatic CRC patients. One DLT, grade 3 diarrhea, was observed. 
Common grade 3 cediranib-related toxicities included hypertension, diarrhea, fatigue, and 
anorexia. There were no pharmacokinetic interactions between cediranib and 5-FU or free 
plasma oxaliplatin.65 Currently, a phase III trial has been initiated, in which FOLFOX plus 
bevacizumab is compared with FOLFOX plus cediranib as first-line treatment of metastatic 
CRC.66
Combine targeted therapy and chemotherapy with caution, more is not always 
better
To further improve the outcomes of combinations of agents targeting the VEGF 
pathway and chemotherapy, recently two large studies have been published in which 
an EGFR-targeting drug was added in patients with metastatic CRC as first-line therapy. 
Unexpectedly, adding panitumumab or cetuximab, resulted in worse outcome and 
increased toxicity.67,68 Panitumumab was added to bevacizumab and oxaliplatin- and 
irinotecan-based chemotherapy. PFS was 10.0 and 11.4 months, and OS was 19.4 and 24.5 
months for the groups with or without panitumumab respectively.67 Similarly, cetuximab, 
added to capecitabine, oxaliplatin, and bevacizumab, resulted in significantly shorter PFS, 
9.4 compared with 10.7 months for patients with or without cetuximab respectively. OS 
and RR were comparable.68 Although a combination of agents targeting multiple signal-
transduction pathways appears reasonable, the results from these studies show that theory 
may differ from practice. The underlying mechanisms for these results are unclear. There are 
no available data of a possible pharmacokinetic interaction. A possible pharmacodynamic 
interaction induced by EGFR inhibition could have led to diminished therapeutic effects 
of bevacizumab and / or chemotherapy, perhaps through EGFR-mediated alterations of 
downstream targets required for the activity of bevacizumab, but this is speculative.
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CONCLuSIONS AND FuTurE PErSPECTIVES
Though combining VEGF pathway inhibitors with conventional chemotherapy is 
theoretically attractive, this has currently only been proven for a few indications. 
Bevacizumab can improve the outcomes of conventional chemotherapy, but this is highly 
dependent on tumor type, stage, and chemotherapeutic regimen. With respect to kinase 
inhibitors, which in general are more difficult to combine with chemotherapy, randomized 
studies evaluating their added value are ongoing. Obviously, the availability of biomarkers 
enabling the identification of patients likely to benefit from combined regimens will augment 
the risk-benefit ratio of this approach. Biomarkers currently assessed include radiological 
tests to determine parameters such as vascular density, permeability, and volume.27,29 With 
respect to soluble markers, baseline VEGF levels and outcome to antiangiogenic therapy as 
monotherapy have shown conflicting results. The predictive value in combination regimens 
remains to be established.69,70 Increased levels of placental growth factor were associated 
with better outcome in CRC patients treated with bevacizumab and chemoradiation.71 
Furthermore, inflammatory proteins may be potential biomarkers; increased interleukin-6 
levels were associated with worse outcome in patients with CRC and HCC, treated with 
bevacizumab and sunitinib respectively.28,71 Also, circulating endothelial cells and EPC 
may emerge as useful biomarkers. Polymorphisms in the VEGF gene are another promising 
predictive factor. The VEGF-2578 AA genotype was associated with better OS in patients with 
MBC treated with bevacizumab and paclitaxel.72 Whether or not this holds true for other 
combination regimens and other polymorphisms remains to be established. Clearly, the 
need for markers predictive for outcome to combinations of conventional chemotherapy 
and VEGF pathway-targeting drugs is high. In particular through the introduction of such 
predictive markers and thereby improved treatment individualization, combinations of 
conventional chemotherapy and VEGF pathway-targeting drugs are likely to redeem their 
great promise.
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Designing combination drug phase I trials has become increasingly complex, due to the 
increasing diversity in classes of agents, mechanisms of action, safety profiles and drug- 
administration schedules. With approximately 850 agents currently in development for 
cancer treatment, it is evident that combination development must be prioritised, as 
based on a specific hypothesis, as well as a projected development path for the involved 
combination.
 In this manuscript the most relevant issues and pitfalls for combination drug phase I trial 
design are discussed. Several phase I study designs that incorporate controls to circumvent 
bias due to imbalances in observed background toxicity are discussed.
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INTrODuCTION
Designs for phase I trials in general and combination drug phase I trials in particular are 
facing several challenges with the increasing diversity of classes of agents and mechanisms 
of action. In addition, these new classes of anticancer agents are often administered 
continuously rather than intermittently, and they manifest safety profiles that are 
completely different from those of conventional cytotoxic agents. Determining the best 
dose for new combination drug treatments will have to be balanced against these aspects. 
Longer observation periods than the usual 3–4 weeks are required, given that continuously 
administered drugs may show relevant toxicity only after a prolonged exposure.1 There 
are currently approximately 850 agents in the development for cancer treatment,2 which 
could potentially be combined into approximately 400,000 two-drug combinations, not 
to mention potential combinations involving already marketed agents. Computational 
modelling of new drug combinations may be a way forward, but as long as this has not 
been developed, we will have to work with realistic phase I study modelling and planning.
rationale
A phase I study of a new combination of drugs is only the first clinical step in the development 
of that specific combination and should be considered a means, not an end in itself. Before 
commencing a combination drug phase I trial, a plan for (tumour-type specific) subsequent 
developmental phase II/III studies must clearly be defined. The choice for tumour type 
should be based on a scientific rationale, ideally including data in an appropriate preclinical 
model or on the basis of clinical results for the individual agents.
It all starts with an hypothesis
A single ideal template to perform a combination drug phase I trial will likely never 
exist. Every trial has to be designed based on prior knowledge of the preclinical and 
clinical pharmacology of the individual agents. Given the enormous number of potential 
combinations, in addition to a proper rationale and further development plan as outlined 
above, an appropriate hypothesis to guide the protocol design is also crucial. We have 
identified three potential general hypotheses for such studies. Whilst the hypothesis 
is leading for the trial design, one should obviously always keep an open eye to detect 
unexpected observations.
Type 1 hypothesis: interaction at the pharmacokinetic (PK) level
Data on metabolism and pharmacokinetics of each of the drugs involved may suggest a 
potential interaction at the PK level, for example, if drug A is a putative CYP3A4 inhibitor 
while drug B is a substrate for CYP3A4. PK drug interactions are particularly plausible when 
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both drugs are oral, as there may be unanticipated interactions related to drug absorption 
and/or first-pass metabolism.
 Obviously, in phase I trials based on this hypothesis extensive PK sampling is warranted, 
and the design will have to include PK of the single agent(s) as well as of the combination. 
This means that a single agent dose will have to be a part of the design, and intrapatient and 
interpatient variabilities will have to be taken into account (Figure 1).
Drug administraon  
PK-sampling drug A 
Wash-out drug A 
A 
B (administered daily)
AA
Time to steady state drug B
PK-sampling drug B 
Cycle 2 Cycle 1 Cycle 3 and further 
Figure 1| Single agent as well as drug combination pharmacokinetic analysis enabling intrapatient 
evaluation. Drug A is administered i.v. every 3 weeks and drug B is administered orally every day.
If the hypothesised interaction would lead to an anticipated increased drug exposure, the 
first dose-level should be defined cautiously low. Given the hypothesis, dose-escalation to 
the next cohort can only take place once the PK-analysis in the previous cohort is completed 
and can be taken into account. The outcome of this analysis can upfront be incorporated 
in the projected dose-levels, by introducing PK-based dose-escalation rules, such as, for 
instance, ‘If steady state of drug A increases less than factor X due to the addition of drug B, 
and no dose-limiting toxicity (DLT) is observed: escalate to dose-level 3. Otherwise escalate 
to dose-level 2.’
Type 2 hypothesis: interaction at PD level without interaction at PK level
In some combinations no PK interaction is anticipated based on the respective single 
agent data, but evidence supports a potential PD interaction, like an increase in a specific 
toxicity or an additional effect on a mechanism-related biomarker. In these studies neither 
extensive PK-sampling nor a run-in single agent phase would be required. However, limited 
PK-sampling may be advisable to enable verification that the right hypothesis was chosen 
and to allow exclusion of a totally unexpected PK interaction as a cause in case of observed 
excessive toxicity. Such limited sampling can be done at each dose-level or only in dose-
expansion cohorts at the maximally tolerated dose (MTD).
 Obviously, the follow-up assessments of patients should be scheduled in a way that 
optimal monitoring of the toxicity for which an interaction is anticipated can be ensured. 
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The follow-up schedule can be different for a combination in which QT-interval prolongation 
is expected during the first 5 days after intravenous administration of drugs A and B as 
compared to a combination in which a prolonged neutropaenia between day 10 and day 
20 is anticipated after intravenous administration of drug A and daily oral administration of 
drug B.
Type 3 hypothesis: no interaction at PK or at PD level
This hypothesis would render the phase I part of a developmental path extremely short. 
All we need to know is the feasibility of the drugs involved given at their respective 
recommended single agent doses. The challenge will thus be to factor this feasibility part 
into the phase II trial design.
 In case of a Type 1 or 2 hypothesis a phase I study has to define one or more MTDs (see 
paragraphs 4, 5 and 6), in contrast to a Type 3 hypothesis in which just the feasibility at one 
or limited dose levels has to be shown (paragraph 7).
Defining the MTD in Types 1 and 2 studies
In theory the number of MTDs of two drugs is infinite and does describe a curve, which 
we can call an envelope of tolerability. Obviously, the full envelope of tolerability of a drug 
combination will never be described, but defining multiple MTDs as derivatives of the 
envelope will generate knowledge on the dosing-range of the combination (Figure. 2).
 At first glance, the MTD often seems to be determined by the data generated during the 
trial. However, some choices made with regard to the pre-defined dose and dose-escalation 
steps are crucial and will have an impact on the MTD(s) defined: the drug schedule and 
administration sequence, order of pre-defined escalation steps and whether or not to 
compromise on a dose of an active agent.
 
Drug schedule and administration sequence
Additive or synergistic effects of combinations of agents may be dependent on specific 
drug scheduling and will have to be taken into account. For example, combining sunitinib 
(standard schedule 4 weeks on, 2 weeks off) with capecitabine (standard schedule 2 weeks 
on, 1 week off) will have to lead to choices regarding the drug-administration schedules. 
In this example, if a direct drug-drug interaction is anticipated with respect to exposure to 
either drug due to the other (or its metabolites), then a constantly changing drug exposure 
might result if the common single agent on/off schedules are applied. Other potential 
schedules would lead to more consistent drug exposures and the choice of which schedules 
to explore in a phase I trial should preferably be supported by data from preclinical studies. 
Similar issues could arise when an intravenously administered drug is combined with an 
oral agent.
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Furthermore, the sequence in which the drugs are administered might impact on tolerability 
and/or efficacy. Particularly for drugs with a short half-life a PK interaction could necessitate 
specific sequences of administration. But also PD interactions will have to be taken into 
account, when selecting the best sequence of administration.
Dose drug A 
Dose drug B 
Full dose single 
agent drug A 
Full dosesingle agent drug B 
No interacon at all 
Inducon of drug A rendering lower exposure to drug A due to drug B. 
No other interacon 
Curve at full dose level 
Curves at full dose level  
Interacon resulng in lower dose of drug A due to PD (toxicity) interacon  
 
OR/AND pharmacokinec interacon resulng in an increased exposure
to drug A 
 
Interacon resulng in lower dose of drug A and B due to PD (toxicity)  
interacon OR/AND pharmacokinec interacon resulng in an increased 
exposure to drug A and drug B 
Figure 2 | Sample of envelopes of tolerability (as types of envelopes are infinite) of a two-drug 
combination. An established MTD will be a single point on its curve. And although often only a single 
MTD is determined, many more MTDs do exist. The location of the determined MTD on its envelope is 
often a result of trial design.
MTD depends on escalation steps
As previously described, solely on the basis of a different use of the pre-defined dose-
escalation steps, at least four different MTDs can be determined in a ‘simple’ combination 
phase I trial involving only two drugs (Figure 3).3 As mentioned earlier, the true number of 
MTDs is infinite, so even this represents a crude way to define the envelope of tolerability.
39Dose-escalation models for combination phase I trials in oncology | 
In considering issues such as schedule, sequence and escalation steps, one might not 
want to limit to the identification of only a single MTD. It might even be preferred to study 
different schedules and drug-sequences and thus identify a multitude of MTDs in a single 
phase I combination study. Given the fact that phase I trials are aiming to define tolerated 
doses, and cannot identify the most optimal schedule, the identified multiple MTDs can 
subsequently be studied in a randomised phase 2 trials to pick the winner.
1 
1 
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3 4 5 
6 7 
8 
3
1 
1 1 1 1 1 
2 2 2 3 3 
4 
9
4 5 
6 7 
8 9 
Drug A  Drug B Drug A  Drug B Drug A  Drug B Drug A  Drug B
Figure 3 | Four maximally tolerated doses (MTDs) determined with two drugs, solely depending on 
escalation steps. (Numbers are dose levels. Grey blocks are the dose-levels exceeding the MTD.)
Compromising on the dose of an active agent?
Intuitively, physicians are reluctant to lower the dose of an agent known to be active. 
Although this is understandable in daily oncology practise, it may in theory be incorrect 
and hamper the options of exploiting a possible synergistic or additive effect. So, for 
most combinations, one should be prepared to (initially) compromise on the dose of an 
active agent, however, there may be rational exceptions to this. First of all, in a curative 
multimodality treatment in which a systemic agent is used as a radiosensitiser, the study 
population will not be a standard phase I population without further treatment options, 
but will consist of patients in whom cure is the goal. Lowering the dose of radiation 
might reduce the chances of cure, in return for an unknown benefit. On the other hand, 
no other population can be identified to study potential beneficial combinations during 
radiotherapy, so a very trial-specific approach should be defined.
 Secondly, if the mechanism of action of the added agent, for example, a poly(ADP-ribose) 
polymerase (PARP)-inhibitor, is clearly dependent on the in vivo effects induced by the 
standard treatment, it is logical not to compromise on the dose of the standard treatment. 
The rationale of adding a PARP-inhibitor to conventional cytotoxic therapy, like a schedule 
of carboplatin and paclitaxel, is the inhibitory effect of a PARP-inhibitor on the repair of 
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DNA-damage caused by alkylating agents. Applying the full dose of the cytotoxic therapy 
ascertains that the circumstances to determine the most rational MTD are optimised.
 A third exception applies to studies incorporating agents, known to be almost inactive 
below a given standard dose, such as ifosfamide, and can fix the dose of that agent, but 
the involved protocols should include a clause allowing a decreased dose of that agent if 
pharmacokinetic studies show an increased exposure due to drug-drug interactions.
Interaction at PD level focusing on toxicity
MTD/DLT-incidence in perspective of known toxicity profiles
Combination phase I studies should preferably be initiated if knowledge is available on the 
single agent toxicity profile of the involved agents. Combination phase I trials should aim 
to model the toxicity as function of dose and PK. While defining the limits of ‘tolerability’ 
based on an incidence of unacceptable side-effects is relatively straight-forward in single 
agent phase I trials, this turns out to be more difficult for combination phase I studies. And 
yet defining MTD and DLT is critical to the outcome of these studies.
 A few rather philosophical questions need to be addressed for combinations in which 
one of the two agents already has a high incidence of dose-limiting toxicities: how to 
handle a limited increase in DLT-incidence that crosses the classical phase I DLT-incidence 
cut off (33.3%) due to the addition of the second drug? For example, docetaxel has a high 
incidence of febrile neutropaenia (25–35% of patients) and most of these events occur 
during the first cycles of treatment. In combination with docetaxel, even agents with a very 
limited febrile neutropaenia rate in theory can raise the incidence of this dose limiting side-
effect above the classical upper boundary of acceptability. So for each trial a choice has to 
be made whether or not it is acceptable to shift this boundary upwards.
 Another issue is whether the definition of tolerability should be approached differently 
if the two drugs have overlapping limiting side-effects as compared to a combination with 
non-overlapping toxicity. If, for instance, drugs A and B are both dose limited by diarrhoea 
at an incidence of 25% and 20%, respectively, it is highly likely that diarrhoea will be the DLT 
of the combination as well (Figure 4). In this circumstance, there is no rationale to be more 
liberal in setting the limits of acceptability of toxicity, by allowing a higher incidence of this 
specific toxicity to define DLT/MTD. If more liberal criteria would be applied in this case, they 
could just as well be applied for defining DLT/MTD of the respective single agents.
 More difficult are situations with non-overlapping toxicity, adding drug C (with a 
hypertension incidence of 20%) to the same drug A. No standard recipe can be given here 
and the design should anticipate on two different scenarios: non-overlapping toxicity can 
occur in the same patients (rendering an incidence of toxicity of 25%) or in other patients 
with a potential incidence of toxicity up to or even above 45% (Figure 4).
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Type of toxicity and duration of observation
It remains a matter of debate, also in single agent phase I studies, whether short lasting and 
more chronic toxicity should have the same impact in defining the DLT and therewith the 
MTD. In combination phase I trials, this is even more complex, especially given the fact that 
many phase I trials are studies combining cytotoxic therapy with agents more specific to 
the cancer (cell). Due to the chronic exposure during treatment with the latter, the resulting 
toxicity usually also has a chronic character and can affect the tolerability by other means 
than the more acute toxicity related to cytotoxic therapy.
 Cumulative toxicity is known for some conventional cytotoxic agents such as doxorubicin 
(cardiotoxicity), taxanes, oxaliplatin (both neuropathies) and etoposide (leukaemogenic) 
and is just as important in determining the possible maximal total duration of therapy as 
is the dosing per cycle. Long-term toxicities are frequently only recognised just prior to or 
after registration of an agent. This may also be true for the more modern cancer (cell) specific 
agents (e.g. cardiotoxicity due to sunitinib4) and in early stages of drug development it will 
be unknown if lowering the dose per administration will allow drug administration for a 
more prolonged period of time. Incorporating such evaluation time frames will render 
phase I trials undoable. This type of toxicity can best be explored in (randomised) phase II 
trials.
+ 
+
Drug A
25
5
70
Drug B
20
2
78
Drug C
2
20
Same DLT criteria for 
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Figure 4 | Toxicity in the same domain versus non-overlapping toxicity. 
DLT, dose-limiting toxicity.
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Avoiding background noise on toxicity
One of the challenges in conducting combination drug phase I trials is to carefully 
weigh whether or not the frequency of observed toxicity is representative for the novel 
combination or that, due to chance, the toxicity attributable to just one of the drugs occurs 
in the trial in a higher than usual incidence.
 Two instruments may be helpful by valuing the toxicity data generated more carefully: 
(1) the 3 + 3 + 3 design and (2) introducing control groups into phase I studies.
The 3 + 3 + 3 design
The classical 3 + 3 design allows dose-escalation based on the frequency of encountered 
DLTs. If in a cohort of three patients no DLTs are encountered, the next dose-level will be 
explored. In the case of two DLTs out of three patients, the MTD is considered exceeded, 
and a lower dose level is further evaluated for its MTD potential. In the case of one DLT out 
of three patients, an extra three patients are enroled at that dose-level. If two or more DLTs 
occur in six patients, the MTD is considered exceeded.
 By using the classical 3 + 3 design, implicitly an incidence of <33.3% of severe toxicity 
is considered acceptable, whereas determining this incidence is based on a very limited 
number of patients.
 The chance that dose-escalation is ‘falsely’ halted is intrinsically related to the incidence 
of the severe toxicity of the new drug combination. This incidence is off course unknown, 
but prior data may point towards a relatively high incidence of severe toxicity, making the 
investigators eager to address this issue before commencing the trial.
 By using the classical 3 + 3 design in a drug combination phase I trial with an unknown 
but true incidence of severe toxicity of 5% the chance of a ‘falsely’ halted dose-escalation 
can be calculated by using formula 1 and is: 3%, but it rapidly increases to 29% and 51% if 
the unknown but true incidence of severe toxicity increases to 20% and 30%, respectively 
(Table 1).
Formula 1a : x3 + 3 * (x2 * y + x2 * y2 + x2 * y3 + x2 * y4)
OR
Formula1b : 1 – {y3 + 3 * y5 * x}
(x = unknown but true incidence of severe toxicity; y =1 – x).
The recently briefly mentioned 3 + 3 + 3 design3 decreases the chance of ‘falsely’ halting 
dose-escalation by means of the addition of enrolment of three extra patients at the same 
cohort as soon as two DLTs in six patients are observed. The extra three patients do allow 
the investigators a more refined grip on the incidence of severe toxicity of the treatment 
under evaluation. This strategy will result in a decrease of ‘falsely’ halting dose-escalation 
from 29% to 19% (by itself a reduction of approximately one-third!) if the unknown but true 
incidence of severe toxicity is 20% as can be calculated from formula 2 (Table 1).
43Dose-escalation models for combination phase I trials in oncology | 
Formula 2 : 1 – {y3 + 3 * y5 * x + 12 * y7 * x2}
A specific issue that needs some extra thought is the situation of two DLTs occurring in 
nine patients. From a mathematical viewpoint, it does not matter if these two DLTs occur 
in the first three patients or in the last three patients. The latter situation will never occur, 
given the fact that after 0 DLTs in the first three patients, the dose will already be escalated 
after these three patients. It is more delicate how to handle the situation of two DLTs in the 
first three patients. In the classic 3 + 3 design, this would be the signal for exceeding the 
MTD, as a further expansion of three patients will not get the incidence below 33.3%. But 
in the 3 + 3 + 3 design, there is a chance that the following six patients are without a DLT 
rendering an incidence of severe toxicity below the threshold of 33.3%. In our opinion this 
is not worthwhile, based on the following two arguments.
 First of all, if in two of three patients a DLT has occurred, while the true but unknown 
incidence of severe toxicity is 30%, the chance of ending up with just two of nine is 12%. So 
even if the incidence is within the acceptable range, only 1 of 8 trials will succeed to prove 
so.
 The second argument against dose-expansion in the presence of two DLTs in the first 
three patients is that it facilitates ‘falsely’ continuing dose-escalation to a greater extent 
than it limits ‘falsely’ halting dose-escalation. The chance of 2 of 3 will occur in 14 of 100 
trials in which the true but unknown incidence is 25%, whereas this occurs in 29 of 100 trials 
if the unknown incidence of severe toxicity is 40%.
 So, applying the 3 + 3 + 3 design excluding the ‘2-out-of- the-first-3-situation’ is the same 
as applying the 3 + 3 design and only in the case in which after expansion to six patients two 
DLTs are observed, a further expansion to nine patients will be done. The advantage of this 
approach can be calculated with formula 3, and examples are shown in the last column of 
Table 1.
Formula 3 : 1 – {y3 + 3 * y5 * x + 9 * y7 * x2}
It is clear that the 3 + 3 + 3 design is only of additional value if the incidence of severe toxicity 
is anticipated to be in the upper range of what may be considered acceptable. On the other 
hand, there is no harm done by applying this to all phase I trials, as it will only be used at 
a point where the classic phase 3 + 3 design already definitely has halted dose-escalation.
Introducing controls in phase I studies
Diminishing the effect of chance by introducing a control population is a standard procedure 
in phase II and III trials, rendering results better interpretable for a larger population. In 
phase I studies in the field of oncology controls have not been used up to now. However, 
particularly in combination phase I studies they might help in distinguishing added toxicity 
related to the added drug, from the toxicity related to the backbone standard.
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Table 1 | Chances of falsely halting dose-escalation as a function of the Incidence of unknown but true 
severe toxicity and the trial design
Incidence of 
unknown but 
true severe 
toxicity
Formula 
parameters
Chance of ‘falsely’ halting 
dose-escalation using 
classic 3 + 3 design; 
(formula 1)
Chance of ‘falsely’ halting 
dose-escalation using  
3 + 3 + 3 design  
(incl 2 of 3*); (formula 2)
Chance of ‘falsely’ halting 
dose-escalation using  
3 + 3 + 3 design  
(excl 2 of 3*); (formula 3)
5% x=0.05 
y=0.95
0.03 0.01 0.01
20% x=0.20 
y=0.80
0.29 0.19 0.22
30% x=0.30 
y=0.70
0.51 0.42 0.44
* 2 of 3 refers to two dose-limiting toxicities (DLTs) occurring in the first three patients in a specific dose-level.
Each patient its own control
Using every patient as his or her own control is a simple way to introduce a controlled 
situation. In cycle 1, for instance, the patients can be treated with drug A, followed by a 
second cycle in which the combination of drug A + B is administered, without changing the 
dose of drug A (Figure 5). This approach will generate information on additional toxicity due 
to the added agent and leans on the premise, as discussed in Section 4, that thoughts are 
given to the increment in toxicity that is allowed. In this model, dose-escalation decisions 
should relate to the increment in toxicity between cycles 1 and 2 but also include rules with 
regard to the absolute incidence of toxicity. If this latter is not incorporated, the following 
might occur: 3 of 3 patients experience febrile neutropaenia during cycle 1 (not imaginary 
as this will happen in 2% of cohorts of three patients treated with docetaxel). No matter 
how many episodes of febrile neutropaenia do occur in cycle 2, there will be no increment 
in toxicity and dose-escalation will be done.
 This model has some major limitations that need to be addressed in each specific trial 
to which it is applied. For example, most usually a preventive measure (like dose-reduction) 
is taken to avoid repetition of toxicity observed in the previous cycle, whereas in this model 
the single difference between cycles 1 and 2 should only be the addition of drug B and not a 
change in dose. Replacing these patients, on the basis of non-evaluability, is not appropriate 
as it results in an observation bias rendering an underestimation of toxicity.
 If this model is applied, then only agents can be used of which the toxicity has completely 
disappeared at the start of cycle 2 and that do not have cumulative toxicity. For example, 
combining oxaliplatin with placebo might result in an increment in neurotoxicity that falsely 
would be assigned to the placebo.
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Figure 5 | Using each patient as its own control to decide on dose-escalation. Treatment A can be 
either standard treatment or an investigational drug. 
C: compare and if within pre-defined criteria: escalate; DL, dose-level; MTD, maximally tolerated dose.
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Each patient its own control plus randomisation
A second control-method can be added to the model described in the previous paragraph 
by using a randomisation between a group of patients treated according to the model 
described in paragraph 5.2.1 and a group of patients treated with the combination from 
the start. This generates intrapatient information as well as information between the two 
cohorts of patients. Obviously defining the dose-escalation rules for this double-controlled 
phase I trial will be equally challenging (Figure 6).
DL 1 
Treatment A 
DL 1 
Treatment A 
DL 1 
Treatment A 
DL 1 agent X DL 1 agent X 
Cycle 1
DL 1 
Treatment A 
DL 1 
Treatment A 
DL 1 agent X DL 1 agent X 
DL 1 
Treatment A 
DL 1 agent X 
Cycle 2 Cycle 3 and further
®
Figure 6 | At each dose level there is an intrapatient comparison (like that in Figure 4) and an interpatient 
comparison (between the two arms) before deciding on dose-escalation.
R: randomisation
Bayesian approach
This strategy is proposed to deal with the issue of background toxicity if an agent is added 
to standard treatment, especially for treatments with curative intent, for example, chemo-
radiotherapy for locally advanced head and neck cancer, given the fact that alterations in 
the standard treatment can compromise survival. Due to coinciding differences in patient 
group characteristics, the observed incidence of severe toxicity might be higher than that 
expected, even if the added agent was dosed at placebo-level. To circumvent the issue of 
background noise, the Bayesian approach introduces, next to enroling controls at each 
dose-level, adaptive (continual reassessment) design.
 However, if a new agent is added to the standard treatment, the incidence of observed 
toxicity in the trials designating the standard treatment as standard can be used as the a 
priori probability of severe toxicity by means of an adaptive design, by invoking a Bayesian 
approach. Differences in the settings of the current and the pivotal trial can be accounted 
for in the prior probability. The prior probability should be clearly defined before enroling 
the first patient.
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As a small number of controls are enroled at each dose-level (Figure 7), safety data generated 
in the control group, across the dose-levels, are combined with the prior, resulting in a more 
stable and importantly a more robust estimate of the background toxicity in that specific 
population treated solely with the standard treatment. So, the impact of the initial prior will 
thus decrease as more control data are gathered.
 Then, at each dose-level that estimate is used to relate the observed toxicity in the 
group treated with the additional agent added to the standard treatment, to correct for 
coincidence as well as patient selection issues. It is important to note that the adaptive 
design of the Bayesian model uses accumulated data of patients treated solely with the 
standard treatment at all previous dose-levels to decide on dose-escalation (Figure 7).
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Figure 7 | Randomised phase I drug combination trial in which an agent is added to standard treatment: 
continual reassessment of toxicity of the standard treatment in order to compare the toxicity of the 
new combination to controls. 
C: compare and if within pre-defined criteria: escalate. DL, dose-level; MTD, maximally tolerated dose; R: randomisation. n=1 
and 3 are arbitrarily chosen to support the illustration.
A Bayesian approach renders probabilities, and that is an important difference that definitely 
needs a change in mind-set of phase I investigators. Such a probability is presenting the 
data in the opposite way as we are used to in phase I trials, as usually we interpret incidence 
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data in small groups of patients, deliberately ignoring the large uncertainties inherently 
related to a limited sample size.
Determining feasibility in Type 3 studies
If no PK or PD interaction is anticipated, the feasibility of a combination can be proven in a 
kind of phase I/II trial. If we assume that drug A is already regarded as standard treatment 
for a certain tumour type, then patients with this tumour type can be enroled in a trial in 
which all patients start with a combination of drug A and drug B, both at full dose. Such an 
approach is feasible in, for example, the non-small lung cancer patient population in which 
the epidermal growth factor inhibitor erlotinib is combined with a novel c-MET inhibitor 
of which single agent MTD already has been determined. After the first treatment period 
(the feasibility-test period) randomisation can be performed between drug erlotinib plus or 
minus the c-MET inhibitor rendering a randomised phase II population (Figure 8). Instead 
of the classical DLT rules applied in phase I trials, this type of trials should incorporate go/
no go rules based on a safety-interim evaluation observed in the first treatment period in a 
pre-defined number of patients.
 A more conservative approach would utilise two cohorts, beginning with full dose of 
drug A combined with slightly lower dose of drug B. If the safety-interim analysis does not 
detect an excess of toxicity, then subsequent patients can be enroled in the cohort using full 
dose of both drugs.
Erlonib (full single agent dose) 
Erlonib (full single agent dose) 
Erlonib (full single agent dose) 
c-MET inhibitor (full single agent dose) 
c-MET inhibitor (full single agent dose) 
®
Randomised phase II study Feasibility test periode
Figure 8 | Testing of feasibility in drug combinations in which no pharmacokinetic or pharmacodynamic 
interaction is anticipated and one of the agents is regarded as standard treatment for this population. 
As example: erlotinib, regarded as standard therapy, is combined with a novel c-MET inhibitor. 
®: randomisation.
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CONCLuSION
Dose-finding studies are the first step in the clinical development of new combination 
treatment strategies. Combination phase I studies are extremely complex. Designing phase 
I studies is as important as the conduct itself and should be done by dedicated phase I 
researchers since a standard template cannot be made.
 If there is a rationale to develop a specific drug combination, a hypothesis should be 
generated. This hypothesis, based on the anticipated levels of interaction, will be guiding 
for the design of the phase I study, although one should always be open to detect the 
unexpected. A strong consideration is to design studies aiming to potentially determine 
multiple MTDs with final dose determination in randomised phase II trials. Introducing 
controls and the 3 + 3 + 3 design are strategies allowing more grip on combinations with 
high incidence of severe toxicity. Key opinion leaders in the field of phase I oncology trials 
should make joint considerations towards future trial design in combination phase I studies.
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AbstrAct
background: This study aimed to define the maximally tolerated dose (MTD) of sunitinib 
combined with two different infusion schedules of ifosfamide. 
Methods: Patients with advanced solid tumours, good performance score, good organ 
function, and no standard therapy available were eligible. Continuous once daily sunitinib, 
in escalating doses per cohort, was combined with ifosfamide, 9 g/m2 for 3 days or 6 g/m2 
for 5 days, administered every 3 weeks. Pharmacokinetic (PK) and pharmacodynamic (PD) 
assessments were performed.
results: With growth-factor support, the MTD of sunitinib combined with either ifosfamide 
schedule was 12.5 mg in 32 patients enrolled. Neutropenia-related adverse events were 
dose-limiting toxicities. Sunitinib did not affect ifosfamide PK. Ifosfamide significantly 
decreased exposure to sunitinib and increased exposure to its metabolite, SU12662. No 
consistent changes in PD parameters were observed.
conclusion: With growth-factor support, the MTD of sunitinib with both ifosfamide 
schedules was 12.5 mg. Ifosfamide produced decreased sunitinib blood levels because of 
CYP3A induction. As PK interactions cannot explain the relatively low sunitinib doses that 
can be combined with ifosfamide, synergy in toxicity is likely. Whether this also holds true 
for anti-tumour activity needs to be further explored. 
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INTrODuCTION
The introduction of tyrosine kinase inhibitors (TKIs) specifically inhibiting tumour-driving 
factors was accompanied with high expectations with regard to their activity against solid 
malignancies. Their single-agent activity in most tumour types is, however, modest, with 
obvious exceptions in tumours such as renal cell carcinoma (RCC) and gastrointestinal 
stromal tumours (GIST).1,2
 One potential way to augment the activity of TKIs is to combine them with conventional 
cytotoxic agents. In particular, combinations of TKIs targeting the vascular endothelial 
growth factor (VEGF) pathway and conventional cytotoxic agents seem attractive, given 
several potential mechanisms that may yield synergistic anti-tumour effects. Vascular 
endothelial growth factor produced by tumour cells results in the formation of new 
vasculature that is abnormal in structure and more permeable than normal vasculature. This 
causes a high interstitial pressure within the tumour, hindering the penetration of drugs into 
tumours.3 Inhibition of VEGF-mediated effects has been shown to decrease intra-tumoural 
interstitial pressure, thereby enhancing the delivery of concomitantly administered drugs.3-5 
Other mechanisms that may contribute to synergistic interaction between VEGF-pathway 
inhibitors and conventional cytotoxic drugs include prevention of endothelial progenitor 
cell mobilisation from the bone marrow induced by chemotherapy and decreased 
production of tumour factors conferring resistance against chemotherapy.6-10
 Sunitinib is a potent inhibitor of VEGF receptors (VEGFR)1–3, KIT, platelet-derived growth 
factor receptor-α and-β, and Fms-like tyrosine kinase-3 (Flt3), and is one of the first and most 
commonly used VEGFR-TKIs. It is currently registered for the treatment of advanced RCC and 
imatinib-refractory GIST2,11 and is being explored for its anti-tumour activity in a wide range 
of other tumour types. A potential attractive agent to combine with sunitinib is ifosfamide, 
an alkylating agent with established activity against a similar wide range of tumour entities 
including breast cancer, testicular cancer, lung cancer, sarcomas, and central nervous system 
(CNS) tumours such as medulloblastomas.
 This study aimed to define the MTD of ifosfamide combined with sunitinib. Two different 
infusion schedules of ifosfamide were explored. In addition, extensive PK and PD studies 
were conducted.
PATIENTS AND METHODS
Patient selection
Patients with histologically or cytologically confirmed advanced or metastatic solid tumours, 
for whom no standard therapy was available, with an Eastern Cooperative Oncology Group 
(ECOG) performance status <2, were eligible. Other inclusion criteria were evaluable or 
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measurable disease according to RECIST version 1,12 age 18 years, life expectancy 12 weeks, 
adequate bone marrow (neutrophil count 1.5 x 109 cells per L; platelets 100 x 109 cells per 
L; and haemoglobin 6.0 mmol/L), liver (serum bilirubin 1.5 x upper limit of normal (ULN) 
and serum ASAT and ALAT 2.5 x ULN or, if liver metastases were present, 5 x ULN), and renal 
function (serum creatinin 1.5 x ULN and creatinine clearance 60 ml/min), two functioning 
kidneys, systolic blood pressure <150 mm Hg, and diastolic blood pressure <90 mm Hg 
(treatment with two anti-hypertensive drugs was allowed). Main exclusion criteria were 
history of cardiovascular disease, known HIV seropositivity, and signs or symptoms of CNS 
metastases.
 The study was designed and conducted under the approval of appropriate institutional 
review boards (METC 2006–273 and CME 06–273) and in accordance with the principles 
embodied in the Declaration of Helsinki. Written informed consent was obtained from each 
participant.
Study design and drug dosing, escalation, and administration
Daily oral sunitinib was planned to be evaluated in three dose cohorts, 12.5 mg, 25 mg, 
and 37.5 mg, in combination with a fixed dose of ifosfamide, according to one of the 
standard schedules of monotherapy ifosfamide: 9 g/m2 administered as 3-day continuous 
intravenous infusion (CIV) at 3-weekly intervals. After establishing the MTD of sunitinib with 
this dose and schedule of ifosfamide, this sunitinib dose was evaluated with ifosfamide at 6 
g/m2 given as 5-day CIV. The latter ifosfamide schedule was chosen as in multidrug cytotoxic 
schedules; ifosfamide is frequently administered for 5 days, for example, in combination 
with cisplatin and etoposide. Additional patients were treated at the MTD of sunitinib with 
both ifosfamide regimens to get a better insight into the safety profile of the combination 
and to study PK drug-drug interactions. With regard to the latter, patients enrolled in these 
dose-expansion cohorts initiated sunitinib at day 8 of the first cycle instead of at day 1, 
which enables the investigation of the PK of sunitinib alone. On the basis of the mean half-
life of sunitinib (40–60 h), it was anticipated that steady state of sunitinib levels was reached 
before initiating the second cycle of ifosfamide. Samples for PK evaluation were collected 
during the first two treatment cycles. After a protocol amendment because of prolonged 
neutropenia, granulocyte-colony stimulating factor (pegfilgrastim 6 mg once per cycle) was 
administered to all patients. Twelve days before the first administration of study treatment 
and throughout the whole study, concurrent treatment with known CYP3A4 inhibitors or 
inducers was not allowed.
 Using the Common Terminology Criteria for adverse events (CTCAE), version 3.0, dose-
limiting toxicity (DLT) was defined as the following toxicity during the first treatment 
cycle: grade 4 neutropenia 7 days, febrile neutropenia, grade 4 thrombocyto- penia, 
serum creatinine 2 x ULN, and any drug-related grade 3 or 4 non-haematological toxicity 
excluding the following events: nausea and vomiting without optimal supportive care, 
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grade 3 fatigue <7 days, and hypertension not refractory to anti-hypertensive medication. 
If patients developed a systolic blood pressure >160 mm Hg, a diastolic blood pressure 
>100 mm Hg, or an increase in diastolic blood pressure >20 mm Hg, which (despite anti-
hypertensive medication with an ACE inhibitor and a calcium-channel blocker) was not 
adequately controlled within 2 weeks, treatment with sunitinib was stopped. In case of 
grade 4 hypertension, sunitinib was also discontinued. A dose delay or interruption for 
longer than 2 weeks was also classified as DLT.
 A classic 3+3 design was applied, implying that if a DLT was observed in one patient, 
three additional patients were recruited at that dose level, with the dose level escalating if 
no further DLT occurred at that level. If a DLT was observed in 2 patients in a cohort, it could 
be concluded that the MTD had been exceeded. MTD was defined as the highest dose level 
with a DLT incidence of <33%.
 Before commencing each ifosfamide cycle, patients had to have neutrophils X 1.5 x 109 
cells per L and platelets 100 x 109 cells per L. If a patient experienced an ifosfamide-related 
DLT, the dose of ifosfamide was reduced by 25%. A dose reduction of more than 50% of 
the initial ifosfamide dose was not allowed. In those patients experiencing a DLT related 
to sunitinib, sunitinib was withheld for a maximum of 2 weeks. If toxicity resolved to grade 
0 or 1, continuation at the next lower dose cohort level was allowed for the subsequent 
courses. Patients were treated for a maximum of six ifosfamide cycles. Those patients who 
experienced a benefit from the combination of sunitinib and ifosfamide were allowed to 
continue treatment with sunitinib monotherapy. Treatment was continued until disease 
progression or unacceptable toxicity.
PK sampling and analysis
In patients enrolled in the expansion cohorts, blood samples for PK analysis were collected.
 For ifosfamide and its most important metabolites, 2-dechloroethyl- ifosfamide, 
3-dechloroethyl-ifosfamide, and 4-hydroxy-ifosfamide blood samples were collected in the 
presence of lithium heparin as anti-coagulant before infusion and 3, 6, 10, and 24 h after 
the start of ifosfamide infusion, and thereafter every 12 h until the end of infusion, before 
the end of infusion and 1, 3, 6, 12, and 24 h after the end of infusion during the first two 
treatment cycles. Blood samples were centrifuged within 15 min after collection for 10 min 
at 3000 g at 4°C. Subsequently, an aliquot of exactly 1ml of the plasma supernatant was 
transferred into a vial containing 100 μl of a 2M semicarbazide solution and was stored at 
<70°C until analysis of 4-hydroxy-ifosfamide. The remaining plasma was stored at <70°C, 
without any additive, until the simultaneous analysis of ifosfamide and its 2-dechloroethyl 
and 3-dechloroethyl metabolites. Ifosfamide and the 2-dechloroethyl and 3-dechloroethyl 
metabolites were simultaneously quantitated by a validated liquid chromatography tandem 
triple quadrupole mass spectrometry (LC-MS/MS) assay. Analytes were extracted by liquid-
liquid extraction from 10 l aliquots of plasma with cyclofosfamide as internal standard. For 
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4-hydroxy-ifosfamide, a separate LC-MS/MS method was developed and validated. Aliquots 
of 50 μl of semicarbazide-stabilised plasma were extracted by liquid-liquid extraction with 
the same internal standard. Peak area ratios were a function of the concentration from 
50.0 to 5000 ng/ml for all analytes, with the within and between-run precisions 4.9 and 
5.2%, respectively, and the average accuracy ranging from 90.0 to 105.4%. Individual PK 
parameters for ifosfamide, 2-dechloroethyl-ifosfamide and 3-dechloroethylifosfamide, and 
4-hydroxy-ifosfamide were estimated using noncompartmental analysis (1/y weighting 
factor) using the software programme WinNonLin 5.0 (Pharsight, Mountain View, CA, USA).
 For the analysis of sunitinib and its active metabolite SU12662, blood samples were 
taken before dosing every 3–4 days and every day during the second ifosfamide cycle. Blood 
samples were centrifuged within 15 min after collection for 10 min at 3000 g at 4°C. The 
plasma was stored at <-70°C, in tubes wrapped with aluminium foil, until the simultaneous 
analysis of sunitinib and SU12662, as recently published.13
Statistical data analysis
Statistical analysis, using software package SPSS (version 15 (Softonic International, San 
Francisco, CA, USA)), of the changes in sunitinib concentration was carried out by Wilcoxon 
signed ranks test using the pre-ifosfamide sunitinib concentration as comparator. Changes 
in ifosfamide concentration have been evaluated using the same test. Correlation of the 
auto-induction rate of ifosfamide and changes in sunitinib concentrations was carried out 
by the Pearson’s correlation test.
biomarker analysis
Circulating endothelial cell (CEC) enumeration, considered to reflect vascular damage, 
was determined using the CellSearch system (Veridex, LCC, Raritan, NJ, USA).14 Plasma 
concentrations of VEGF and soluble VEGFR2 (sVEGFR2) were determined using ELISA (R&D 
Systems, Minneapolis, MN, USA) according to the manufacturer’s instructions.
rESuLTS
Dose escalation, MTD, and dose intensity
In total, 32 patients were enrolled (Table 1). At the first dose level (sunitinib 12.5mg and 
ifosfamide 9 g/m2 for 3 days), a DLT occurred in two out of six patients; both experienced a 
prolonged, uncomplicated neutropenia (>7 days). This was pre-specified as exceeding the 
MTD. The protocol was amended and subsequent patients were treated with pegfilgrastim. 
The first dose level was repeated and no DLTs were observed. However, in the subsequent 
25mg sunitinib cohort, three DLTs occurred in five patients (two grade 4 febrile neutropenia; 
in one patient, hypertension accompanied by chest pain), indicating that the MTD was 
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exceeded, rendering 12.5mg sunitinib plus ifosfamide 9 g/m2 for 3 days combined with 
pegfilgrastim to be the MTD. After confirming the tolerability at this dose level (in total, one 
DLT in nine patients: grade 3 febrile neutropenia), the safety of this sunitinib dose was tested 
with the second ifosfamide regimen (6 g/m2 for 5 days), also supported with pegfilgrastim. 
In nine patients, one DLT was observed (grade 3 ifosfamide-induced encephalopathy).
 The dose intensities of sunitinib at the MTD were 93 and 98% during combination 
treatment with the 3-day and 5-day schedule, respectively. A median of 4 and 3.5 cycles of 
ifosfamide was administered, resulting in an ifosfamide dose intensity of 93 and 96% for the 
3-day and 5-day schedule, respectively.
Table 1 | Demographics and baseline characteristics (in numbers (%) if not otherwise specified)
Age (median, years) 53 (range 29–74)
Gender
Male 16 (50) 
Female 16 (50)
WHO performance status
0 11 (34)
1 21 (66)
Tumour type
Sarcoma 15 (47) 
Chondrosarcoma 2 (6) 
Leiomyosarcoma 2 (6) 
Liposarcoma 2 (6) 
Ewing sarcoma 2 (6) 
Pleomorphic sarcoma 2 (6) 
Other sarcoma types 5 (16)
Carcinoma of unknown primary tumour 3 (9) 
Neuroendocrine carcinoma 2 (6) 
Non-small-cell lung cancer 2 (6) 
Melanoma (uveal and mucosal) 2 (6) 
Miscellaneousa 8 (26)
Previous non-hormonal systemic anticancer treatment
0 5 (16)
1 18 (56)
2 5 (16)
3 2 (6)
4 2 (6)
Abbreviation: WHO, World Health Organisation. aBile duct carcinoma, breast cancer, adenoid cystic carcinoma, endometrial 
cancer, urothelial cancer, pancreatic cancer, chordoma and cervical carcinoma; for all the cases n, 1.
58 | Chapter 4
Toxicity
The non-haematological toxicity of sunitinib and ifosfamide was mainly grade 1–2 toxicity. 
Haematological toxicity was more pronounced, as grade 3–4 neutropenia was observed 
in 19 patients (59%), resulting in one or more episodes of febrile neutropenia in 7 patients 
(22%) (Table 2). At the MTD, in almost every patient in the 3-day schedule (eight out of 
nine; 89%), grade 3–4 neutropenia, and in four patients febrile neutropenia, occurred 
during combination therapy, whereas only three out nine (33%) patients treated with the 
5-day schedule had grade 3–4 neutropenia, and no episodes of febrile neutropenia were 
observed.
Table 2 | Adverse events during combination therapy of sunitinib and ifosfamide (number of patients 
(%))
First cycle adverse events Adverse events at all  
combination cycles
All grades Grade 3/4 All grades Grade 3/4
Haematological toxicity
Anaemia 28 0 31 2
Thrombocytopenia 19 4 22 9
Neutropenia 14 10 21 19
Febrile neutropenia 3 3 7 7
Non-haematological toxicity
Fatigue 24 2 29 4
Nausea 20 0 24 0
Constipation 20 0 24 0
ALAT and/or ASAT 20 0 21 0
Alopecia 19 0 26 0
Vomiting 14 0 19 0
Creatinine/renal 9 0 12 1
Hypo-/hyperkalaemia 5/1 1/0 5/1 2/0
Bilirubin 5 0 6 0
Diarrhoea 4 0 5 0
Pyrosis 3 0 5 0
TSH increase/decrease 2/2 0 2/2 0
Neurotoxicity 2 1 8 1
Anorexia 2 0 11 1
Haemorrhage 1 1 1 1
ALAT, alanine transaminase; ASAT, aspartate aminotransferase; TSH, thyroid-stimulating hormone.
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Pharmacokinetics
Pharmacokinetic data of sunitinib and ifosfamide were obtained in six patients per 
ifosfamide schedule at the MTD. Plasma concentration time curves of ifosfamide, 
2-dechloroethyl-ifosfamide, 3-dechloroethyl-ifosfamide, and 4-hydroy-ifosfamide were 
not affected by sunitinib (Figure 1). Ifosfamide concentrations were significantly lower 
at 48 h (C48h) compared with 24 h (C24h) in the 3-day and 5-day schedule (40% and 17%, 
respectively; both P=0.028), in line with the known ifosfamide capacity to induce its own 
CYP3A-mediated metabolism.15
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Figure 1 | Mean concentrations (plus s.d.) of ifosfamide, 4-hydroxy-ifosfamide (4-OH-ifosfamide), 
2-dechloroethyl-ifosfamide (N2-DCE-ifosfamide), and 3-dechloroethyl-ifosfamide (N3-DCE-ifosfamide) 
administered alone (open symbols: bars up) or in combination with sunitinib (closed symbols, bars 
down) during the 3-day (open and closed circles) and 5-day (open and closed triangles) continuous 
infusions.
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Sunitinib trough concentrations decreased during ifosfamide infusions during the 3-day 
and 5-day schedule (Figure 2 upper graphs). As presented in Figure 3 (upper panel), trough 
concentrations were significantly lower at 1, 2, and 3 days (P<0.05) after the start of ifosfamide 
infusion in the 3-day schedule, whereas during the 5-day schedule, the decrease was less 
pronounced, not reaching statistical significance. The decrease in sunitinib was paralleled 
by an increase in the trough concentrations of its pharmacologically active metabolite 
SU12662 (Figure 2, lower graphs), which reached statistical significance in both the 3-day 
and 5-day ifosfamide schedules (Figure 3, middle panel). However, the sum of sunitinib and 
its pharmacologically active metabolite, SU12662, slightly decreased during the ifosfamide 
infusions, reaching significance only 1 day after the start of ifosfamide infusion in the 3-day 
schedule (P<0.05) (Figure 3, lower panel).
 The auto-induction rate of ifosfamide, expressed as C48h /C24h, was correlated to the 
decrease in sunitinib trough concentrations, expressed as Cday2/Cday0 (R
2=0.47; P=0.019) 
(Figure 4).
biomarker analysis
Circulating endothelial cell enumeration and determination of plasma concentrations 
of VEGF and sVEGFR2 with serial sampling were successful in 22 patients. A wide range 
in relative changes in the number of CECs from baseline to post-cycle 2 (0.05–35.2) and 
post-cycle 5 (0.09–5.2) was observed. Relative changes from baseline to post-cycle 2 and 
post-cycle 5 were widespread for VEGF (0.04–14.1 and 0.25–5.6, respectively) and less 
outspoken for sVEGFR2 (0.63–1.4 and 0.46–1.1, respectively). No consistent change in time, 
correlation with dose levels, with the occurrence of febrile neutropenia, or tumour response 
was observed for VEGF or sVEGFR2 plasma concentrations or number of CECs.
Anti-tumour activity
All 32 patients were assessable for efficacy. Partial responses were seen during the 3-day 
schedule in three patients (one patient with adenocarcinoma of unknown primary, one 
patient with a sarcoma NOS, and one patient with a liposarcoma). Disease stabilisation was 
observed in 17 patients in whom a prolonged >3 months) disease stabilisation was observed 
in 9 patients (7 out of 23 patients during the 3-day schedule and 2 out of 9 patients during 
the 5-day schedule). The latter group consisted of patients with uveal melanoma, chordoma, 
chondrosarcoma, Ewing sarcoma, uterus sarcoma, endometrial carcinoma, small-cell 
neuroendocrine carcinoma, non-small-cell lung cancer, and carcinoma of unknown primary 
(all entities n=1).
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Figure 2 | Individual plasma concentration time curves of sunitinib in combination with 3-day (n=6) 
and 5-day (n=5) ifosfamide schedule (upper graphs) and of SU12662 in combination with 3-day (n=6) 
and 5-day (n=5) ifosfamide schedule (lower graphs). One patient in the 5-day schedule has not been 
included in the figure as cycle two was delayed by 2 weeks. Bars represent the ifosfamide infusion 
schedules and arrows the first sunitinib administrations.
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Figure 3 | Absolute concentration of sunitinib (upper panel), SU12262 (middle panel), and the sum 
of sunitinib plus SU12662 (lower panel) in patients after the 3-day and 5-day continuous infusions 
of ifosfamide. P-values (Wilcoxon signed rank test) of significant lower or higher relative trough 
concentrations compared with the trough concentrations observed before the start of ifosfamide 
infusions (that is, day 0) are presented. Day – 1 is the sample taken the day before the start of ifosfamide 
infusion and days 1, 2, and 3 are the samples taken 24, 48, and 72 h after the start of ifosfamide 
infusions, respectively. Data are presented as the mean±s.d. of six observations; n=5 for day 2 in the 
3-day schedule.
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Figure 4 | Linear relationship (R2=0.47; P=0.019) between auto- induction of ifosfamide and decrease in 
sunitinib trough concentrations during the 3-day (closed red circles) and 5-day (closed blue triangles) 
ifosfamide infusions.
DISCuSSION
This is one of the first full reports on a combination of sunitinib with a conventional cytotoxic 
agent and the first on the combination of ifosfamide with a VEGFR-inhibiting TKI. Combined 
with ifosfamide at 9 g/m2 given continuously over 3 days, it seemed that the MTD of sunitinib 
is mainly determined by neutropenia-related events. With growth factor support, sunitinib 
at the lowest evaluated dose of 12.5 mg daily was feasible in combination with ifosfamide 
at 9 g/m2 for 3 days and at 6 g/m2 for 5 days. Importantly, our data on the occurrence of 
neutropenia-related adverse events should be appreciated in the context of toxicity from 
ifosfamide monotherapy. Ifosfamide given at 9 g/m2 for 3 days, as an established treatment 
schedule, has an observed incidence in a phase III trial of 62.7% grade 3–4 neutropenia when 
given as first-line therapy. In addition, during a mean number 3.7 cycles of therapy, 19.6% 
of the patients encountered febrile neutropenia.16 Furthermore, sunitinib administered as 
a single agent produces grade 3–4 neutropenia in 12% of patients.2 Given these figures, it 
comes as no surprise that neutropenia-related adverse events were the determining toxicity 
for the MTD of the combination. On the basis of the findings in this study, it is clear that the 
occurrence of neutropenia-related events is not attributable to changes in drug exposure.
Recently, several trials on sunitinib combined with conventional cytotoxic agents have 
been reported, although only in abstract form. The majority of the tested combinations 
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also yielded a high incidence of neutropenia-related events, which were frequently 
dose-limiting toxicities. This held true for the combinations of sunitinib with docetaxel, 
irinotecan, FOLFIRI, carboplatin/ paclitaxel, or gemcitabine/cisplatin, preventing 
sunitinib from being administered at full single-agent.17-25The only two combinations not 
hampered by neutropenia-related adverse events were sunitinib with capecitabine or with 
gemcitabine.26,27
 What becomes apparent from these studies is the fact that the schedule in which 
sunitinib is administered is likely to largely impact the tolerability of combinations in terms 
of neutropenia-related events. The recommended dose of sunitinib as a single agent was 
initially reported as 50 mg administered daily for 28 days every 6 weeks. However, we choose 
to administer sunitinib continuously. Evidence accumulates that persistent inhibition of the 
VEGF pathway might be advantageous over intermittent dosing, although both dosing 
schedules have not been directly compared yet. For combinations, however, toxicity might 
be more pronounced using sunitinib continuously rather than intermittently, as recovery 
from toxicity induced by the cytotoxic agent might be hampered in the presence of sunitinib. 
Accordingly, preliminary data on the combination of sunitinib with FOLFIRI suggest that 
continuous dosing of sunitinib was not feasible because of neutropenia, whereas in 
contrast, sunitinib administered in a 4-week on, 2-week off schedule could be applied at a 
dose of 37.5 mg in combination with FOLFIRI.22 From a mechanism of action point of view, 
the least desirable administration schedule of sunitinib might be best combinable with 
chemotherapy. In contrast, sunitinib continuously administered, as well as administered in 
the 4-week on 2-week off schedule in combination with capecitabine, was tolerated at the 
same sunitinib dose (37.5 mg per day); however, as mentioned before, neutropenia was not 
a major issue in that specific combination.27
 Besides the neutropenia-related adverse events, the combination of (a relatively low 
dose of ) sunitinib, using continuous administration, and ifosfamide was well tolerated 
(Table 2).
 Assessing the PK of both drugs, a clear influence of ifosfamide on the PK of sunitinib 
was observed. This interaction resulted in a decreased systemic exposure to sunitinib and 
an increased exposure to its active metabolite, SU12662. Although the exact contribution 
of the active metabolite SU12662 to the toxicity and efficacy pattern of sunitinib in humans 
is unknown, preclinical data point towards equipotent inhibitory capacities.28 Ifosfamide 
is a potent inhibitor of CYP3A, the enzyme mainly responsible for conversion of sunitinib 
into SU12662.29 This observed drug-drug interaction is in line with findings in healthy 
subjects showing a decreased systemic exposure to sunitinib when concomitantly treated 
with the potent CYP3A inducer rifampicin30 and an increased exposure in the presence 
of ketoconazole, a potent CYP3A inhibitor.31 Pharmacokinetic drug-drug interactions 
have been studied combining sunitinib with gemcitabine, capecitabine, paclitaxel, and 
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docetaxel with or without trastuzumab, but no relevant PK interactions were observed in 
these studies.19,21,26,27
 As a relatively low dose of sunitinib in combination with a standard dose of ifosfamide 
already results in DLT, which cannot be explained by PK interactions, synergy in toxicity 
seems most likely. An explanatory hypothesis for the occurrence of the described 
neutropenia-related events while combining ifosfamide with sunitinib might consist of 
a dual hit. Initially, neutrophils decrease because of the administration of ifosfamide. The 
physiological response of mobilisation and proliferation of haematopoietic progenitor cells 
to restore the neutrophil count is hampered because of inhibition by sunitinib of tyrosine 
kinases involved in haematopoietic progenitor cell survival and proliferation, such as Flt3 
and colony-stimulating factor receptor (CSF-1R). Importantly, a multiple drug combination 
should not be discarded as a result of its low combinability because of synergy in toxicity 
alone, as this synergistic interaction may also occur at tumour cell level.
 As PD parameters, CEC numbers and plasma concentrations of VEGF and sVEGFR2 were 
assessed. Alterations in CEC numbers is likely to reflect vascular damage,32 but no consistent 
changes in CEC numbers could be seen, either during therapy or between the two sunitinib 
doses explored. In contrast to monotherapy with sunitinib,33 no consistent pattern in the 
changes in plasma concentrations of VEGF and sVEGFR2 was observed.
 In conclusion, the MTD of daily sunitinib combined with continuously infused ifosfamide 
(9 g/m2 for 3 days) supported by pegfilgrastim is 12.5 mg. The same dose of sunitinib is 
feasible using an ifosfamide schedule of 5 days (total dose per cycle 6 g/m2). Concomitant 
treatment with ifosfamide significantly decreased the systemic exposure to sunitinib, 
whereas the exposure to its active metabolite, SU12662, increased because of CYP3A 
induction. As PK interactions cannot explain the fact that ifosfamide can be combined safely 
only with relatively low sunitinib doses, synergy in toxicity is likely. Whether this holds true 
for anti-tumour activity needs to be determined, and it is particularly attractive to explore 
this further in tumour types against which both sunitinib and ifosfamide as monotherapy 
exhibit anti-tumour activity, such as soft tissue sarcomas, as well as lung and breast cancer.
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AbSTrACT
Pazopanib is a recently approved, novel tyrosine kinase inhibitor specifically designed to 
impair angiogenesis by abrogating vascular endothelial growth factor receptor 2 (VEGFR-2) 
to exert its function. Pazopanib inhibits VEGF-induced endothelial cell proliferation in 
vitro and angiogenesis in vivo and demonstrates antitumor activity in mouse models. 
Furthermore, the pazopanib concentration resulting in maximal inhibition of VEGFR-2 
phosphorylation in vivo was in line with the steady-state concentration required to inhibit 
growth of tumor xenografts, suggesting that pazopanib’s mechanism of action is indeed 
through VEGFR-2 inhibition.
 In a phase I trial, a generally well-tolerated dose was identified at which the majority of 
patients achieved pazopanib plasma concentrations above the concentration required for 
maximal in vivo inhibition of VEGFR-2 phosphorylation in preclinical models. Administered 
as monotherapy, evidence of antitumor activity was observed in phase II studies in several 
tumor types, including soft tissue sarcoma, renal cell cancer (RCC), ovarian cancer, and non-
small cell lung cancer (NSCLC). Recently, the U.S. Food and Drug Administration granted 
approval for treatment with pazopanib in patients with RCC based on the longer progression-
free survival time observed with this agent in a placebo-controlled, randomized trial. This 
review summarizes the preclinical and clinical pharmacokinetics and pharmacodynamics of 
pazopanib, as well as data on clinical activity, that ultimately resulted in its recent approval. 
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INTrODuCTION
The advent of tyrosine kinase inhibitors (TKIs) has considerably changed the daily practice 
of oncology. This type of anticancer agent can be classified within the larger group of 
the so-called cancer(-cell)-specific therapies, and several of these compounds also target 
infiltrating host cells supporting tumor growth, such as endothelial cells and fibroblasts. 
Over the last several years, major advances have been made in elucidating the pathogenesis 
of tumor growth and metastasis. This has resulted in the identification of numerous tumor 
growth-driving factors, such as VEGFR-2 and platelet-derived growth factor receptor 
(PDGFR). By inhibiting the activity of these factors, it was aimed to specifically intervene in 
tumor pathogenesis and to avoid untoward effects on normal cells.
 After the introduction of imatinib, the first TKI used in solid tumors, the therapeutic 
armamentarium in solid malignancies was expanded by registration of several other TKIs. 
These include the epidermal growth factor receptor (EGFR) inhibitors erlotinib and gefitinib, 
the dual EGFR and human epidermal growth factor receptor (HER)-2 inhibitor lapatinib, and 
the VEGFR inhibitors sunitinib, sorafenib, and, recently, pazopanib. Importantly, none of 
the TKIs are entirely specific for one target. In particular, the VEGFR inhibitors target a wide 
spectrum of kinases, including the PDGFR and fibroblast growth factor receptor (FGFR). 
Additionally, sorafenib is also a strong Raf inhibitor.
 In addition to different mechanisms of action with regard to antitumor activity, TKIs 
are also characterized by a toxicity pattern that is substantially different from that of 
conventional cytotoxic agents. Furthermore, the need to administer these agents more 
or less continuously necessitates a different assessment of tolerability than with classic 
cytotoxic drugs. Compliance with anticancer therapy, and therefore its success, is, to 
a large extent, determined by its toxicity and tolerance. Therefore, getting insight into 
the mechanisms accounting for TKI-mediated toxicity and its manageability is of great 
importance.
 Pazopanib (GW786034), a synthetic indazolylpyrimidine, is a novel multitargeted TKI 
targeting several tumor and tumor environment factors thought to play an important role 
in a broad spectrum of tumor types. The first outcomes of several phase II studies have been 
reported, suggesting antitumor activity in patients with diverse tumor types and showing 
that pazopanib is generally well tolerated. Recently, the first phase III data became available, 
resulting in approval of this agent by the U.S. Food and Drug Administration (FDA) for the 
treatment of patients with RCC. Currently, phase III trials in other tumor entities are ongoing. 
As described, multiple kinases are inhibited by pazopanib. However, the observation that 
bevacizumab, a pure VEGF inhibitor, also has activity in patients with RCC strongly suggests 
that pazopanib’s mechanism of action in RCC is largely through VEGFR-2 inhibition. 
Importantly, it is conceivable that its antitumor effect in other types of cancer depends on 
inhibition of receptors other than VEGFR-2.
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This review summarizes the preclinical and clinical pharmacokinetics (PK) and 
pharmacodynamics of pazopanib as well as data on its clinical activity.
PrECLINICAL DATA
Mechanism of Action
Angiogenesis plays a critical role in the progression of solid malignancies from tumor 
volumes as small as 1–2 mm3.1 Numerous proangiogenic factors are involved in this process, 
with the VEGF family being the most important. The human VEGF family consists of VEGF-A 
(referred to as VEGF), VEGF-B, VEGF-C, VEGF-D, and placenta growth factor. Members of the 
VEGF family bind to the cell surface receptors VEGFR-1, VEGFR-2, and VEGFR-3 on endothelial 
cells to initiate cellular signaling. Of these, VEGFR-2 is the primary tyrosine kinase receptor 
mediating VEGF signaling.
 Because of its central role in angiogenesis, VEGF is considered a pivotal factor in the 
pathogenesis of many tumor types. Increased expression of VEGF has been found in many 
tumor types, including breast cancer (BC), colorectal cancer (CRC), and lung cancer, and is 
associated with a poor prognosis and response to therapy.2,3 Moreover, inhibition of the 
VEGF pathway has been demonstrated to exhibit antitumor activity in clinical studies in a 
wide range of tumor types, including RCC, CRC, NSCLC, and BC.4-7
 Under physiological conditions, VEGFR is only activated by ligand binding. Subsequently, 
ATP is recruited and binds in the so-called ATP-binding pocket of the tyrosine kinase 
region of the receptor. This is followed by the transfer of a phosphate group from ATP to 
VEGFR itself and to various other substrates in a process called phosphorylation. Through 
phosphorylation, downstream signaling pathways become activated, ultimately resulting 
in cellular effects, including proliferation of endothelial cells and recruitment of endothelial 
progenitor cells derived from the bone marrow, both of which are pivotal for angiogenesis.
 Inhibition of VEGF-VEGFR driven processes can be achieved by several approaches. 
Monoclonal antibodies either target the extracellular domain of the VEGFR or trap 
VEGF, thereby preventing VEGF binding to VEGFRs. Another mechanism is through TKIs 
competitively binding to the ATP-binding pocket of the intracellularly located tyrosine 
kinase domain of VEGFR. Consequently, the binding of ATP to VEGFR is hampered, resulting 
in inhibition of the signal transduction from VEGFR.
 Pazopanib is a TKI designed to inhibit angiogenesis by abrogating VEGFR-2 function 
(Figure 1). A widely used parameter reflecting the inhibitory effects of a drug on the kinase 
activity of a certain factor is the inhibition of the autophosphorylation of that factor in vitro. 
The pazopanib concentration required to produce 50% inhibition (IC50) of human VEGFR-2 
kinase activity is 0.03 μM (Table 1).8
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Figure 1 | VEGFR-2 downstream pathway. By binding to the intracellular domain of VEGFR-2, pazopanib 
abrogates this pathway.
Abbreviations: BAD, Bcl-2-associated death promoter; Casp-9, caspase 9; cPLA2, cytosolic phospholipases A2; DAG, 
diacylglycerol; eNOS, endothelial nitric oxide synthase; Erk, extracellular signal-related kinase; FAK, focal adhesion kinase; 
FKHR, forkhead box O1; Grb2, growth factor receptor-bound protein 2; IP3, inositol 1,4,5-trisphosphate; MEK, mitogen-
activated protein kinase/extracellular signal-related kinase; mTOR, mammalian target of rapamycin; PG, prostaglandin; PIP2, 
phosphatidylinositol-bisphosphate; PI3, phosphoinositide 3-kinase; PKC, protein kinase C; PLC- γ, phospholipase C γ; SOS, 
son of sevenless; VEGFR, vascular endothelial growth factor receptor.
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Figure 2 | Steady-state exposure to pazopanib in the individual patients in the phase I study. Reprinted 
from Hurwitz HI, Dowlati A, Saini S et al. Phase I trial of pazopanib in patients with advanced cancer. 
Clin Cancer Res 2009;15:4220-4227, with permission of the American Association for Cancer Research.
In comparison, sorafenib and sunitinib, other TKIs inhibiting VEGFR-2, have IC50 values of 
0.09 and 0.009 μM for inhibiting VEGFR-2 activity, respectively.9,10 Furthermore, pazopanib 
inhibited VEGF-induced proliferation in a human umbilical vein endothelial cell (HUVEC) 
culture in vitro (IC50, 0.02 μM). As observed with other TKIs, pazopanib is not entirely specific 
for one target. Besides VEGFR-2, comparable inhibitory effects were found against VEGFR-1, 
VEGFR-3, PDGFR-α, PDGFR-β, and c-Kit (Table 1).8 Pazopanib inhibition of VEGF-induced 
proliferation of HUVECs in vitro was more pronounced than that of basic FGF-induced 
HUVEC proliferation (IC50, 0.72 μM). Fur thermore, VEGF-induced as well as basic FGF-
induced angiogenesis in a mouse corneal micropocket model was impaired by pazopanib, 
although the inhibition was more pronounced when VEGF was used as the stimulant.8
Preclinical PK Data
Pazopanib is orally available, with 49% bioavailability in dogs.11 In mice, the level needed 
for maximal inhibition of VEGFR-2 phosphorylation occurs in vivo at approximately 
40 μM.8 The discrepancy between in vivo and in vitro requirements can be attributed to 
>99.9% protein binding for pazopanib. PK analysis showed that tumor growth inhibition 
in a xenograft model using a CRC cell line is correlated with the steady-state concentration 
(Ctrough) and not with the peak plasma concentration (Cmax). In addition, the Ctrough required 
for in vivo inhibition of tumor growth in a xenograft model was almost equivalent to the 
concentration required for in vivo inhibition of VEGFR-2 phosphorylation (approximately 
40 μM), suggesting that the drug concentration of pazopanib required for in vivo VEGFR-2 
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inhibition can predict the PK requirements for in vivo antitumor activity of pazopanib.8 In 
mice, a single dose of 30 mg/kg resulted in plasma concentrations >40 μM for >8 hours.8
Table 1 | IC50 of the indicated enzyme activity in a cell-free assay
Enzyme Kinase IC50 (μM)
VEGFR-1 0.010
VEGFR-2 0.030
VEGFR-3 0.047
PDGFR-α 0.071
PDGFR-β 0.084 
c-Kit 0.074
FGFR-1 0.14
FGFR-3 0.13
FGFR-4 0.8
c-Fms 0.146
Abbreviations: c-Fms, colony-stimulating factor receptor; FGFR, fibroblast growth factor receptor; IC50, 50% inhibitory 
concentration; PDGFR, platelet-derived growth factor receptor; VEGFR, vascular endothelial growth factor receptor.
Adapted from Kumar R, Knick VB, Rudolph SK et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human 
with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 
2007;6:2012-2021, with permission of the American Association for Cancer Research.
Preclinical Efficacy and Toxicity
The antitumor activity of pazopanib was demonstrated in several human tumor xenograft 
models in mice, most prominently in an RCC model but also in CRC, NSCLC, and multiple 
myeloma (MM) models. Less potent inhibition was observed in melanoma, BC, and prostate 
cancer models.8,12 Sunitinib and sorafenib, as antiangiogenic class members of pazopanib, 
do share preclinical activity in several tumor types, including RCC, thyroid cancer, pancreatic 
cancer, and hepatocellular cancer (HCC). Furthermore, sorafenib has activity in MM, 
melanoma, and osteosarcoma, whereas sunitinib also exerts antitumor activity in small cell 
lung cancer, urothelial cancer, and acute myeloid leukemia models.
 After cessation of pazopanib, rapid regrowth of MM cells was seen, underlining the 
importance of continuous exposure.12 Because pazopanib has no significant effect on 
the proliferation of most tumor cell lines in vitro, inhibition of angiogenesis is likely the 
mechanism underlying the antitumor effects observed in vivo.
 In addition to its preclinical efficacy as a single agent, synergistic cytotoxic effects of 
low-dose pazopanib combined with conventional chemotherapy (melphalan) or other 
molecular targeted agents (bortezomib) were observed in MM cell lines.12
 Currently, no published data are available on preclinical toxicity with pazopanib.
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CLINICAL DATA
PK Data
Clinical PK data on single-agent pazopanib are available from 63 patients who were enrolled 
in a phase I study.13 Three-times-a-week (50 mg), once-a-day (OD) (50–2,000 mg), and twice-
a-day (BID) (300 mg or 400 mg) schedules were evaluated at 13 dose levels. Pazopanib was 
absorbed orally with median time to maximum concentration (tmax) values in the range of 
2.0–4.0 hours and 2.0–8.0 hours following single and multiple dosing, respectively. Although 
of less relevance because preclinical data strongly suggest that, for antitumor activity Ctrough 
levels are more important, Cmax increased with higher doses of pazopanib. By comparing 
Ctrough at day 22 with the concentration 24 hours after a single dose, accumulation appeared 
to be 1.2- to 4.5- fold.13 The steady-state exposure was dependent on the dose and frequency 
of administration (Figure 2). Steady- state exposure plateaued at doses ≥800 mg/day and 
was ≥15 μg/ml (≈34 J.M) in 93% of patients receiving a dose of 800 mg OD. This Ctrough 
plasma pazopanib concentration of ≥15 μg/ml appeared to correlate with clinical activity in 
patients with RCC as well as with the pharmacodynamic effect of hypertension.13 A separate 
phase I, PK study was performed in HCC patients, showing that, at the maximum-tolerated 
dose (MTD) of 600 mg daily (QD), Ctrough was ≥15 μg/ml in 67% of patients.
14
 Pazopanib was eliminated slowly, with mean half-life values in the range of 20.3–52.3 
hours.13
Drug-Drug Interactions
Two interaction studies are available exploring several doses of pazopanib in 
combination with lapatinib and with paclitaxel. Concurrent administration with lapatinib 
(750–1,500 mg OD), an orally available potent ErbB-1 and ErbB-2 TKI, alters the PK of 
pazopanib, given an increased Ctrough of pazopanib. Lapatinib concentrations were similar 
to those observed after monotherapy.15 In contrast, pazopanib administered concomitantly 
led to a higher mean Cmax and area under the curve of paclitaxel, by approximately 40% 
and 45%, respectively.16 Whether paclitaxel affects the PK of pazopanib has not yet been 
reported.
recommended Dose for Further Studies
In the phase I study, pazopanib was generally well tolerated with continuous daily dosing 
of pazopanib ≤2,000 mg OD. An MTD was not determined. Four patients experienced dose-
limiting toxicities (DLTs) at 50 mg OD (n=2), 800 mg OD (n=1), and 2,000 mg OD (n=1). The 
two DLTs occurring at 50 mg OD were gastrointestinal hemorrhage from a metastatic lesion 
in the small bowel in a patient with RCC and grade 3 extrapyramidal involuntary movements 
resulting from a potential drug-drug interaction between trazadone and pazopanib. Grade 
3 hypertension and subsequently recurring grade 3 proteinuria were seen at the 800-mg 
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pazopanib OD dose despite dose reductions, whereas a DLT comprising grade 3 fatigue 
occurred at the 2,000-mg OD dose, which improved to grade 1 after a dose reduction to 
800 mg OD.13 Despite the DLTs at 50 mg OD and 800 mg OD, dose escalation to 2,000 mg was 
feasible. In the absence of a MTD, the choice of the 800-mg dose as the recommended dose 
for further studies was based on the observation of a plateau in Ctrough at doses ≥800 mg/day, 
significant changes in dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) 
at doses of 300–400 mg BID, a threshold concentration that correlates with preclinical 
activity in patients, and pharmacodynamic effects of hypertension, as discussed below. 
OD administration was recommended for further studies because the fluctuation between 
Cmax and Ctrough with OD dosing was low (~2), rendering drug exposure similar to that with 
continuous infusion.13
 In contrast to pazopanib, for which no MTD has been defined based on toxicity, the MTD 
of sunitinib was set at 50 mg daily for 28 days every 6 weeks, given an excess in toxicity 
(grade 3 asthenia and grade 3 hypertension) observed at doses >50 mg/day.17 For sorafenib, 
skin and gastrointestinal toxicities were dose limiting, rendering an MTD of 400 mg BID.18
 The MTD of pazopanib in patients with HCC has been determined to be 600 mg QD, 
although the observed toxicity has not been reported yet.19
Antitumor Activity
One phase III trial showed a beneficial effect of pazopanib in patients with RCC19 and resulted 
in approval by the FDA. In other tumor types, some interesting signs of anti-tumor activity 
with pazopanib were observed, though it should kept in mind that activity data from phase 
I/II trials should be interpreted with extreme caution.
 In the phase I study, of the 63 patients included, a partial response (PR) was observed 
in three patients and 14 patients achieved stable disease (SD) for >6 months (Table 2).13 Of 
interest is the activity seen in the 10 included patients with RCC: two patients achieved a PR 
(at the 300-mg BID and 1,400-mg OD doses), SD was observed in four patients (at the 300-
mg BID, 800-mg OD [n=2], and 2,000-mg OD doses), and progressive disease (PD) occurred 
in four patients, all at doses ≤400 mg OD. A Ctrough ≥15 μg/ml was achieved in 83% of patients 
with RCC who achieved a PR or SD, whereas all four patients experiencing PD had a Ctrough 
<15 μg/ml.13
 In a randomized discontinuation phase II trial, 225 patients who had received, maximally, 
one prior line of systemic therapy for RCC received pazopanib at a dose of 800 mg OD for 12 
weeks. Pazopanib was continued if a response was achieved at 12 weeks, but in cases of SD 
at 12 weeks, patients were randomized between placebo and continuation of pazopanib. 
Following an interim analysis by the independent data monitoring committee that showed 
a high response rate (38%) in the first 60 patients at week 12, all randomized patients were 
unblinded and allowed to cross over to pazopanib.20 Sixty-nine percent of patients had 
received no prior systemic therapy and 31% had failed one prior systemic therapy (cytokine- 
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or bevacizumab-based therapy).20 In all 225 patients, the complete response (CR) + PR rate 
at 12 weeks was 35%, whereas an additional 45% of patients achieved SD.20 Subsequently, 
a placebo-controlled, randomized phase III trial (n=435) was conducted in therapy-naïve 
or cytokine-pretreated patients with RCC.18 At the interim analysis, a significantly longer 
progression-free survival (PFS) interval was observed (9.2 months versus 4.2 months). The 
response rate (CR + PR) was also more favorable in the pazopanib-treated patients (30% vs 
3%), and a response had a median duration of 59 weeks.19 The difference in overall survival 
was statistically not significant, given the interim O’Brien-Fleming boundary.19 Furthermore, 
clean survival data will most likely not become available because patients on placebo could, 
upon progression, receive pazopanib. No worsening of quality of life was observed in the 
patients treated with pazopanib, versus placebo.19
Table 2 | Signs of activity of single-agent pazopanib
Tumor type n of 
patients
Outcome
Phase I
Solid malignancy [13] 63 3 patients with PR–2 RCC, 1 pancreatic islet cell 
tumor; 14 patients with SD ≥6 mos
HCC [14] 17 SD in 6 of 10 patients treated at MTD;  
PR in 1 of 10 patients treated at MTD
Phase II
Advanced or metastatic RCC [20] 225 Response at 12 wks–CR/PR, 35%; SD, 45%; PD, 11%; 
unknown 10%
Relapsing STS after or during 
chemotherapy [21] 49%; adipocytic STS, 
26%; other STS, 39%
142 PFR12wk–leiomyosarcoma, 44%; synovial sarcoma,
Advanced ovarian cancer [23] 36 CA-125 response in 11 patients (31%)
Stage I–II NSCLC (preoperative treatment) 
[24]
35 Median treatment duration, 18 days; PR, 9%;  
SD, 89%; PD, 3%; 20 (87%) patients had a reduction 
in tumor volume
Relapsed or refractory multiple myeloma 
[26]
21 Median TTP, 52 days; at 6 wks: SD, 47%; PD, 53% 
Phase III
Advanced or metastatic RCC [19] 435 Pazopanib versus placebo: PFS, 9.2 mos versus  
4.2 mos (P<.001); RR (CR + PR), 30% versus 3%
Abbreviations: CA, cancer antigen; CR, complete remission; HCC, hepatocellular carcinoma; MTD, maximum-tolerated dose; 
NSCLC, non-small lung cancer; PD, progressive disease; PFR, progression-free rate; PFS, progression-free survival; PR, partial 
response; RCC, renal cell cancer; RR, response rate; SD, stable disease; STS, soft tissue sarcoma; TTP, time to progression.
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The phase II European Organization for Research and Treatment of Cancer 62043 trial 
explored pazopanib (800 mg OD) in patients with relapsing or refractory soft tissue 
sarcoma (STS).21 The primary endpoint of that study was the 12-week progression-free rate 
(PFR12wk), because the response rate is thought to not adequately reflect the antitumor 
activity of many drugs in STS.22 An interesting PFR12wk, meeting the predefined criteria 
of a potentially active agent, was found in patients with leiomyosarcomas, patients with 
synovial sarcomas, and the group of patients with other eligible STSs (44%, 49%, and 39%, 
respectively). In contrast, there was insufficient activity in adipocytic STS.21
 Furthermore, preliminary data from a small phase II study in women with progressive, 
platinum-pretreated ovarian cancer showed a cancer antigen 125 response (defined as a 
confirmed decrease ≥50% from baseline) in 11 (31%) patients, with a median duration of 
response of 113 days.23
 In preliminary data from a proof-of-concept phase II study evaluating preoperative 
treatment with pazopanib (800 mg OD; median duration, 18 days) in stage I–II NSCLC 
patients, 87% of patients had a reduction in tumor volume, with volume changes in the 
range of -86% to +17%, whereas three patients achieved a PR.24
 In patients with advanced HCC, signs of activity were observed at the MTD, with six of 10 
patients achieving prolonged SD and one of 10 patients achieving a PR. Furthermore, using 
DCE-MRI, a decline of 40% in imaging markers was seen in those 10 patients.15
 No data on single-agent pazopanib in BC patients are available. However, the combination 
of pazopanib (400 mg OD) and lapatinib (1000 mg/day) was recently compared with single-
agent lapatinib (1,500 mg/day) in a randomized, phase II trial in patients with advanced 
or metastatic HER-2-positive BC. Previous chemotherapy or HER-2-directed therapy for 
advanced or metastatic disease was not allowed. A predefined interim analysis after 62 
patients were accrued showed PD rates at 12 weeks, the primary endpoint, of 19% versus 
27%, whereas the response rates were 44% versus 30%, both favoring the combination.26
 Insufficient activity of pazopanib in patients with MM, as shown by a complete lack of 
response at 6 weeks and a termination of the phase II trial.25
Adverse Events
The most common adverse events in the phase I study were hypertension, diarrhea, hair 
depigmentation, and nausea.13 A similar toxicity profile was seen in the phase II and phase 
III studies.19,20,21,23,24
 Similar to other agents targeting the VEGF–VEGFR pathway, hypertension is frequently 
reported during pazo-panib treatment.6,13 In the phase I study, a study-specific hypertension 
definition was used in order to not underestimate the incidence: ≥15 mmHg rise from 
baseline in mean arterial blood pressure on three separate occasions and/or the initiation or 
escalation of antihypertensive medications. Antihypertensive medications were started or 
increased if blood pressure exceeded 160/100 mmHg on three occasions over any 2-week 
80 | Chapter 5
period. By this definition, the incidence was 62%; according to National Cancer Institute 
Common Toxicity Criteria, version 2.0, 29% had grade 3 hypertension. The overall incidence 
of hypertension was similar in patients with and without a history of hypertension (71% 
vs 62%).13 All episodes of hypertension in the phase I study were easily manageable with 
antihypertensive medication; however, temporary interruption or dose reduction because 
of hypertension was needed in two patients.13 Hypertension seems to be correlated with a 
Ctrough ≥15 μg/ml, because 77% of the patients above this cutoff developed hypertension, 
versus only 39% of the patients below this level.14 In the three largest studies conducted to 
date, the incidence of hypertension was 37%–40% (grade 3 or 4, 4%–8%).19-21 Of interest, 
cumulative incidence analysis revealed that, in general, patients develop hypertension 
within 4 weeks after treatment initiation, and only a few patients develop it thereafter.21
 Hair depigmentation, as reported for other agents targeting c-Kit, was observed in 
32%–38% of patients and seen at pazopanib doses ≥600 mg/day.13,19,27 Other frequent, 
mostly mild, toxicities comprised fatigue, anorexia, diarrhea, and skin discoloration. 
Laboratory findings show mild and infrequent bone marrow suppression, whereas 
elevations in aspartate aminotransferase and/or alanine amino-transferase are relatively 
common but rarely a reason for treatment discontinuation (Table 3). Moreover, pazopanib-
induced isolated hyperbilirubinemia is, in most cases, a benign manifestation of Gilbert’s 
syndrome, as shown by UGT1A1 polymorphism in 84% of patients.28 Collectively, it appears 
that pazopanib is generally well tolerated, which is important given the necessity of 
administering this agent for prolonged periods of time. In the two largest phase II studies of 
pazopanib, 6%–15% of patients discontinued treatment because of adverse events.20,21
DISCuSSION
Pazopanib is one of the novel drugs belonging to the rapidly expanding class of TKIs and 
was recently approved for patients with advanced RCC. Although other mechanisms may 
contribute, the main mechanism underlying its antitumor activity in RCC is thought to 
be the inhibition of VEGFR-2, although other inhibited factors will play a role as well and 
might even be of greater relevance in tumor types other than RCC. In vivo, a threshold for 
inhibition of VEGFR-2 by pazopanib has been established, a level paralleling its antitumor 
activity in vivo in preclinical models. Furthermore, it was revealed that a Ctrough above the 
threshold associated with VEGFR-2 inhibition, rather than Cmax, is associated with antitumor 
activity. In humans, a comparable Ctrough level is reached in the majority of patients treated 
at pazopanib doses of 800 mg/day. Based on the finding that doses >800 mg do not result 
in higher Ctrough values, increasing the dose to >800 mg is unlikely to yield better outcomes.
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Table 3 | Reported toxicity in studies on single-agent pazopanib in patients with solid tumors13,14,19-21,23,24,26
Incidence (%)
Toxicity All grades Grade 3 or 4
Nausea 26–42 0–2
Vomiting 17–24 0–2
Anorexia 22–25 0–2
Diarrhea 30–63 4–8
Abdominal cramps/pain 11–16 0–3
Fatigue 19–46 2–11
Headache 10–20 0
Hemorrhage 13 2
Hypertension 40–62a 3–29a
Dysgeusia 13–24 0
Hair discoloration 32–43 1
Skin hypopigmentation 8–37 0
Rash 6–16 <1
Alopecia 8–10 0
Dizziness 5–12 <1
Neutropenia 21–34 1–4
Lymphopenia 19–46 4–14
Thrombocytopenia 10–32 1–2
Bilirubin 13–38 0–6
Aspartate aminotransferase 38–54 2–8
Alanine aminotransferase 24–53 0–19
Creatinine 13–32 0–4
Hypoglycemia 17–33 0–5
Hyperglycemia 33–41 0–3
Hypocalcemia 33–38 0–3
Hyperkalemia 17–26 3–5
Hypophosphatemia 16–34 2–4
aStudy-specific criteria in one trial resulting in the highest incidences.
At a dose of 800 mg, pazopanib is well tolerated, even with long-term use. The side-effect 
profile seems consistent with the tyrosine kinases inhibited. In several phase II trials 
conducted in STS, RCC, relapsing ovarian cancer, and NSCLC, early hints of antitumor 
activity of pazopanib were seen. In the first phase III study, a longer PFS time was observed 
in patients with RCC, resulting in the FDA approval of pazopanib.
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Putting pazopanib into perspective and comparing it with other VEGFR TKIs that have 
been approved for a longer time are difficult and have to be done on the basis of indirect 
comparisons, given the lack of data from comparative trials among the several treatment 
options. With respect to the first-line treatment of patients with RCC, with the clear cell 
subtype and belonging to the so-called good and intermediate prognostic groups, 
according to the Memorial Sloan-Kettering Cancer Center classification,29 three treatment 
options are currently approved: sunitinib, pazopanib, and the combination of bevacizumab 
and interferon. Sorafenib failed to show superiority relative to interferon-α in treatment-
naïve patients.30 Approval of all three treatment options was granted on the basis of longer 
PFS times; however, in the meantime, sunitinib was shown to lead to longer overall survival 
than with interferon-α (26.4 months versus 21.8 months).31 The two pivotal trials on the 
combination of bevacizumab and interferon-α showed superiority over monotherapy 
interferon-α as a result of a longer PFS time, 8.5 months versus 5.2 months and 10.2 months 
versus 5.4 months, respectively.32,33 An indirect comparison was made between sunitinib 
and the combination of bevacizumab and interferon-α, suggesting superiority for sunitinib; 
however, no firm conclusions can yet be drawn.34 In contrast to the other two treatment 
options, pazopanib has not been compared with interferon-a but with placebo, hindering 
a direct comparison. This issue soon will be clarified because a phase III study comparing 
pazopanib with sunitinib is currently enrolling patients. Altogether, based on the current 
data, pazopanib can be regarded as an alternative first-line therapy for these patients, 
in particular for those not tolerating sunitinib or the combination of bevacizumab and 
interferon-α.
 For second-line treatment of RCC patients following cytokine-based therapy, three 
treatment options have gained approval: sunitinib, sorafenib, and pazopanib. Approval for 
sunitinib was based on two single-arm studies,35,36 whereas sorafenib and pazopanib were 
approved on the basis of placebo-controlled trials rendering longer PFS intervals with these 
agents.19,37
 In the two single-arm studies of sunitinib in RCC patients pretreated with cytokine-based 
therapy, sunitinib resulted in objective response rates of 34%–40% and a PFS time of 8.3–8.7 
months.35,36 Pazopanib in second-line treatment was tested in the placebo-controlled trial 
that also examined first-line treatment; the proportion of patients who were cytokine 
pretreated (47%) had a longer PFS duration, 7.4 months versus 4.2 months, while receiving 
pazopanib as compared to placebo.19 Sorafenib treatment led to a longer PFS interval, 5.5 
months versus 2.8 months, in a cytokine-pretreated population.37 Indirectly comparing 
these two trials, neither agent is clearly superior to the other with regard to survival, making 
arguments like differences in the toxicity profiles more important.
 In conclusion, the recent approval of pazopanib for patients with advanced RCC is a 
result of a rational stepwise development using translational research. Based on preclinical 
and early clinical data on pazopanib, further exploration of pazopanib is warranted in tumor 
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types other than RCC. The currently ongoing phase III studies and studies examining the 
feasibility of pazopanib in combination with other antitumor agents will be instrumental in 
defining the place of pazopanib as a novel antitumor agent.
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background: The vascular endothelial growth factor receptor (VEGFR) pathway plays a 
pivotal role in solid malignancies and is probably involved in chemotherapy resistance. 
Pazopanib, inhibitor of, among other receptors, VEGFR1-3, has activity as single agent and is 
attractive to enhance anti-tumour activity of chemotherapy. We conducted a dose-finding 
and pharmacokinetic (PK)/ pharmacodynamics study of pazopanib combined with two 
different schedules of ifosfamide.
Methods: In a 3 + 3 + 3 design, patients with advanced solid tumours received escalating 
doses of oral pazopanib combined with ifosfamide either given 3 days continuously or 
given 3-h bolus infusion daily for 3 days (9 g/m2 per cycle, every 3 weeks). Pharmacokinetic 
data of ifosfamide and pazopanib were obtained. Plasma levels of placental-derived growth 
factor (PlGF), vascular endothelial growth factor-A (VEGF-A), soluble VEGFR2 (sVEGFR2) and 
circulating endothelial cells were monitored as biomarkers.
results: Sixty-one patients were included. Pazopanib with continuous ifosfamide infusion 
appeared to be safe up to 1000 mg per day, while combination with bolus infusion ifosfamide 
turned out to be too toxic based on a variety of adverse events. Ifosfamide- dependent 
decline in pazopanib exposure was observed. Increases in PlGF and VEGF-A with concurrent 
decline in sVEGFR2 levels, consistent with pazopanib-mediated VEGFR2 inhibition, were 
observed after addition of ifosfamide.
Conclusion: Continuous as opposed to bolus infusion ifosfamide can safely be combined 
with pazopanib. Ifosfamide co-administration results in lower exposure to pazopanib, not 
hindering biological effects of pazopanib. Recommended dose of pazopanib for further 
studies combined with 3 days continuous ifosfamide (9 g/m2 per cycle, every 3 weeks) is 
800 mg daily.
89Pazopanib + ifosfamide | 
INTrODuCTION
Given the heterogeneity of cancer, it is conceivable that combinations of anti-tumour 
agents render the best outcomes for patients with advanced solid malignancies.
 The combination of conventional cytotoxic therapy with inhibition of the vascular 
endothelial growth factor receptor (VEGFR) pathway is attractive for several reasons. The 
VEGFR inhibition reduces the interstitial pressure of tumours rendering higher intratumoural 
levels of concomitantly administered cytotoxic agents and enhances effects of several 
cytotoxic agents at the tumour cell level.1-3 In addition, most VEGFR-inhibiting agents have 
no overlapping toxicities with conventional cytotoxics.
 Pazopanib is a tyrosine kinase inhibitor targeting the VEGFR1-3, the platelet-derived 
growth factor receptors α and β and c-kit.4 It received marketing approval for patients 
with metastatic renal cell carcinoma and for patients with advanced non-adipocytic soft 
tissue sarcomas.5,6 The recommended dose of pazopanib is 800 mg once daily with fatigue, 
diarrhoea, nausea, hypertension and elevated liver-enzymes as most common toxicities.6
 Ifosfamide is standard of care for different tumour types including advanced soft tissue 
sarcomas, where a continuous and bolus infusion schedule have shown equivalent activity.7 
Myelosuppression, febrile neutropenia (FN) and encephalopathy are the most relevant 
toxicities.7
 Given the potential of the combination of pazopanib and ifosfamide, we performed a 
phase I study to determine the recommended dose of pazopanib combined with ifosfamide 
in two different schedules.
PATIENT AND METHODS 
Patient selection
Patients with advanced or metastatic solid tumours for whom ifosfamide-based therapy 
was considered appropriate or for whom no standard therapy was available were eligible. 
Other inclusion criteria included: ECOG performance status <2, evaluable or measurable 
disease (RECIST 1.1),8 age 18 years, adequate bone marrow, liver, and renal function, and 
systolic blood pressure (BP) <160 mm Hg and diastolic BP <90 mm Hg (two antihypertensive 
drugs allowed). Main exclusion criteria were: history of cardiovascular disease other than 
hypertension and signs/symptoms of central nervous system metastases.
 The study was approved by the institutional review boards and conducted in accordance 
with the principles embodied in the Declaration of Helsinki. Written informed consent was 
obtained from each participant prior to enrollment.
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Study design
Daily oral pazopanib was evaluated in combination with a fixed dose of ifosfamide 
9 g/m2 per cycle, either given as 3 days continuous intravenous infusion (CIV) or as 3 h bolus 
intravenous infusion (BIV) for 3 consecutive days, both at 3-weekly intervals. Pazopanib was 
escalated in serial cohorts at a dose of 400,800 and 1000 mg daily. If the maximal tolerated 
dose (MTD) would be exceeded at 400 mg then an extra cohort exploring pazopanib at 
200 mg daily was added.
 The 3 + 3 + 3 design, a novel model recently proposed aiming to reduce falsely halting 
dose escalation in combination phase I trials, was applied in the original protocol.10 If a dose-
limiting toxicity (DLT) was observed in one patient, three additional patients were recruited 
at that dose level, with dose escalation proceeding if no further DLT occurred at that dose 
level. If DLT was observed in two out of six, three additional patients were enrolled. If a 
DLT occurred in 2 out of 3, >2 out of 6 or >2 out of 9 patients in a cohort, MTD had been 
exceeded. The MTD was defined as the highest dose level with a DLT incidence of <33%.
 In order to be exposed to steady-state concentrations of pazopanib and to determine 
the effects of ifosfamide administration on pazopanib pharmacokinetics (PK), patients in 
the dose-escalation phase started on pazopanib 7 days prior to the first cycle of ifosfamide. 
At the MTD, six additional patients were treated in an expansion cohort to get better insight 
into the safety profile, to confirm the MTD, and to further study the PK interaction. For the 
latter, pazopanib was started 7 days after the first ifosfamide cycle in the patients in the 
expansion phase, which enabled an intra-patient comparison of ifosfamide PK with or 
without the presence of pazopanib (Figure 1).
Dose escalaon phase
Pazopanib
Dose expansion phase
Pazopanib
Sampling
Ifosfamide Ifosfamide
Sampling Sampling
Ifosfamide Ifosfamide
Figure 1 | Study design. 
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Using the Common Terminology Criteria for adverse events, version 3.0, DLT during the first 
treatment cycle (in the dose expansion phase during the first two treatment cycles) was 
defined as: grade 4 neutropenia 7 days, FN, grade 4 thrombocytopenia, creatinine clearance 
50 ml/min, grade 3–4 proteinuria or any drug-related grade 3 or 4 non-haematological 
toxicity. Hypertension was considered DLT in case of symptomatic hypertension; persistent 
(>24 h) and asymptomatic systolic BP >170 mm Hg and/or diastolic BP >100 mm Hg; systolic 
BP 160–170 and/or diastolic BP 90-100 that could not be controlled within 2 weeks; or an 
increase of diastolic BP >20 mm Hg, which despite antihypertensive medication was not 
adequately controlled within 2 weeks. A dose delay or interruption exceeding 2 weeks was 
classified as DLT. If neutropenia comprised the predominant DLT at a certain dose level, 
that and subsequent levels were explored in combination with granulocyte cell stimulating 
factor (pegfilgrastim 6 mg once per cycle).
 Patients were treated for a maximum of six ifosfamide cycles. Patients experiencing 
clinical benefit from the combination of pazopanib and ifosfamide were allowed to continue 
treatment thereafter with pazopanib until disease progression or unacceptable toxicity.
PK sampling and analysis
Concentrations of ifosfamide and its most important metabolites, 2-dechloroethyl-
ifosfamide, 3-dechloroethyl-ifosfamide and 4-hydroxy-ifosfamide were quantitated as 
previously reported in 11–16 samples per ifosfamide cycle.11
 For the analysis of pazopanib, 15 samples per patient were drawn and quantitated as 
previously reported.12
Statistical data analysis
Plasma concentrations of ifosfamide and its metabolites were plotted as a function of time. 
Area under the curve (AUC) was calculated by the trapezoidal method. Non-compartmental 
PK analysis including half-life (T½, h) was calculated using the software package WinNonlin 
version 6.1. Total body clearance of ifosfamide was calculated by dividing the administered 
dose by the AUC of ifosfamide. Statistical analysis were made using the software package 
SPSS (v20). Correlation of the changes in AUC or clearance and half-life was evaluated by a 
two-sided paired t-test for subjects in the expansion cohorts.
 Median plasma pazopanib concentration-time profiles were generated for subjects in 
the dose escalation cohorts. The area under the plasma pazopanib concentration–time 
curve from 0 to 24 h (AUC (0–24)) was calculated using nominal blood sample collection 
times after administration of pazopanib on day 21 cycle 1 (pazopanib alone) and day 3 cycle 
2 (pazopanib plus ifosfamide) for subjects in the expansion cohorts.
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biomarker analysis
Biomarker samples were collected in all patients at baseline and prior cycle 2 day 1. During 
the escalation phase, an additional sample was drawn prior to day 1 cycle 1 and during the 
expansion prior to the first pazopanib dose. Circulating endothelial cell (CEC) enumeration 
was determined with a flow-cytometry-based method.13 Plasma concentrations of VEGF-A, 
soluble VEGFR2 (sVEGFR2) and placental-derived growth factor (PlGF) were determined 
using ELISA (R&D Systems, Minneapolis, MN, USA) according to the manufacturers’ 
instructions.
rESuLTS
Dose escalation, MTD and dose intensity
In total, 61 patients were enrolled (Table 1), 29 in the CIV schedule and 32 on the BIV 
schedule. In all, 15 out of 61 patients were not evaluable for determination of DLT of the 
combination and were replaced. The most common reason was early progression (n=5). Two 
other patients were registered but did not receive a dose of study drug at all. Three patients 
appeared not to tolerate the single agent treatment they received before the second agent 
was added. As the aim of this study was to identify the MTD of the combination of pazopanib 
and ifosfamide, it was decided to replace these patients. Five others were not evaluable due 
to a diversity of reasons including withdrawal of consent (not based on toxicity), and an 
allergic reaction to mesna, which was prophylactically administered with ifosfamide.
 In the CIV arm, no DLTs were observed in the three evaluable patients at the first dose 
level, whereas 1 DLT (FN) was observed at a dose level with 800 mg pazopanib (six evaluable 
patients). At the highest pre-defined dose level of 1000 mg pazopanib two DLTs occurred 
(FN and encephalopathy) in nine patients. During expansion phase (n=6) at this dose level, 
no additional DLTs were observed. At the MTD in the CIV arm, the dose intensity of ifosfamide 
and pazopanib was 92% and 93%, respectively, with a median number of ifosfamide cycles 
of 4.
 In the first two patients treated with 400 mg pazopanib in the BIV arm, an episode of 
FN was encountered. Adding G-CSF to the 400 mg pazopanib dose level three DLTs were 
observed in nine patients (grade 3 encephalopathy, grade 3 proteinuria and grade 3 
pneumonia during neutropenia). The dose of pazopanib was de-escalated to 200 mg and 
supported with G-CSF. In two out of the first nine evaluable patients DLTs occurred (one case 
each of grade 3 encephalopathy and FN). The subsequent dose expansion in another six 
patients resulted in three more DLTs (pneumonia during neutropenia and grade 5 cardiac 
arrest in one patient, renal toxicity and grade 3 fatigue).
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Table 1 | Demographics and baseline characteristics
Age (median, years) 56 (range 18–76)
Gender
Male 40 (65)
Female 21 (35)
WHO
0 23 (38)
1 38 (62)
Tumour type
Sarcoma (incl GIST) 19
Melanoma 6
Urothelial carcinoma 6
Ovarian carcinoma 5
Carcinoma of unknown primary 5
Prostate 4
Gastric carcinoma 3
Oesophageal carcinoma 3
Miscellaneous 10
Previous non-hormonal systemic anticancer treatment
0 12
1 29
2 11
3 3
4 4
5 1
Abbreviation: GIST, gastro-intestinal stromal tumour.
Toxicity
In addition to hematological toxicity, the main grades 3–4 toxicities during combination 
therapy were fatigue and hypophosphatemia, irrespective of treatment schedule. Grade 
3–4 vomiting was more pronounced in the BIV-treated patients, whereas all grades of 
hypertension and grade 3/4 neutropenia occurred more often in the CIV group. (Table 2).
Pharmacokinetics
Pazopanib had no impact on plasma half-life, AUC or clearance, of ifosfamide or any of 
its metabolites. Figures 2 and 3 depicts the ifosfamide concentrations with and without 
concomitant administration of pazopanib.
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Table 2 | Most frequent adverse events during the first and during all combination cycles
CIV (n=26) bIV (n=27)
First cycle  
adverse events
Adverse events  
at all combination 
cycles
First cycle  
adverse events
Adverse events  
at all combination 
cycles
Grade  
3/4
All 
grades
Grade  
3/4
All 
grades
Grade  
3/4
All 
grades
Grade  
3/4
All 
grades
Anaemia 1 21 5 26 0 23 4 27
Thrombocytopaenia 1 7 3 13 3 14 5 17
Neutropaenia 23 24 25 25 13 16 15 19
Fatigue 2 24 6 25 2 20 5 23
Nausea 1 24 2 25 2 22 2 23
Vomiting 0 15 0 21 5 20 6 21
Mucositis 0 8 0 11 0 4 0 8
Anorexia 0 17 0 22 1 15 4 18
Constipation 0 17 0 19 0 13 0 15
Diarrhoea 0 10 0 15 1 7 1 11
Hypertension 1 10 2 13 1 3 2 4
Encepahlopathy 1 10 1 14 2 9 3 14
ALAT 0 13 0 19 0 11 1 12
ASAT 0 14 1 19 0 12 0 16
Hypophosphatemia 2 11 5 13 1 12 5 17
Proteinuria 1 11 1 12 0 9 0 15
Abbreviations: ALAT, alanine aminotransaminase; ASAT, aspartate aminotransferase; BIV, bolus intravenous infusion; 
CIV, continuous intravenous infusion.
In contrast, pazopanib concentrations declined by ~35% within 72 h during concomitant 
ifosfamide infusion in patients in the dose escalation phase during CIV (Figure 4). There 
seems to be a time-dependent effect, resulting in comparable median plasma pazopanib 
concentrations at the end of ifosfamide infusion across dose-levels of pazopanib (Figure 
4). There seems to be a time-dependent effect, resulting in comparable median plasma 
pazopanib concentrations at the end of ifosfamide infusion across dose-levels of pazopanib 
(Figure 4).
 PK analysis in patients treated in the dose expansion phase revealed that the mean 
AUC (0–24) of pazopanib was reduced by ~27% upon co-administration of ifosfamide as 
compared with the AUC of pazopanib single agent (Figure 5).
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Figure 2 | Mean concentrations (plus SD) of ifosfamide administered alone (closed symbols: bars up) 
or in combination with pazopanib (open symbols, bars down) during the 3-days continuous infusions. 
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Figure 3 | Mean concentrations (plus SD) of ifosfamide administered alone (closed symbols, bars up) or 
in combination with pazopanib (open symbols, bars down) during 3 consecutive bolus infusion days.
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Figure 4 | Median plasma pazopanib concentration time profile (dose escalation, in patients with 
continuously given ifosfamide).
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Figure 5 | Pazopanib area-under-curve (AUC) administered as single agent (day 21, cycle 1) versus 
combined administration with continuous ifosfamide (day 3, cycle 2) in the dose expansion phase.
biomarker analysis
During the treatment with pazopanib, there was a dose-dependent increase in PlGF and 
VEGF-A with a concurrent decline in sVEGFR2 (Table 3). Importantly, this phenomenon 
remained intact after the addition of ifosfamide. No consistent pattern was seen by 
enumeration of CEC (data not shown).
Anti-tumour activity
Of 45 patients evaluable for response, 10 partial responses were observed: 4 in the CIV-
treated patients (2 patients with synovial sarcoma, 1 each with ovarian and prostate cancer) 
and 6 patients in the BIV schedule (urothelial cancer (n=2), one each with sarcoma not 
otherwise specified, mesothelioma, ovarian cancer and an cancer of unknown primary). 
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Prolonged disease stabilisation defined as stable disease for at least 3 months was noted in 
nine and five patients in the CIV and BIV group, respectively.
Table 3 | Biomarkers in the dose escalation cohorts (baseline normalised to 1)
Ifosfamide 
schedule
biomarker Pazopanib  
dose
baseline After 7 days pazopanib but 
prior to first ifosfamide
Prior to second 
ifosfamide
CIV PlGF 400 1 1.75 1.35
800 1 6.87 8.46
1000 1 7.13 4.39
VEGF-A 400 1 1.08 0.54
800 1 5.26 5.72
1000 1 3.85 2.73
sVEGFR2 400 1 0.89 0.88
800 1 0.77 0.70
1000 1 0.76 0.69
bIV PlGF 200 1 1.81 1.75
400 1 2.40 3.24
VEGF-A 200 1 1.72 3.12
400 1 1.96 2.20
sVEGFR-2 200 1 0.89 0.81
400 1 0.79 0.77
Abbreviations: BIV, bolus intravenous infusion; CIV, continuous intravenous infusion; PlGF, placental-derived growth factor; 
sVEGFR2, soluble VEGFR2; VEGF-A, vascular endothelial growth factor-A.
DISCuSSION
In this study, we explored safety and tolerability of the combination of pazopanib and 
ifosfamide, and its possible dependence on the ifosfamide infusion schedule. Pazopanib 
in combination with BIV-administered ifosfamide turned out to be intolerable. In contrast, 
if ifosfamide is continuously administered over 3 days, pazopanib could be escalated to 
dose levels exceeding the registered single agent dose of 800 mg daily. The inclusion of 
a dose higher than the registered single agent dose was done, since in a previous study a 
drug-drug interaction between ifosfamide and sunitinib resulted in a decreased exposure 
to sunitinib.11 This observation was confirmed in the current study, showing a PK interaction 
between pazopanib and ifosfamide.
 Our study clearly underlines that the administration schedule of one of the drugs of a 
combination can have a major impact on the tolerability of the combination. One of the 
98 | Chapter 6
reasons that could account for the observed differences in tolerability between the two 
schedules of ifosfamide might be a schedule-dependent drug-drug interaction. Previously, 
pazopanib has demonstrated PK interactions with conventional chemotherapy, resulting 
in higher exposure to paclitaxel or the combination of paclitaxel and carboplatin.14-16 In 
contrast, combining pazopanib with full-dose gemcitabine was feasible up to 800 mg 
pazopanib and no PK interaction was found.17 Currently, extensive PK analysis did not show 
an impact of pazopanib on serum levels of ifosfamide or its metabolites.
 In contrast, pazopanib exposure was clearly lowered by concurrent infusion of ifosfamide. 
This effect of ifosfamide on pazopanib levels yielded in similar pazopanib concentrations at 
the end of the ifosfamide infusion, regardless of the dose of pazopanib given. A potential 
underlying mechanism might be ifosfamide’s inductive effects on CYP3A18 for which 
pazopanib, in addition to being a weak inhibitor, is also a substrate.19 If the induction of 
CYP3A by ifosfamide is indeed the cause of the decreased pazopanib exposure, this could 
imply that other drugs able to induce CYP3A should be avoided during pazopanib therapy 
but this warrants further exploration.
 Yet, this PK interaction does not explain the striking difference in tolerability between 
the CIV and BIV schedule. In a study in patients with soft tissue sarcoma, BIV and CIV 
administrations of ifosfamide were compared demonstrating CIV to be slightly less toxic 
in terms of a lower rate of treatment discontinuation due to toxicity and a lower incidence 
of grade 3–4 dyspnoe and infection. However, CIV induced a higher incidence of grade 3–4 
anaemia and grade 2–3 nausea than BIV ifosfamide. 7 The higher incidences of grade 3–4 
neutropenia in the CIV schedule (88%; 23 out of 26 patients) compared with the BIV (48%; 
13 out of 27 patients) observed in this study were in contrast with the study by Lorigan et al 
in which comparable incidences in CIV- and BIV-treated patients for grade 3–4 neutropenia 
incidence (62.7% vs 60.0%) were found.7 This strongly suggests that the potentiating effect 
of pazopanib on the occurrence of neutropenia depends on the chosen infusion schedule. 
Auto-induction of ifosfamide is 52% higher during bolus infusion as compared with 
continuous infusion20 and as a result higher concentrations of ifosfamide are generated. 
Accordingly, the AUC0–72 of ifosfamide in our trial was indeed higher during bolus infusions 
as compared with the continuous infusion (3149 μg*h/ml vs 2234 μg*h/ml, respectively).
 Three cytokines known to reflect biological effects from VEGFR-TKIs showed alterations in 
PlGF, VEGF-A and sVEGFR levels following exposure to pazopanib consistent with inhibition 
of VEGFR2 activity.21 Ifosfamide did not nullify these pazopanib-induced biological effects, 
so ifosfamide does not hinder pazopanib to exert biological effects despite its lowering 
effects on pazopanib-levels.
 This study shows that the upper boundary of safe dosing is, at least, 1000 mg per day 
pazopanib with CIV ifosfamide 9 g/m2. Like the single-agent pazopanib dose-finding study, 
the tolerable dose is higher than the currently approved dose, chosen on the basis of PK 
parameters and analyses of biological activity.11 On the basis of the facts that the exposure 
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to pazopanib during ifosfamide is comparable in patients using 1000 mg per day and 800 
mg per day after 48 h (Figure 4) and that the pharmacodynamic parameters showed that the 
short period of lower pazopanib levels using 800 mg compared with 1000 mg pazopanib 
did not have any effects on the pazopanib-induced biological effects, both in line with 
findings from the phase I trial on pazopanib monotherapy,12 we recommend as dose for 
further studies 800 mg pazopanib and CIV ifosfamide 9 g/m2.
 Importantly, this is the first phase I study to apply the 3 + 3 + 3 design. This pre-planned 
design for combination phase I trials aims to eliminate chances of falsely halting dose 
escalation, based on a high a priori chance of developing a DLT of one of the drug.10 In the 
CIV arm, two out of the first six patients at the 1000 mg pazopanib dose level experienced 
a DLT. According to the conventional 3 + 3 design, this would have been interpreted as 
toxicity exceeding MTD. However, no DLTs were encountered in the other nine patients 
enrolled in this dose level. This strongly underscores the clinical applicability of this 3 + 3 + 3 
approach in establishing the tolerability of drug combinations.
 In conclusion, this study has clearly demonstrated that tolerability of pazopanib and 
ifosfamide is dependent on the infusion schedule. An evident explanation for the observed 
differences is not readily available. Furthermore, ifosfamide appeared to lower pazopanib 
levels, but despite the lower levels of pazopanib, it still exerted biological activity. In addition, 
this study stresses the importance of the 3 + 3 + 3 design for exploring drug combinations in 
phase I studies when one of the agents is known to induce high rates of toxicity. Last, based 
upon our data the dose recommended for pazopanib when combined with CIV ifosfamide 
9 g/m2 is 800 mg, while a combination with bolus ifosfamide is not feasible. Further studies 
on the combination of pazopanib and ifosfamide are currently being designed.
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background: There are several reasons why combining an inhibitor of the vascular 
endothelial and the platelet derived growth factor receptor (VEGFR and PDGFR) with a 
taxane might induce synergistic anti-tumor activity. This phase I study aimed to determine 
the maximal tolerated dose (MTD) of the combination of pazopanib with two different 
schedules of docetaxel.
Patients and Methods: In a 3+3+3 design, patients with advanced solid tumors received 
escalating doses of oral pazopanib combined with docetaxel either given every 3 weeks 
(D3w) or weekly at days 1,8 and 15 every 28 days (D1w). Pharmacokinetic data of docetaxel 
and pazopanib were obtained through extensive sampling and WinNonlin modelling.
results: Forty-six patients were enrolled to 6 dose-levels. Both schedules of docetaxel could 
be combined with 400 mg/day pazopanib. The MTD of D3w docetaxel was 50 mg/m2, while 
for D1w MTD it was 20 mg/m2. In the D3w schedule, the administration of pazopanib led to 
a 33% lower docetaxel clearance (mean 31.5 versus 21.1 L/h/m2; P=0.019) and >50% increase 
in AUC0-∞ (mean 1,602 versus 2,414 ng*h/mL; P=0.029) compared to docetaxel single agent 
data. Data for the D1w schedule were comparable.
Conclusion: Both treatment schedules of docetaxel combined with pazopanib are feasible 
but at doses for both drugs that are considerably lower than the recommended single 
agent doses. This is largely due to a clinically relevant pharmacokinetic interaction with 
pazopanib, substantially increasing docetaxel exposure. This interaction is most likely due 
to CYP3A4 and OATP1B1 inhibition. 
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INTrODuCTION
Activation of the signalling transduction pathways of the vascular endothelial growth 
factor receptor (VEGFR)- as well as the platelet derived growth factor receptor (PDGFR) are 
thought to be involved in tumor initiation and progression in various tumor types. In the 
last decade, several compounds targeting these pathways have been approved in several 
tumor types. Combining such agents with conventional cytotoxic agents has been explored 
quite extensively, as it is believed that based upon the unique mechanisms of action, these 
combinations might have synergistic anti tumor activity. Reduction of interstitial pressure, 
(pseudo-)normalisation of tumor-vasculature increasing drug penetration and blocking the 
mobilisation of endothelial progenitor cells induced by cytotoxics have been considered to 
be biological mechanisms underlying this synergism.1
 Pazopanib is an orally available potent tyrosine kinase inhibitor known to inhibit 
VEGFR1-3, PDGFR α and β, and c-Kit2 and has been approved for treatment of patients 
with metastatic renal cell carcinoma and advanced non-adipocytic soft tissue sarcomas.3,4 
The recommended dose of pazopanib is 800 mg once daily with fatigue, diarrhea, 
nausea, hypertension and elevated liver-enzymes as most common toxicities.4 Pazopanib 
is metabolized mainly through CYP3A4 mediated conversion to inactive metabolites. 
Patients with impaired liver functions do not tolerate pazopanib at its recommended dose, 
although this cannot fully be explained by pharmacokinetics.5 Co-medication, influencing 
the absorption and metabolism of pazopanib is known to dramatically alter the area under 
the curve (AUC) of this drug.6
 Docetaxel, a semisynthetic taxane, is one of the most commonly used antitumor 
agents and acts by disrupting the essential microtubular network in cells. Docetaxel is an 
intravenously administered anticancer drug with marketing approval for the treatment of 
a range of solid tumors including breast, prostate, lung and gastric carcinoma. Although 
highly active, docetaxel is well known for its side-effects, including (febrile) neutropenia and 
neurotoxicity. In addition, docetaxel is prone for an altered exposure due to concomitantly 
administered medication. This is partly due to its phase I metabolism (mainly through 
CYP3A iso-enzymes), and probably also because of its hepatic transport via OATP1B.7-9
 This study aimed to determine the feasibility and the maximal tolerated doses (MTD) 
of the combination of pazopanib with two different schedules of docetaxel, and to assess 
potential interactions between these drugs. 
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PATIENTS AND METHODS
Patients with advanced or metastatic solid tumors for whom docetaxel-based therapy was 
considered appropriate, or for whom no standard therapy was available, were eligible. 
Other inclusion criteria included: ECOG performance status <2, evaluable or measurable 
disease according to RECIST 1.1,10 age ≥18 years, and systolic blood pressure <160 mmHg 
and diastolic blood pressure <90 mmHg (two antihypertensive drugs were allowed to 
control blood pressure). At laboratory evaluation an adequate bone marrow (hemoglobin 
≥5 mmol/L; platelets ≥100 x 109/L, absolute neutrophil count ≥1.5 x 109/L), liver (bilirubin 
<1.25 upper limit of normal (ULN); serum alanine and aspartate aminotransferase <2 x ULN; 
alkaline phosphatase <2.5 x ULN) , and renal function (creatinine clearance ≥ 50 mL/min 
and proteinuria grade 0 or 1) was also an entry criterion. Main exclusion criteria were: 
history of cardiovascular disease other than hypertension, and signs/symptoms of central 
nervous system metastases. 
 The study was approved by the institutional review board (MEC-2009-462) and 
conducted in accordance with the principles embodied in the Declaration of Helsinki. 
Written informed consent was obtained from each participant prior to enrolment.
Study design
Daily oral pazopanib was evaluated in combination with intravenously administered 
docetaxel, either given every 3 weeks (D3w) or weekly on days 1, 8 and 15 every 28 days 
(D1w). First, the MTD with D3w was determined while alternately escalating pazopanib and 
docetaxel (see Table 1 for the chosen dose-escalation steps). In D1w the starting dose of 
pazopanib was one dose level lower than the MTD in D3w. For docetaxel the starting dose 
was also based upon the recommended dose of the D3w schedule using a conversion table. 
For both the D3w and D1w schedules, dose de-escalation guidelines were incorporated if 
MTD was exceeded at the first dose level.
 The 3+3+3 design, a novel model recently proposed aiming to reduce falsely halting 
dose escalation in combination phase I trials, was included in the original protocol.11 Briefly, 
if a dose limiting toxicity (DLT) was observed in one patient, three additional patients were 
recruited at that dose level. The dose escalation proceeded, if no further DLT occurred at 
that specific dose level. If a DLT was observed in 2 out of 6, another three additional patients 
were enrolled. If a DLT occurred in 2 out of 3, >2 out of 6, or >2 out of 9 patients in a cohort, 
the MTD had been exceeded. The MTD was defined as the highest dose level with a DLT 
incidence < 33% out of at least 9 patients.
 In order to be exposed to steady-state concentrations of pazopanib and to 
adequately determine effects of docetaxel administration on pazopanib PK, patients in 
the dose-escalation phase started on pazopanib seven days prior to the first docetaxel 
administration. At the MTD, six additional patients were treated in an expansion cohort 
105Pazopanib + docetaxel | 
to get better insight into the safety profile, to confirm the MTD, and to further study the 
putative pharmacokinetic interaction. For the latter, pazopanib was started one day after 
the first docetaxel administration, enabling intra-patient comparison of docetaxel PK with 
and without pazopanib. 
 Using the National Cancer Institute – Common Terminology Criteria (NCI-CTC) for 
adverse events, version 3.0, a DLT during the first treatment cycle (in the dose expansion 
phase during the first two treatment cycles) was defined as: any toxicity giving rise to a 
dose omission on day 8 or 15 docetaxel in the weekly schedule; febrile neutropenia (FN); 
grade 4 neutropenia ≥7 days; grade 4 thrombocytopenia; grade 3–4 proteinuria or any 
drug-related grade 3–4 non-haematological toxicity. Hypertension was considered DLT 
in case of symptomatic hypertension; persistent (>24 hours) and asymptomatic systolic 
blood pressure (BP) ≥170 mmHg and/or diastolic BP ≥110 mmHg; systolic BP 160–170 
and/or diastolic BP 90–110 that could not be controlled within two weeks. A dose delay or 
interruption for longer than two weeks was classified as DLT. 
 Patients were treated for a maximum of six docetaxel cycles. Patients experiencing 
clinical benefit from the combination of pazopanib and docetaxel were allowed to continue 
treatment thereafter with pazopanib until disease progression or unacceptable toxicity.
Pharmacokinetic sampling and analysis 
For the analysis of docetaxel 11 (in the escalation phase) or 14 (in the expansion phase) 
plasma samples per patient were obtained and quantitated as previously reported.12
 For the analysis of pazopanib, 7 (in the escalation phase) or 14 (in the expansion phase) 
samples per patient were drawn and quantitated as previously reported.13
Statistical Data Analysis
Plasma concentrations of docetaxel were plotted as a function of time. Areas under the 
curves extrapolated to infinity (AUC0-∞) were calculated using the trapezoidal method. Non-
compartmental PK analysis was calculated using the software package Phoenix WinNonlin 
(Pharsight, Mountain View, CA). Total body clearance of docetaxel was calculated by 
dividing the administered dose by the AUC0-∞ of docetaxel. Statistical analyses were made 
using the software package SPSS version 20 (SPSS Inc). Correlation of the changes in AUC, 
peak plasma concentration (Cmax) or clearance was evaluated by a two-sided paired t-test for 
subjects in the expansion cohorts.
 Pazopanib plasma concentration data was analyzed via non-compartmental analysis 
using Phoenix WinNonlin. Parameters recovered were Cmax and AUC0-τ (area under the plasma 
concentration-time curve within a 24h dosing interval). Parameters were summarized as 
means +/- SD. 
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Table 1 | Dose escalation steps (D3w: docetaxel every 3 weeks; D1w: docetaxel weekly on days 1, 8 and 
15 every 28 days; DLTs: dose-limiting toxicities)
Pazapanib-dose 
mg/day
Docetaxel-dose 
mg/m²
Number of 
evaluable patients
DLTs
D3w
Dose level 1 400 60 5 3
Dose level 2 400 50 6 0
Dose level 3 600 50 3 2
Dose level 2 expansion 400 50 6 1
D1w
Dose level 1 200 20 6 1
Dose level 2 400 20 6 1
Dose level 3 400 25 3 2
Dose level 2 expansion 400 20 6 2
rESuLTS
Dose escalation, MTD and dose intensity
Overall, 46 patients (equally distributed over D3w and D1w) were enrolled. Five patients 
were not evaluable (Table 2). Most of the non-evaluable patients did not receive the 
combination of drugs, for example because of early progression or clinical deterioration.
 Table 1 summarizes the dose levels and the observed DLTs per dose level. In D3w, 3 
DLTs were observed in five patients at the first dose level (400 mg pazopanib plus docetaxel 
60 mg/m2): one episode of febrile neutropenia, two episodes of mucositis grade 3. At the 
dose level of 400 mg pazopanib plus docetaxel 50 mg/m2 no DLT was observed in six 
patients. Subsequent escalation of pazopanib to 600 mg plus docetaxel 50 mg/m2) resulted 
in two out of three patients with a DLTs: one episode of grade 3 increased transaminases and 
one episode of prolonged neutropenia grade 4 for more than eight days. Dose expansion 
was performed with six patients at 400 mg pazopanib plus docetaxel 50 mg/m2, resulting in 
one additional DLT: cardiac failure resulting in therapy-refractory cardiogenic shock (grade 
5) in a patient with pre-existent hypertension.
 At the MTD, the relative dose intensity of docetaxel and pazopanib was 98.6% and 95.5% 
respectively, with a median number of four combination therapy cycles.
 In the D1w schedule, one DLT (grade 3 increased transaminases) was observed in the 
first cohort of 200 mg pazopanib plus docetaxel 20 mg/m2. At the second dose level (400 
mg pazopanib plus docetaxel 20 mg/m2) one DLT consisting of ataxia grade 2 resulting in 
dose omission of docetaxel was observed. The third dose level (400 mg pazopanib plus 
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docetaxel 20 mg/m2) exceeded the MTD based upon the observation of two DLTs (one 
episode of grade 3 encephalopathy considered to be related to pazopanib and one episode 
of grade 3 nausea). Six patients were enrolled in the dose expansion (400 mg pazopanib 
plus docetaxel 20 mg/m2) giving rise to two additional DLTs: one episode of grade 3 fatigue 
and one episode of grade 3 haemorrhage, resulting in 3 DLTs in 12 patients in total at this 
dose level.
Table 2 | Demographics and baseline characteristics
Age (median, years) 58 (31–73)
Gender
Male 29
Female 17
WHO performance score
0 6
1 40
Tumor type
Sarcoma
Gastro-intestinal stromal tumor 5
Other types sarcoma 4
Urothelial Cancer 6
Gastric cancer 6
Oesophageal cancer 3
Pancreatic cancer 4
Colorectal cancer 2
Head and neck squamous cell cancer 4
Breast Cancer 2
Adenoid cystic carcinoma 2
Cutaneous squamous cell cancer 2
Miscellaneous 6
Previous number of non-hormonal systemic anticancer treatment
0 8
1 18
2 14
3 3
4 0
5 3
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At the MTD the relative dose intensity of docetaxel and pazopanib was 92.6% and 88.5% 
respectively, with a median number of two combination therapy cycles.
Toxicity
Neutropenia was the most frequently observed grade 3/4 toxicity in D3w, while it hardly 
occurred in D1w. (Table 3) Other toxicities were comparable between D3w and D1w, with 
fatigue, gastrointestinal toxicity (nausea, vomiting, constipation and diarrhea), anorexia, 
increased transaminases and proteinuria occurring most frequently. The majority of 
toxicities occurring during combination therapy became apparent during the first cycle. 
(Table 3)
Table 3 | Most frequent adverse events during the first and during all combination cycles (D3w: 
docetaxel every 3 weeks; D1w: docetaxel weekly on days 1, 8 and 15 every 28 days)
D3w (n=20) D1w (n=21)
First cycle 
adverse events
Adverse events at 
all combination 
cycles
First cycle  
adverse events
Adverse events at 
all combination 
cycles
Grade  
3/4
All 
grades
Grade  
3/4
All 
grades
Grade  
3/4
All 
grades
Grade  
3/4
All 
grades
Anaemia 0 14 1 19 0 14 0 15
Thrombocytopaenia 0 1 0 3 0 3 0 3
Neutropaenia 14 16 14 17 0 1 1 1
Fatigue 1 18 5 19 1 20 3 20
Nausea 0 9 0 14 0 11 1 16
Vomiting 1 7 2 10 0 5 1 8
Mucositis 2 8 2 11 0 6 0 8
Anorexia 0 12 1 18 0 11 0 15
Constipation 0 8 0 11 0 14 0 14
Diarrhea 0 11 0 13 0 11 0 15
Hypertension 2 2 2 3 2 7 2 9
Sensory neuropathy 0 6 0 11 0 11 0 12
ALAT 1 9 1 11 3 11 4 12
ASAT 1 11 1 14 1 12 2 13
Proteinuria 0 14 0 14 0 13 0 16
Abbreviations; ALAT, alanine aminotransaminase; ASAT aspartate aminotransferase
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Pharmacokinetics
In D3w the concurrent administration of pazopanib resulted in a 33% lower docetaxel 
clearance (mean 31.5 versus 21.1 L/h/m2; P=0.019) and more than 50% increase in AUC0-∞ 
(mean 1,602 versus 2,414 ng*h/mL; P=0.029) compared to docetaxel single agent data 
(Table 4 and Figure 1A). Also in D1w, a clinically relevant (39%) decrease in docetaxel 
clearance during concomitant administration of pazopanib was observed (mean 25.4 
versus 18.3 L/h/m2; P=0.043 (Table 4 and Figure 1B).
 The mean pazopanib Cmax and AUC0-τ did not change significantly (P>0.405) when dosed 
in combination with docetaxel, compared to pazopanib monotherapy. (Table 4 and Figure 
2). A ~30% increase in docetaxel exposure when co-administered with pazopanib was 
confirmed by a geometric mean ratio approach. 
Table 4 | Pharmacokinetic parameters (mean and ranges within brackets) of docetaxel and pazopanib 
in de dose expansion cohorts at the maximally tolerated dose (docetaxel 50 mg/m2 given every 3 
weeks (D3w) or docetaxel 20 mg/m2 weekly on days 1, 8 and 15 every 28 days (D1w); 400 mg per day 
pazopanib for D3w and D1w).
D3w D1w
Docetaxel PK Without 
pazopanib
With 
pazopanib 
p-value Without 
pazopanib
With 
pazopanib 
p-value
Docetaxel clearance 
(L/h/m2)
31.5
(28.5–34.2)
21.1
(18.0–24.3)
0.019 25.4
(14.1–32.3)
18.3
(16.0–23.9)
0.043
AUC0-∞ (ng*h/mL) 1602
(1462–1735)
2414
(2060–2774)
0.029 857
(620–1417)
1113
(837–1249)
0.072
Cmax (ng/mL) 1415
(1195–1625)
2085
(1394–2558)
0.075 694
(457–1073)
903
(543–1336)
0.101
Pazopanib PK Without 
docetaxel
With 
docetaxel 
Without 
docetaxel
With 
docetaxel 
Cmax (μg/mL) 34.1
(9.66–63.9)
38.5
(12.2–53.0)
0.429 35.7
(21.1–67.8)
39.3
(16.3–60.1)
0.506
AUC0-τ (μg*h/mL) 647
(176–1363)
625
(254–1070)
0.837 672 
(437–1280)
752 
(305–1208)
0.405
Abbreviations: AUC, area under the curve; Cmax, peak plasma concentration 
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Figure 1 | Mean concentrations (plus SD) of docetaxel administered alone (closed symbols, bars up) or 
in combination with pazopanib (open symbols, bars down) once daily pazopanib in combination with 
docetaxel administered at 3-weekly interval (A) and 1-weekly interval (b).
Figure 2 | Individual pazopanib AUC0-τ after administration of 400 mg pazopanib alone, or in 
combination with docetaxel (Panel 2A: docetaxel 50 mg/m2 given every 3 weeks (D3w) or docetaxel 
20 mg/m2 weekly on days 1, 8 and 15 every 28 days (D1w)
Antitumor activity
Of the 15 evaluable patients in D3w one patient with metastatic breast cancer, previously 
treated with 5 different chemotherapy schedules including paclitaxel, achieved a partial 
response. In eight other patients, a progression-free survival of at least 3 months was 
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observed (2 patients with adenoid cystic carcinoma, and one patient with each one of 
the following entities: Gastro-intestinal stromal tumor; myoepithelial carcinoma; synovial 
sarcoma; pancreatic cancer; esophageal cancer and submandibular gland tumor). Of the 
15 evaluable patients allocated to the D1w schedule, one patient with metastatic urothelial 
cancer had a partial response, while two patients had a prolonged disease stabilisation 
for longer than three months: one patient with a gastro-intestinal stromal tumor and one 
patient with gastric cancer.
DISCuSSION
The current trial evaluated the safety, tolerability, and pharmacokinetics of intravenously 
administered docetaxel, given in two different schedules, combined with orally taken 
pazopanib. For both schedules, MTDs for both pazopanib and docetaxel could be 
established. 
 Importantly, in combination with docetaxel given either D3w or D1w, the MTD of 
pazopanib in this study was 400 mg/day, which is substantially lower than the MTD of single 
agent pazopanib at 800 mg daily. The same held true for docetaxel with MTDs of 50 mg/m2 
and 20 mg/m2 for D3w and D1w, respectively, being significantly lower than the approved 
single agent dosages (75 to 100 mg/m2 for D3w and 30 to 35 mg/m2 for D1w, respectively). 
This significantly lower dose intensity of docetaxel in combination with pazopanib can be 
explained by a relevant drug-drug interaction, resulting in an up to 50% increased exposure 
to docetaxel when combined with pazopanib.
 Our findings on this clinically relevant drug-drug interaction, although based on a small 
sample size, are in line with two other phase I studies, combining docetaxel with either 
sorafenib or axitinib, other VEGFR-targeting tyrosine kinase inhibitors.14,15 Similar to the 
current study, both trials found increased docetaxel AUCs upon co-administration of the 
tyrosine kinase inhibitor.14,15 Fortunately, in contrast to the impact of pazopanib on docetaxel 
PK, no consistent effect of docetaxel on the exposure to pazopanib could be detected.
 Docetaxel and pazopanib are both substrates for CYP3A4, and therefore prone for 
possible drug-drug interactions if combined with each other.16 In pre-clinical studies 
pazopanib was shown to be a weak CYP3A4 inhibitor. Similar to the current findings, 
concomitant administration of another taxane, paclitaxel, and pazopanib (800 mg) also 
resulted in a profound PK interaction, with an observed 18% decrease in clearance, a 26% 
increase in AUC, and a 36% increase in Cmax of paclitaxel. This interaction is considered to be 
the result of the inhibition of CYP3A4 and/or CYP2C8.17
 In contrast to paclitaxel, which is metabolized by two iso-enzymes, docetaxel is solely 
and almost completely metabolized by CYP3A4.9 Consequently, it can be hypothesized that 
pazopanib increases the exposure to taxanes mainly by inhibiting CYP3A4 metabolism as 
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the increase in exposure to docetaxel as observed in our trial is in the same range as found 
for paclitaxel when combined with pazopanib. In addition, also the transport of docetaxel in 
the liver by OATP1B-type carriers may be influenced by pazopanib.9 Recent in vitro studies, 
using HEK293 cells that expressed OATP1B1, explored the inhibiting effects of several 
tyrosine kinase inhibitors on this transporter. Also pazopanib was studied and showed a 
strong inhibition of OATP1B1.18 
 Remarkably, and despite previous indications of clinically relevant drug-drug 
interactions between TKIs and taxanes, two dose-finding studies on the triple combination 
of pazopanib, paclitaxel, and carboplatin started with full single agent doses for each of the 
drugs in the first dose level. Not surprisingly, both trials observed excessive toxicity, even 
after lowering the pazopanib dose to 400 mg.19,20 One of these trials continued to explore 
full dose carboplatin with full dose paclitaxel with 200 mg pazopanib and this combination 
appeared to be feasible.20 PK-analyses showed a pazopanib-induced increase in Cmax of 
paclitaxel and carboplatin of >40% and >54%, respectively.20 
 The observed patterns of DLTs and toxicity profile of the combination of pazopanib and 
docetaxel were in accordance with the known single agent side effects of both study drugs. 
No remarkable patterns were detected and in general this combinations at the MTD were 
well tolerated. It might be worthwhile to test the combination of pazopanib with docetaxel 
for its efficacy in patients with for example breast, lung or gastric cancer.
 In summary, 400 mg of pazopanib can be safely combined with docetaxel when given 
at either 50 mg/m2 D3w or 20 mg/m2 D1w. A significant effect of pazopanib on docetaxel 
exposure, as observed by a 34% increase in AUC, was found. This effect is most likely based 
on CYP3A4 and OATP1B inhibition by pazopanib. However, at the recommended doses 
obtained from this study, the combination of pazopanib and docetaxel can safely be 
administered and further evaluation assessing potential antitumor activity is proceeding.
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AbSTrACT
background: Because chemotherapy for metastatic breast cancer (MBC) is associated with 
relevant toxicity, sequential monotherapy trastuzumab followed by cytotoxic therapy at 
disease progression might be an attractive approach.
Methods: In a multicenter phase II trial, 101 patients with overexpression of human 
epidermal growth factor receptor 2 (HER2+) MBC were randomized between combination-
therapy trastuzumab (Herceptin) plus docetaxel (H+D) and sequential therapy of single-
agent trastuzumab followed at disease progression by docetaxel alone (H→D) as first-line 
chemotherapy for metastatic disease. The primary endpoint was progression-free survival 
(PFS) after completed sequential or combination therapy.
results: For the H+D group the median PFS was 9.4 vs. 9.9 months for the H→D group 
and 1-year PFS rates were 44% vs. 35%, respectively. However the overall response rates 
(ORRs) were 79% vs 53%, respectively (P=.016), and overall survival was 30.5 vs 19.7 months, 
respectively (P=.11). In the H→D group, response rates to monotherapy trastuzumab 
and subsequent docetaxel were 34% and 39%, respectively, with a median PFS during 
single-agent trastuzumab of 3.9 months. The incidence and severity of neuropathy were 
significantly higher in the H+D group. Retrospective analysis of trastuzumab treatment 
beyond progression (applied in 46% of patients in the H+D group and 37% in the H→D 
group) showed a correlation with longer overall survival in both treatment arms (36.0 vs 
18.0 months and 30.3 vs. 18.6 months, respectively).
Conclusion: First-line treatment in patients with MBC with H→D resulted in a similar PFS 
compared with H+D, but the response rate was lower and the overall survival nonsignificantly 
shorter.
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INTrODuCTION
Metastatic breast cancer (MBC) remains an incurable entity. The goals of therapy therefore 
are aimed at symptom palliation by control of disease progression with preservation 
of quality of life (QoL) and prolongation of survival. Given the fact that chemotherapy is 
associated with relevant side effects, treatment modalities whereby the introduction of 
chemotherapy may be delayed are worthwhile to explore.
 Overexpression and/or amplification of human epidermal growth factor receptor 
2 (HER2+) occurs in approximately 20% of breast cancers. It is associated with worse 
outcomes, including shortened overall survival (OS), compared with HER2- breast cancer.1,2 
Blocking HER2 by means of the monoclonal antibody trastuzumab is beneficial in patients 
with HER2+ MBC and results in survival benefit.3-6 Three trials have evaluated the activity 
of single-agent trastuzumab as first-line therapy for MBC,4,5,7 whereas many more have 
investigated a combination regimen of trastuzumab and a variety of chemotherapeutic 
agents as first- to third-line therapy, mostly however in a nonrandomized setting.3,6-10 
Currently the combination of trastuzumab (Herceptin) and docetaxel (H+D) is considered 
one of the standard first-line cytotoxic treatment modalities for patients with HER2+ MBC. 
The value of adding trastuzumab to docetaxel, however, has been studied only in the 
pivotal phase II trial (M77001) that randomly assigned 186 women to docetaxel with or 
without trastuzumab. This study showed superior outcomes for the combination regimen 
on all efficacy parameters, including a significant OS benefit (31.2 vs 22.7 months).6
 For a long time, the issue of combination vs. sequential chemotherapy has been contro-
versial. As this issue has not been well studied, it remains a matter of debate. In general 
the combination of different drugs yields an increased overall response rate (ORR) in 
comparison with monotherapy but at the cost of more toxicity and, unfortunately, does not 
always result in a prolonged time to progression and/or overall survival.
 With respect to the sequential therapy of trastuzumab and chemotherapy, a single 
study was recently published on the value of monotherapy trastuzumab followed at 
progression by the combination of trastuzumab and docetaxel (H→D) in comparison with 
initial combination therapy H+D as first-line therapy for HER2+ MBC.7
 The current randomized phase II study aimed to determine whether it is worthwhile to 
explore a sequential approach in women with HER2+ MBC, assessed by progression-free 
survival (PFS) as well as the rate of PFS at 1 year (PFS1 yr). Secondary endpoints were response 
rate (RR), OS, and toxicity of both treatment regimens.
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PATIENTS AND METHODS
Women with progressive HER2+ advanced breast cancer or MBC requiring first-line 
chemotherapy were eligible. HER2+ was defined as score 3+ assessed by immunohisto-
chemistry (test, Dako Denmark A/S, Glostrup, Denmark ) and/or gene amplification by 
fluorescence in situ hybridization (positive if ≥2.2 copy numbers per cell).11 Other eligibility 
criteria were WHO performance status 0 to 2, life expectancy >12 weeks, hemoglobin value 
≥9.7 g/dL, white blood cell count ≥3.0 Χ 109/L, neutrophil count ≥1.5 Χ 109/L, platelet count 
≥100 Χ 109/L, creatinine clearance ≥60 mL/min or creatinine ≤1.5 Χ upper limit of normal 
(ULN); bilirubin level ≤1.0 Χ ULN; alkaline phosphatase level ≤5.0 Χ ULN; ALT and/or AST 
levels ≤1.5 Χ ULN; left ventricular ejection fraction (LVEF) >50%.
 Exclusion criteria were previous anti-HER2 or taxane-containing therapy, uncontrolled 
serious illness, history or presence of central nervous system metastases, radiation therapy 
within 2 weeks or myocardial infarction within 6 months of study entry, and previous 
invasive malignancy.
 The HERTAX trial was a randomized, phase II trial conducted in 22 centers in the 
Netherlands and coordinated by the Dutch Breast Cancer Trialists’ Group (BOOG). Patients 
were centrally randomized in a 1:1 ratio between H+D and H→D. Block randomization was 
used (2, 4, or 6 patients per block in order to avoid selective enrollment of patients based 
on previous treatment allocation in a center) after stratification for a participating center. 
Doses and regimens are shown in Figure 1. Docetaxel was administered over a 60-minute 
period. Corticosteroids were administered according to the standard procedure of each 
institution. No primary prophylaxis with growth factor support was allowed and antibiotics 
were not routinely administered. After the recognition that once every 3 weeks trastuzumab 
administration (6 mg/kg) was likely equivalent to the weekly schedule,5 once every 3 weeks 
regimen was allowed for patients not receiving docetaxel concurrently. It was planned 
that docetaxel in either arm would be given for 6 cycles or longer at the discretion of the 
investigator. Either treatment was continued until disease progression, intolerable toxicity, 
or patient withdrawal.
 The ethical review boards of the participating centers approved the study, and written 
informed consent was obtained from all patients. The study has been conducted in 
accordance with the principles embodied in the Declaration of Helsinki.
Study Evaluations
Prestudy evaluations performed ≤3 weeks before randomization included tumor 
assessments, electrocardiography, LVEF measurement, blood counts, and clinical chemistry 
examinations. During study, laboratory evaluations and toxicity assessments (using the 
National Cancer Institute-Common Toxicity Criteria version 2) were performed every 3 
weeks. Tumor assessment and LVEF measurements were performed every 6 and 9 weeks, 
respectively. Tumor response assessment was done by the local investigator according to 
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response evaluation criteria in solid tumors (RECIST).12 Complete response (CR) or partial 
response (PR) had to be confirmed no less than 6 weeks after the first observation. Overall 
response assessment was reviewed centrally at data analysis.
Figure1 | Treatment Flow Chart of the HERTAX Trial: PD, Progressive Disease. (*) After a Loading Dose 
of 4 mg/kg (#) in the Absence of Progressive Disease or Intolerable Toxicity, Additional Cycles Added at 
the Discretion of the Treating Physician.
PFS in the H+D group (PFScomb) was defined as time from start of treatment to the date of 
documented disease progression, initiation of another systemic anticancer treatment without 
documented objective (radiologic) tumor progression, or death, whichever occurred first. In 
the H→D group, the following definitions were used: (1) PFS on trastuzumab (PFStras) by 
using the same criteria as already mentioned; (2) PFS on sequential therapy (PFSseq) being 
the time between start of treatment and the date of documented progressive disease (PD) 
on subsequent single-agent docetaxel therapy, initiation of another systemic anticancer 
treatment, or death, whichever occurred first. If patients did not receive docetaxel when 
disease progressed on trastuzumab, the PFSseq was defined as the PFStras in order not to 
overestimate the PFSseq. The PFS1 yr was estimated on the basis of Kaplan-Meier plots. OS was 
measured from start of study treatment until death from any cause, with censoring at the 
last visit date for patients still alive.
 Data on the administration and clinical outcome of trastuzumab treatment beyond 
progression on the protocol-specified treatment were collected retrospectively because 
this issue is controversial and potentially might have affected study results.
Statistical Methods
Estimating the PFS1 yr with sufficient precision in both arms was the primary objective. 
Estimating a PFS1 yr of 15% (based on data from patients with MBC irrespective of HER2 
status from the Rotterdam Breast Cancer Database [pretrastuzumab era]), with a standard 
error (SE) of 5%, a sample size in each group of 50 patients was calculated. If trastuzumab 
treatment in general would increase the PFS1 yr to around 50%, the SE of 7% with 50 patients 
would still be acceptable.
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PFS and OS were analyzed using the Kaplan-Meier method and the log-rank test. Hazard 
ratios and their 95% confidence intervals were calculated with an univariate Cox regression 
model. Response rates and grade 3/4 toxicities were compared by means of Χ2 tests or 
Fisher’s 2-sided exact test when expected numbers were low. Ordinal variables, such as 
scored grades of toxicity, were tested with the Mann-Whitney U test.
Figure 2. HERTAX CONSORT Flowchart
Abbreviations: DCCD, data collection cut off date; PD, progressive disease.
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rESuLTS
Between February 2003 and December 2007, a total of 101 patients were randomized 
(Figure 2). Two ineligible patients were excluded, in 1 patient because brain metastases 
became symptomatic before the start of treatment, and in the other patient because final 
workup did not reveal metastatic disease. Because of block randomization within centers, 
a slight imbalance occurred in the treatment arm allocation. On August 1, 2008 (the data 
collection cutoff date for the current analysis), 11 patients were still in the study (10 in the 
H+D group and 1 in the H→D group) (Figure 2), and 33 patients were still alive (21 and 12 in 
the H+D and H→D groups, respectively).
Patient Characteristics and Treatment Delivered During Study
Baseline characteristics and demographics were well balanced between the treatment 
arms (Table 1). In both arms the median number of docetaxel cycles administered was 6 
(range, 1-18). There were no statistically significant differences in dose delays (25% vs 26%; 
P=.86) or dose reductions (11% vs 17%; P=.39) between the H+D group and the H→D group, 
respectively. During the study period, trastuzumab was administered significantly longer 
in the H+D group (9.3 vs 4.1 months; P=.001). Seven patients in the H+D group switched 
to receiving single-agent trastuzumab 3 times a week; this occurred in 3 patients in the 
H→D group. In the H→D group, 4 patients did not receive docetaxel: 3 patients refused 
this therapy, and 1 patient died from infectious endocarditis during trastuzumab treatment 
(Figure 2).
Efficacy
At central review of response assessment, it appeared that 3 patients in the H→D group 
prematurely discontinued trastuzumab and started with docetaxel because PD was 
presumed by the local investigator, but according to RECIST ought to have been classified 
as stable disease (SD) (n=2) or PR (n=1). In contrast, 2 patients were classified as having 
PD and had continued on trastuzumab until the next tumor assessment because the local 
investigator had assessed SD. On achieving a long-lasting PR, 1 patient who was receiving 
combination therapy underwent resection of residual disease (primary tumor, axillary 
lymph nodes, liver metastases) after 21 months of treatment and was classified as having 
a PR for the current analysis. Initiation of another systemic anticancer treatment without 
documented objective (radiologic) tumor progression was applicable in 2 patients in H+D 
and in 3 patients in H→D.
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Table 1 | Patient Characteristics
Combination Arm (H+D)  
(n=53)
Sequential Arm (H D)  
(n=46)
Age Median  50 years 54 years
range 32–74 years 36–74 years
Menopausal State
Premenopausal 19% 22% 
Postmenopausal 68% 74% 
Unknown 13% 4%
WHO PS
0 49% 49%
1 49% 49%
2 2% 2% 
Er+ and/or Pr+ Tumor 49% 52% 
Previous Adjuvant Treatment
Chemotherapy 55% 52% 
Anthracycline-based 45% 43% 
Hormonal treatment 26% 35%
Previous Hormonal Treatment for Advanced/
Metastatic Disease
35% 37%
Involved Tumor Site
Lung 38% 35% 
Liver 51% 46% 
Bone 45% 52%
Predominant Metastatic Site
Single visceral organ 55% 43% 
Multiple visceral organs 15% 15% 
Lymph nodes 17% 11% 
Soft tissue 8% 15% 
Bone 6% 15%
Interval between bC Diagnosis and 
randomization
Median 27.7 months 32.1 months
Range 0.2–213.6 months 0.4–151.3 months
Abbreviations: BC, breast cancer; ER, estrogen receptor; PR, progesterone receptor; WHO PS, World Health Organization 
performance status.
The median PFS in the H→D group during monotherapy with trastuzumab (PFStras) was 3.9 
months with an ORR of 34%. The median PFS in the H+D group and H→D group was 9.4 
and 9.9 months for PFScomb and PFSseq, respectively, which was not significantly different 
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(P=.20) (Table 2; Figure 3B). Of note, the median PFStras was 3.9 months (Table 2; Figure 
3A). PFS1 yr rates for the H+D group and the H→D group were 44% (SE 7%) and 35% (SE 7%), 
respectively.
 The ORR (CR + PR) was significantly higher in the H+D group than in the H→D group (ie, 
in the latter the best response was during either single-agent trastuzumab or single-agent 
docetaxel) (79% and 53%, respectively; P=.016) (Table 2). Conversely, more patients in the 
H→D group achieved SD (13% vs. 38%, respectively). In the H→D group, the separate ORR 
during single-agent trastuzumab treatment was 34% and during subsequent monotherapy 
docetaxel treatment was 39% (Table 2).
 The median OS in the H+D group was 30.5 months, and in the H→D group it was 19.7 
months. Although there was a difference of 10.8 months in favor of the H+D group, this was 
not statistically significant (P=.12) (Table 2; Figure 3C).
Table 2. Efficacy Results of the HERTAX Trial
Within Sequential Arm
Combination  
Arm (H+D)
Sequential  
Arm (H D)
P-Value* Trastuzumab 
Monotherapy
Docetaxel 
Monotherapy
Cr 15%  3% .016  0% 3% 
Confirmed 13%  3%  0% 3% 
Unconfirmed  2%  0%  0% 0%
Pr 64%  50% 34% 36%
Confirmed 58%  38% 27% 23% 
Unconfirmed  6%  12%  7% 13% 
SD 13%  38% 39% 37% 
PFS1yr  44%  35% NA NA NA 
PFS, Median 9.4 months 9.9 months .20 3.9 months NA 
OS, Median 30.5 mo 19.7 mo .12 NA NA
Abbreviations: CR, complete remission; NA, not applicable; OS, overall survival; PFS, progression-free survival; PFS1yr, 
progression-free survival at 1 year; PR, partial remission; SD, stable disease. * P value on the comparison between the 
combination arm and the sequential arm.
Toxicity
All 99 eligible patients were included in the safety analysis. Adverse events typically 
were chemotherapy related. The toxicity profiles of the 2 regimens were comparable in 
the majority of domains (Table 3). However a significantly higher incidence of sensory 
neuropathy was observed in the H+D group (grade 1/4: 62% vs 31%; P=.003). Also there 
seemed to be a shift in severity of this untoward event, as no grade 3/4 sensory neuropathy 
was noticed in the H→D group, whereas this occurred in 8% of the patients in the H+D 
group (P=.053) (Table 3).
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Figure 3. Comparison of estimated (A) progression-free survival (PFS) of trastuzumab plus docetaxel 
vs trastuzumab alone, (b) PFS of trastuzumab plus docetaxel (H+D) vs trastuzumab alone and on 
progression, docetaxel alone arm H→D, and (C) overall survival between trastuzumab plus docetaxel 
(H+D) vs trastuzumab alone and on progression, docetaxel alone arm H→D (Kaplan-Meier plots)
Abbreviations: HR, hazard ratio; CI, confidence interval 
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Figure 4. Comparison of estimated overall survival in patients who were alive at off-study between 
(A) those patients receiving trastuzumab after HERTAX trial treatment vs. those who did not receive 
any trastuzumab after HERTAX trial treatment and (b) after further stratification for previous HERTAX 
treatment arm (Kaplan-Meier Plots)
Abbreviations: HR, hazard ratio; CI, confidence interval; TBP, trastuzumab beyond progression.
The incidence of febrile neutropenia (FN) was 23% in the H+D group compared with 15% in 
the H→D group (P=.35) (Table 2). Furthermore, no significant difference in decline in LVEF 
between the 2 treatment arms was observed (Table 3).
 Three patients died during the study: 2 in the H+D group (both being attributable to 
study treatment [interstitial lung disease; diarrhea during FN]), whereas the third patient 
died of infectious endocarditis during monotherapy with trastuzumab, which was 
considered unrelated to study treatment.
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Table 3. Incidence of Adverse Events
All Grades Grade 3/4
Combination  
Arm (H+D)
Sequential  
Arm (H D) 
P-Value Combination  
Arm (H+D)
Sequential  
Arm (H D) 
P-Value
Nonhematologic Toxicity
Nausea 39% 42% .86  4% 4%  1.00
Vomiting 31% 22% .28 4% 7% .67
Stomatitis 53% 38%  .25 4% 2% 1.00
Diarrhea 39% 33% .50 4% 2% 1.00
Sensory neuropathy 62% 31%  .003 8% 0% .053
Fatigue 88% 67% .20 8% 9% 1.00
Myalgia 40% 29% .24 0% 0%  NA
Peripheral edema 47% 42% .97 0% 2% .48
Left Ventricular Ejection Fraction
Median relative decrease 
(worst value compared with 
baseline)
10% 10%
Relative decrease ≥15% 
(worst value compared with 
baseline)
36% 28% .47
LVEF <40% 4% 5% 1.00
Discontinuation of 
trastuzumab because of 
cardiotoxicity
8% 2% .37
Febrile Neutropenia
Incidence of febrile 
neutropenia 
23% 15% .35
Abbreviations: LVEF, left ventricular ejection fraction; NA, not applicable.
use of Trastuzumab beyond Protocol Treatment
Data on the use of trastuzumab beyond protocol treatment were available from 82 of the 
84 patients who were alive when PD resulted in withdrawing from the study (Figure 2). 
In 41% of patients (34/82), trastuzumab treatment was given beyond the study protocol 
(46% [19/41] in the H+D group vs 37% [15/41] in the H→D group; P=.37). The median 
duration of trastuzumab administration beyond HERTAX study treatment was 7.5 months 
(range, 1–32 months). Median total trastuzumab administration for the whole group (n=82) 
was 18.3 months (range, 2.4–42.3 months), whereas it was 21 vs. 12.7 months for those 
previously treated with H+D and H→D, respectively (P=.048). OS in the patients receiving 
trastuzumab beyond progression (n=34) was 32.2 months vs. 18.5 months in patients 
(n=48) not receiving trastuzumab beyond HERTAX study treatment (P<.0001) (Figure 4A). 
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The difference remained significant after stratification of the 2 groups according to the 
preceding HERTAX treatment regimen (Figure 4B).
DISCuSSION
Combined treatment regimens are compared mostly with single-drug therapy and rarely 
with sequential therapy using the same drugs, although the latter in fact is a more robust 
and fair comparison. To our knowledge, the current study is the only one exploring the value 
of a sequential regimen of trastuzumab alone followed at disease progression by cytotoxic 
chemotherapy with docetaxel alone vs. initial combination therapy with trastuzumab and 
docetaxel in patients with HER2+ MBC. We observed a comparable median PFS in both 
groups, whereas a different ORR was observed; there was an overall survival of 30.5 months 
in the H+D group vs. 19.7 months in the H→D group (P=.11).
 Crossing of the PFS and the OS curves is caused by different reasons. Crossing of the PFS 
curve is most likely caused by the absence of early progression in the sequential arm (H→D), 
as the PFS curve for this treatment arm shows progression on docetaxel after previous 
progression on trastuzumab, resulting in the observation that the PFS curve, by definition, 
starts to decline at a later point in time compared with the PFS curve of the combination 
arm (H+D). Although it might be fairer to compare the slopes of both curves, in the field of 
biostatistics there is as yet no solution to this problem.
 The crossing of the OS curve is partially caused by the early occurrence of treatment-
related deaths in 2 patients treated in the H+D group. The arrears of the combination 
therapy is then made up during treatment, causing the H+D OS curve to cross the H→D 
curve.
 Recently an important study was published reporting on the outcome of sequential 
therapy with trastuzumab alone as initial treatment followed by combination therapy in 
comparison with initial combination therapy.10 Despite the similarities, the Japanese study 
is at several major levels different from the HERTAX study because patients allocated to 
sequential treatment in our study were treated with single-agent docetaxel at disease 
progression during single-agent trastuzumab (H→D) therapy, whereas the Japanese trial 
used the combination of docetaxel and trastuzumab at disease progression (H→H+D). 
Furthermore the docetaxel dosage applied in our study was 100 mg/m2 once every 3 
weeks compared with 60 mg/m2 once every 3 weeks in the Japanese study. Trastuzumab 
treatment beyond progression with first-line chemotherapy using docetaxel was applied 
during subsequent lines of chemotherapy in 90% of the patients in the Japanese study and 
41% of patients in our study.7
 Importantly, the JO17360 Trial Group decided to use a primary endpoint that explicitly did 
not include sequential therapy as it compared the PFS of patients treated with trastuzumab 
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to the PFS of patients treated with the combination of docetaxel and trastuzumab.10 The 
JO17360 trial was terminated prematurely based on a significant difference in PFS favoring 
the combination therapy of trastuzumab and docetaxel compared with single-agent 
trastuzumab. This difference could have been anticipated because the known PFS of single-
agent trastuzumab is about 3.5 months4,5 and the PFS of the same combination therapy 
used in the study of Marty and colleagues was 11.7 months.6
 The comparable PFS found in both treatment arms of our study is in accordance with 
the data from the Japanese study, although the PFS in both treatment arms of the latter trial 
was longer than expected.
 In our study, monotherapy with trastuzumab resulted in a PF-Stras of 3.9 months and an 
ORR of 34%, in accordance with previous reports and confirming the single-agent activity of 
trastuzumab as first-line treatment for HER2+ MBC.4,5 The Japanese study showed a strikingly 
lower ORR (14.8%), but a comparable PFS was observed.7
 The ORR observed in the H+D group (79%) is in line with previous findings of first-
line docetaxel and trastuzumab treatment in patients with HER2+ MBC,13 whereas the 
remarkably lower ORR observed in the Japanese trial (47%) most likely is attributable to the 
lower dose of docetaxel.10 Although a substantial proportion of the patients from the H→D 
group achieved remission on subsequent docetaxel treatment (39%), the ORR remained 
significantly better in the H+D group; however, this did not translate to a superior PFS.
 The median OS of patients in the H+D group is comparable to the findings of the 
pivotal M77001 trial in regard to the combination regimen.6 The difference in OS between 
the 2 treatment groups in our study might be related to the significantly longer duration 
of trastuzumab treatment in the H+D group, not only during the HERTAX therapy period 
(9.3 months in the H+D group vs 4.1 months in the H→D group) but also beyond protocol 
treatment (21 months in the H+D group vs 12.7 months in the H→D group). Also, the 
observation that not all patients received docetaxel therapy at disease progression on 
trastuzumab monotherapy might have affected outcome. At the interim analysis of the 
JO17360, the difference in OS did not reach the prespecified level of significance7 and the 
exact OS data have not been reported yet because of a lack of events, although a hazard 
rate of 2.72 favoring initial combination therapy was observed.10
 After the early termination of the study, combination treatment was allowed 
before disease progression in patients treated with single-agent trastuzumab, with the 
consequence that clear data on the true difference in OS will never be available for the total 
group of enrolled patients.
 Inoue and associates7 reflected that the difference in docetaxel dosing strategy 
between the HERTAX and JO17360 trials did allow an increasing number of docetaxel 
cycles to be administered. However it merely reflects the differences between Europe and 
the United States, where chemotherapy is usually discontinued after 6 cycles of docetaxel 
(75–100 mg/m2) in line with the pivotal trial by Marty and colleagues,6 in contrast to the 
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common use of a lower docetaxel dose and administering more cycles of chemotherapy in 
Japan.
 One of the driving thoughts behind the HERTAX trial was to explore whether it is valid 
to delay chemotherapy and thereby chemotherapy-induced adverse events in patients 
with HER2+ MBC. Because observed toxicity was mainly chemotherapy related, most of the 
toxicity encountered in the sequential approach occurred during the time docetaxel was 
administered, which most likely had an impact on QoL.
 The few differences observed in toxicity were all in favor of the H→D group. Interestingly, 
next to a higher frequency of sensory neuropathy, an increased frequency of grade 3 
neuropathy was observed in the H+D group. Although a higher incidence of paresthesias 
in patients taking docetaxel and trastuzumab was reported in the M77001 phase II trial,6 
the remarkable shift in severity of neuropathy, as found in our study, has not been reported 
before and deserves further attention. Also, 15% of women treated with docetaxel alone 
and 23% of those treated with H+D experienced an episode of FN, which is in line with the 
results found by Marty and associates6 (17% and 23%, respectively) and is consistent with 
the finding of Buzdar and colleagues14 showing a doubling of the incidence of grade 4 
neutropenia during trastuzumab and paclitaxel compared with paclitaxel alone. The lower 
rate of FN (6%–8%) observed in JO17360 compared with our study is attributable to the 
lower docetaxel dose per cycle used in Japan.7
 In view of the controversy of trastuzumab beyond progression treatment, as well as 
the potential impact on the results of the current trial, the data on the use of trastuzumab 
beyond progression and the outcome thereof are informative but need to be interpreted 
with caution, as it was an unplanned and explorative analysis. Obviously a posthoc analysis 
is open to selection bias, as the reason for not receiving trastuzumab beyond progression 
may have been guided by lack of response to trastuzumab as well as by the clinical condition 
of the patient not allowing further systemic treatment and thus implicitly relating to a 
shorter survival. However despite these limitations, the data of the HERTAX study cohort 
are valuable given the fact that the various trials prospectively evaluating this issue have 
been closed prematurely because of slow accrual and the registration of lapatinib.15-17 The 
only prospectively collected data were obtained from a trial evaluating 156 patients with 
HER2+ MBC who progressed during or relapsed after previous trastuzumab therapy and 
were randomized for capecitabine with or without trastuzumab as second-line treatment.15 
A significant prolongation in PFS for the combination therapy (8.2 vs 5.6 months) was 
recently reported, without a translation into a statistically significant OS benefit (25.5 vs 20.4 
months).15 As noted by von Minckwitz and associates,15 the genuine activity of trastuzumab 
beyond progression most likely will not be assessed again in a randomized study. Other 
retrospectively collected data are not consistent on the value of trastuzumab treatment 
beyond progression, although in the majority of reports a benefit is suggested.18-24
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One of the limitations of our study, related to the phase II character, is the relatively small 
sample size, hindering a definite conclusion with regard to OS. Furthermore, it would have 
been interesting if on finishing protocol treatment, patients were enrolled in a subsequent 
randomized study evaluating the continuation of trastuzumab beyond progression. QoL 
assessments were not incorporated, although it would have been informative to compare 
the QoL of patients during the different treatment strategies.
 Altogether, the data of the current study and the Japanese study are pointing in the 
same direction showing superiority of combination-treatment trastuzumab and docetaxel 
compared with initial treatment with single-agent trastuzumab followed by docetaxel 
either with or without trastuzumab, so this should remain the treatment of choice in daily 
clinical practice. However the concept of delaying cytotoxic therapy still should not be 
repudiated, although strategies other than single-agent trastuzumab should be explored. 
Combinations of trastuzumab with other targeted agents are potential candidates, including 
vascular endothelial growth factor inhibitors and epidermal growth factor receptor blockers 
as well as hormonal therapy. For example, anastrozole in combination with trastuzumab in 
patients with estrogen receptor (ER)+, HER2+ breast cancer evaluated in the TAnDEM study, 
resulted in a doubling of the median PFS compared with patients treated with single-agent 
anastrozole.25
CONCLuSION
In summary, despite a comparable PFS in both the sequential treatment arm consisting of 
single-agent trastuzumab followed by single-agent docetaxel and the combination therapy 
arm, the ORR and OS data did not support the sequential approach. Strategies delaying the 
introduction of chemotherapy should focus on combining trastuzumab with other agents.
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Through advances in molecular biology, insight into the mechanisms driving malignancies 
has improved immensely. As a result, various factors playing an essential role in the biology 
of numerous tumor types have been revealed. By using agents that specifically block the 
function of a single factor being crucial for tumor pathogenesis, it was hoped to exert anti-
tumor activity while avoiding toxicities characteristic for conventional chemotherapy. One 
of the processes of crucial importance in the development of cancer thereby rendering it 
a potential target for treatment, is angiogenesis, the formation of new tumor vessels. In 
recent years, several key factors for angiogenesis have been identified, including ligands, 
receptors and transduction signalling factors. Of these, the vascular-endothelial growth 
factor (VEGF) pathway was found to be activated in numerous tumor types and considered 
one of the main drivers of angiogenesis. Roughly, VEGF-mediated angiogenesis can be 
inhibited by two approaches; either by monoclonal antibodies directed towards VEGF or 
its corresponding receptors or by kinase inhibitors targeting the signal transduction of 
the VEGF-receptors. As monotherapy, several kinase inhibitors exert anti-tumor activity in 
tumor types such as renal cell carcinoma and soft tissue sarcoma. However in most tumor 
types, anti-tumor activity of compounds targeting the VEGF pathway is limited. In recent 
years, evidence is mounting that the paradigm of one single factor driving malignant 
behaviour applies rarely and is an oversimplification for most tumors in which there are 
multiple driving pathways being activated in parallel. Consequently, multi-targeting rather 
than single-targeting approaches are required. One of the means to accomplish this is by 
combining targeted agents with conventional cytotoxics. As the VEGF pathway also affects 
the sensitivity of tumor cells to chemotherapeutics, combinations of compounds targeting 
this pathway and conventional cytotoxics are attractive to be explored. In chapter 2 a review 
summarizes and puts into perspective the clinical data on the use of the combination of 
cytotoxic therapy combined with agents inhibiting of the VEGF-VEGFR-pathway published 
so far. Though such a combination is theoretically attractive, combination strategy at the 
time of the writing of the review has been proven for a few indications (metastatic colorectal 
cancer and metastatic breast cancer) with a modest benefit. A lot of effort is still needed to 
find optimal combinations as well as to identify predictive factors that are able to identify 
patients most likely to benefit from combination therapy. 
 Before a combination is put in the armamentarium of the medical oncologist as regular 
treatment, there are many challenges that should be tackled towards a final robust strategy 
with proven efficacy. Dose-finding studies are the first step in the clinical development of new 
combination treatment strategies. Chapter 3 describes several challenges encountered in 
dose-finding studies. Additionally, several potential solutions to critical issues in the design 
of phase I anti-cancer drug combination studies are suggested. It has become increasingly 
complex to construct a trial, due to the increasing diversity in classes of agents, mechanisms 
of action, safety profiles and drug-administration schedules. With over 850 agents currently 
in development for cancer treatment, it is evident that combination development must 
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be prioritized based on a specific hypothesis (for example on the basis of an expected 
pharmacokinetic and/or pharmacodynamic interaction and/or expected anti-tumor 
activity against a particular molecularly defined tumor type), as well as on a projected 
development path for the involved combination. If there is a rationale to develop a specific 
drug combination, a hypothesis with respect to the additional value of the combination 
of the drugs as compared to single agent (sequential) therapy should be generated. This 
hypothesis, based on anticipated levels of interaction, should guide the design of the phase 
I study, although one should always be open to detect the unexpected. Clearly, a dose-
finding study on a single anti-tumor agent will result in a maximally tolerated dose (MTD). 
However, in drug combination studies there are several factors that does increase the 
number of potentials MTDs, like the sequence of drug-administration as well as the steps 
made in drug-escalation (for example keeping one of the drugs at a low dose-level while 
increasing the other and vice versa). A strong consideration is to design studies aiming to 
potentially determine multiple MTDs with final dose determination in randomised phase 
II trials. Introducing controls as well as the novel 3 + 3 + 3 design (in contrast to the classic 
3 + 3 design) are strategies allowing more grip on combinations with high incidence of 
severe toxicity. The 3 + 3 + 3 design reduces the chance of falsely halting dose-escalation in 
studies that use drugs with high rate of severe toxicity, by allowing the number of patients 
at a dose level to be increased to 9, if 2 out of 6 patients experience dose-limiting toxicity 
(DLT). Importantly, we should continuously realise that the MTD of an anti-tumor regimen is 
not necessarily also the optimal biological dose underlining the importance of appropriate 
PD markers adequately reflecting the anti-tumor effects from the regimen under study. 
 In Chapter 4 the first phase I trial in this thesis is reported, aiming to define the MTD 
of sunitinib, in combination with two different infusion schedules of ifosfamide. Sunitinib 
is a potent inhibitor of the VEGF-receptors (VEGFR)1-3, KIT, platelet derived growth factor 
receptor-α and -β, and Fms-like tyrosine kinase-3 (Flt3) and is one of the first and most 
commonly used VEGFR-TKIs. It is currently registered for the treatment of advanced RCC and 
imatinib-refractory GIST. Patients with advanced solid tumors, good performance score, 
good organ function, and no standard therapy available, were eligible. Continuous once daily 
sunitinib, orally given, in escalating doses per cohort, was combined with a standard dose 
ifosfamide, 9 g/m2/3 days or 6 g/m2/5 days, given every 3 weeks. Next to evaluation of safety 
and toxicity, pharmacokinetic (PK) and pharmacodynamic assessments were performed. 
With growth-factor support, the MTD of sunitinib combined with either ifosfamide schedule 
was 12.5 mg once daily, in contrast to the single agent dose sunitinib of 50 mg during 28 
days followed by 14 days rest. Neutropenia-related adverse events were the dose-limiting 
toxicity. No consistent changes in VEGF or sVEGFR2 that might reflect biological activity 
of sunitinib or changes in circulating endothelial cells were observed. Sunitinib did not 
affect ifosfamide PK. In contrast, ifosfamide significantly decreased exposure to sunitinib, 
and increased exposure to its active metabolite, SU12662, due to CYP3A-induction. As PK-
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interactions cannot explain the relatively low sunitinib doses that can be combined with 
ifosfamide, synergy in toxicity at a cellular level is more likely. Whether this also holds true 
for anti-tumor activity needs to be further explored in randomized studies. 
 Chapter 5 is a review focusing on the novel tyrosine-kinase inhibitor pazopanib. This 
drug is specifically designed to impair angiogenesis by abrogating vascular endothelial 
growth factor receptor 2 (VEGFR2) to exert its function. Pazopanib inhibits VEGF-induced 
endothelial cell proliferation in vitro and angiogenesis in vivo and demonstrates anti-tumor 
activity in mouse models. Furthermore, the pazopanib concentration resulting in maximal 
inhibition of VEGFR2 phosphorylation in vivo was in line with the steady state concentration 
required to inhibit growth of tumor xenografts suggesting that pazopanib’s mechanism of 
action is indeed through VEGFR2 inhibition. In a prior study a generally well tolerated dose 
was identified at which the majority of patients achieved pazopanib plasma concentrations 
above the concentration required for maximal in vivo inhibition of VEGFR2 phosphorylation 
in preclinical models. Administered as monotherapy, evidence of anti-tumor activity has 
been observed in phase III studies in several tumor types, including soft tissue sarcoma and 
renal cell cancer (RCC). 
 A dose-finding and pharmacokinetic/pharmacodynamics study of pazopanib 
combined with two different schedules of ifosfamide is described in chapter 6. In this trial 
the 3 + 3 + 3 design has been applied for the first time. Patients with advanced solid tumors 
received escalating doses of oral pazopanib combined with ifosfamide either given 3-days 
continuous or 3-hours bolus infusion daily for three days (9 g/m2 per cycle, every 3 weeks). 
Pazopanib with continuous ifosfamide infusion appeared to be safe up to 1000 mg/day, 
while combination with bolus infusion ifosfamide turned out to be too toxic based on 
variety of adverse events. In the PK analyses, an ifosfamide-induced decline in pazopanib 
exposure was observed. Despite this, increases in placental derived growth factor (PlGF) 
and VEGF-A with concurrent decline in sVEGFR2 levels, consistent with pazopanib-mediated 
VEGFR2 inhibition, were observed after addition of ifosfamide. The recommended dose of 
pazopanib for further studies combined with 3-days continuous ifosfamide (9 g/m2 per 
cycle, every 3 weeks) is 800 mg daily. 
 In another phase I trial pazopanib was combined with two different schedules of 
intravenously administered docetaxel and reported in chapter 7. Patients with advanced 
solid tumors received, next to daily oral pazopanib, docetaxel intravenously either given 
as a 3-weekly infusion or a weekly infusion for three weeks in a row followed by one week 
rest. Both drugs were escalated in serial cohorts by applying the 3 + 3 + 3 model. This study 
showed that both intravenous schedules could be combined with pazopanib at a dose of 
400 mg. The MTD of 3-weekly infused docetaxel was 50 mg/m2, while for the other schedule 
it was 20 mg/m2. These doses are lower than the registered single agent dose of docetaxel. 
This is largely due to a clinically relevant pharmacokinetic interaction with pazopanib, 
substantially increasing docetaxel exposure caused by a 33% lower clearance of docetaxel 
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during concomitant administration of pazopanib. This interaction is most likely due to 
CYP3A4 and OATP1B1 inhibition.
 After determining dose levels in dose-finding studies subsequent phase II studies will 
need to be performed to get a glance on whether or not a specific combination is worthwhile 
to be evaluated in a larger randomised phase III trial. Where in the previous chapters of this 
thesis combinations of two drugs that are given simultaneously are assessed, two drugs can 
also be administrated sequentially. A sequential approach, in general, is better tolerated 
then combination therapy. Therefore as long as overall survival is the treatment goal and 
is comparable, sequential therapy is to be preferred over combination therapy, especially 
if the introduction of cytotoxic therapy with a higher rate of severe toxicity can be delayed. 
Chapter 8 describes this important issue of sequencing versus combining in a randomized 
phase II trial using one of the first targeted drugs in solid malignancies: trastuzumab, here 
in combination with docetaxel. Both drugs as single agents have been shown to exert 
anti-tumor activity in patients with metastatic breast cancer (MBC) expressing HER2, but 
both drugs are usually given in combination with each other. As this combined regimen 
associated with relevant toxicity, a sequential regimen with monotherapy trastuzumab 
followed by cytotoxic therapy upon disease progression was thought to be an attractive 
approach in terms of quality-of-life provided that the outcome of this sequential approach 
is not worse compared to the two drugs concomitantly administered. Patients with HER2-
overexpressing MBC were randomized between combination therapy trastuzumab plus 
docetaxel (H+D) and sequential therapy of single agent trastuzumab followed upon disease 
progression by docetaxel alone (H→D) as first line chemotherapy for metastatic disease. 
The primary end point was progression free survival (PFS) after completed sequential or 
combination therapy.
 The trial showed that for the H+D group and H→D group the median PFS was 9.4 
vs 9.9 months and 1-year PFS rates were 44% vs 35%, respectively. However, the overall 
response rates were 79% and 53%, respectively (p=0.016), and overall survival was 30.5 
versus 19.7 months (p=0.11) favouring the H+D group. In the H→D group, response rates 
to monotherapy trastuzumab and subsequent docetaxel were 34% and 39%, respectively, 
with a median PFS during single agent trastuzumab of 3.9 months. The incidence and 
severity of neuropathy were significantly higher in the H+D group. Retrospective analysis 
of trastuzumab treatment beyond progression, applied in 46% and 37% in the H+D group 
and the H→D group, respectively, showed a correlation with longer overall survival in 
both treatment arms (36.0 versus 18.0 months and 30.3 versus 18.6 months, respectively). 
From this trial it can be concluded that first line treatment in patients with MBC with H→D 
resulted in a similar PFS as compared to H+D, but the response rate was lower and the 
overall survival non-significantly shorter.
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FuTurE PErSPECTIVE
Given the enormous numbers of drugs in development that can in theory be applied in 
countless numbers of various schedules and regimens, it will not be possible to perform 
combination trials on all potential combinations. The process of designing a dose-finding 
study is a cornerstone in the evaluation towards a proven effective therapy. From the very 
first beginning of the development of a drug combination rigorous hypothesis-driven 
selections should be made to end up with combinations that have a high likelihood 
to eventually give benefit to the cancer patient. Hypothesis can be based on presumed 
synergy based on theoretical or preclinical data. Before launching a dose-finding trial 
educated guesses have to be made whether or not PK-interaction is expected. As presumed 
synergy is a PD-interaction (regarding efficacy) the issue of potential interaction at toxicity 
level should be tackled as well.
 Computational models, build upon preclinical and early clinical data on known inhibitory 
and inductive effects of drugs on the most relevant enzymes in drug metabolism, might 
help to identify the combinations with a relevant potential pharmacokinetic interaction. 
 Furthermore, it is worthwhile to try to increase the gain of information retrieved 
from exposing a specific patient to a combination of drugs. For example the possibilities 
of intra-patient dose escalation can be explored. Although, there is a bias, given the fact 
that before a dose can be escalated the patient has to prove that the assigned dose-level 
is well-tolerated, it gives additional information regarding upper-boundaries of dosing. A 
potential pitfall might be toxicity that only reveals after the MTD-observation window has 
been elapsed, however in current phase I models this is not covered either. Another issue 
is that cumulative toxicity might be attributed to the wrong dose-level. So primarily data 
gained after intra-patient dose-escalation should not be considered a definitive answer, but 
a first signal of tolerance. 
 Not only the information gained per enrolled patient should be increased, also the gain 
per dose-finding study must be raised. It should be mandatory that all combination dose 
finding trials combinations should have a methodology that potentially defines at least two 
MTDs. Furthermore, it should be compulsory that these trials also explore differences in 
administration sequence. Once again, an intra patient change in administration sequence 
might be attractive to be applied.
 Strategies stimulating the enrolment of patients with a proven benefit of one of the drugs 
in the combination might successfully accelerate the trial. Enriching patient populations in 
dose-finding trials may also give phase II-like signal. Intertwining phase I and II trials (as well 
as phase II and III) might give early signals of information. However, we should keep in mind 
that these kinds of signals are not a definitive answer but merely a kick start for future phase 
II and subsequent phase III trials.
Key opinion leaders in early drug development should move forward and agree on 
novel models, like the ones suggested above, that construct and implement designs 
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that adequately define MTD-envelopes for promising combinations as well as defining a 
minimum set of quality parameters for dose finding studies.
 However, despite all theoretical novel models that might identify promising 
combinations, in the end, and it also apply to combining anti-cancer drugs, the proof of the 
pudding is in the eating.
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Samenvatting
Door vooruitgang in de moleculaire biologie zijn de inzichten in sturende mechanismen van 
maligniteiten enorm toegenomen. Hierdoor zijn verschillende factoren die een essentiële 
rol in het biologische gedrag van verschillende tumoren ontdekt. Door geneesmiddelen 
in te zetten die het functioneren van een specifieke factor die cruciaal is voor de tumor-
pathogenese blokkeren, werd gehoopt dat er antikanker activiteit van deze middelen 
uitging waarbij de bijwerkingen die karakteristiek zijn voor klassieke chemotherapie 
konden worden vermeden. Een van de belangrijke processen in het ontstaan van kanker 
en daarmee een potentieel aangrijpingspunt voor therapie is angiogenese, de formatie van 
nieuwe bloedvaten. Recentelijk zijn verschillende factoren die angiogenese beïnvloeden 
geïdentificeerd zoals ligand, receptoren en signaaltransductie factoren. Het vascular-
endothelial growth factor (VEGF) -pad blijkt geactiveerd te zijn in veel tumor-types en wordt 
beschouwd als een van de belangrijkste aansturende paden voor angiogenese. Grofweg 
kan VEGF-gemedieerde angiogenese geblokkeerd worden op 2 manieren, te weten door 
monoclonale antilichamen gericht tegen VEGF of de VEGF-receptor (VEGFR) of door kinase-
remmers gericht tegen de signaal transductie van de VEGFR. Ingezet als monotherapie 
hebben meerdere kinase-remmers antikanker effect laten zien in tumor types zoals 
nierkanker en het weke delen sarcoom, echter in de meeste tumoren is de activiteit van 
geneesmiddelen die het VEGF-pad als aangrijpingspunt hebben, beperkt. In de afgelopen 
jaren is steeds duidelijker geworden dat het paradigma dat slechts één factor relevant is 
voor het maligne gedrag van een tumor slechts zelden opgaat en dat er vaak meerdere 
sturende paden parallel aan elkaar geactiveerd zijn. Als gevolg hiervan is een aanpak 
gericht op meerdere aangrijpingspunten een logischer strategie, waarbij dit bijvoorbeeld 
mogelijk is door het combineren van zogeheten doelgerichte middelen met klassieke 
chemotherapie. Omdat het VEGF-pad ook de gevoeligheid van tumorcellen voor klassieke 
chemotherapie beïnvloedt, is het combineren van remmers van het VEGF systeem met 
klassieke chemotherapie aantrekkelijk. In hoofdstuk 2 worden in een review de klinische 
data met betrekking tot deze combinatie doorgenomen en in perspectief geplaatst. Ook al 
is het in theorie een werkzame combinatie, de daadwerkelijke toepassing op het moment 
van schrijven van het review was beperkt tot een beperkt aantal indicaties, te weten 
gemetastaseerd borstkanker en gemetastaseerd dikke darm kanker. Veel inspanning is nog 
nodig om de optimale combinatie te vinden en tevens voor het vinden van factoren die 
adequaat patiënten kunnen identificeren die baat hebben bij deze therapie.
 Voordat een combinatie van antikanker geneesmiddelen daadwerkelijk als reguliere 
therapie ingezet kan worden, zijn er verschillende obstakels die genomen moeten worden 
om te komen tot een strategie met aangetoonde meerwaarde. Een studie gericht op het 
vinden van de toe te passen dosering is de eerste stap in de klinische ontwikkeling van een 
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nieuwe combinatie strategie. Hoofdstuk 3 beschrijft de verschillende uitdagingen die er 
zijn voor de studies die proberen de optimale dosering te vinden. Verschillende oplossingen 
worden aangedragen die behulpzaam kunnen zijn in de aanpak van belangrijke zaken 
bij het ontwerpen van fase I studies die meerdere antikanker middelen combineren. 
De complexiteit is aan het toenemen door de diversiteit in verschillende soorten 
geneesmiddelen, werkingsmechanismen, bijwerkingen-profielen en toedieningsschema’s. 
Met meer dan 850 geneesmiddelen in ontwikkeling is het overduidelijk dat er geen 
mogelijkheid is om elke willekeurige combinatie te testen en dat het ontwikkelen van 
combinaties gebaseerd moet zijn op basis van een specifieke hypothese (bijvoorbeeld 
op basis van een verwachte farmacokinetische en/of farmacodynamische interactie en/
of verwachte antikanker activiteit tegen een moleculair gedefinieerd subtype tumor) 
gecombineerd met een beoogd ontwikkelingstraject voor de te onderzoeken combinatie. 
Als er een rationale is om een bepaalde combinatie te gaan ontwikkelen, dan zou een 
hypothese met betrekking tot de aanvullende waarde van de gecombineerde therapie in 
vergelijking met (sequentiële) monotherapie opgesteld moeten worden. Deze hypothese, 
die gebaseerd moet zijn op geanticipeerde interacties, zou het ontwerp van de fase I 
studie moeten bepalen, alhoewel men altijd open moet staan om het onverwachte wel te 
kunnen detecteren. Vanzelfsprekend is het eindresultaat van een studie die de maximaal 
tolereerbare dosis (MTD) van een antikanker medicijn evalueert, één specifieke dosering. 
Echter, in medicatie combinatie studies zijn er verschillende factoren die het potentiële 
aantal MTDs beïnvloeden, met als voorbeeld de volgorde van medicatie toediening als 
ook de gekozen dosis-escalatie stappen (bijvoorbeeld één van de medicamenten op een 
bepaald dosis-level houden en de ander juist escaleren en vice versa). Het introduceren van 
controles in fase I studies als ook het nieuwe 3 + 3 + 3 studie-ontwerp (ten opzichte van het 
klassieke 3 + 3 ontwerp) zijn strategieën om meer grip te krijgen op combinaties met een a 
priori hoge kans op niet-tolereerbare toxiciteit. Het 3 + 3 + 3 ontwerp vermindert de kans op 
het onterecht staken van de dosis-escalatie in studies die medicijnen combineren met al een 
betrekkelijk hoge incidentie van niet-tolereerbare bijwerkingen, ook wel dosis limiterende 
toxiciteit (DLT). Dit model staat toe dat indien er in 2 van de 6 patiënten een DLT is gezien, 
het totaal aantal patiënten in dat cohort opgehoogd wordt naar 9. Belangrijk is dat we ons 
steeds blijven realiseren dat een MTD niet noodzakelijkerwijs ook de optimale biologische 
dosis hoeft te zijn. Daarmee nog eens het belang benadrukkend van het verkrijgen van de 
geschikte farmacodynamische parameters die een relatie zouden kunnen hebben met een 
potentieel antitumor effect van de combinatie.
 In hoofdstuk 4 wordt de eerste fase I studie van dit proefschrift beschreven. Het doel van 
deze studie was om de MTD te definiëren van de combinatie van sunitinib met verschillende 
infusie schema’s van ifosfamide. Sunitinib is een krachtige remmer van de VEGFR1-3, KIT, de 
bloedplaatjes groeifactor receptor -α and -β en Fms-like tyrosine kinase-3 en het is één van 
de veel gebruikte VEGFR-tyrosine kinase remmers. Sunitinib is momenteel geregistreerd 
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voor de behandeling van het gevorderd heldercellig niercelcarcinoom en imatinib-
ongevoelig geworden gastro intestinale stroma tumoren. Patiënten met een gevorderde 
solide maligniteit, een goede conditie en een goede orgaanfunctie voor wie geen standard 
therapie beschikbaar was, waren geschikt voor het onderzoek. Dagelijks oraal in te nemen 
sunitinib in escalerende dosering per patiënt-cohort werd gecombineerd met een standaard 
dosering van ifosfamide van 9 g/m2 in 3 dagen of 6 g/m2 in 5 dagen, elke 3 weken toe te 
dienen. Naast de evaluatie van veiligheid en verdraagzaamheid werd materiaal afgenomen 
voor farmacokinetiek en farmacodynamiek. Met groeifactor (G-CSF) ondersteuning, blijkt 
de MTD van sunitinib in combinatie met elk van de ifosfamide-schema’s 12.5 mg per dag te 
zijn, terwijl de dosering van sunitinib als enkelvoudige therapie 50 mg per dag is gedurende 
28 dagen gevolgd door 14 dagen rust. Neutropenie-gerelateerde bijwerkingen zijn dosis-
limiterend voor deze combinatie. Er werden geen structurele veranderingen gezien in 
VEGF of de oplosbare VEGFR2 die zouden kunnen wijzen op biologische activiteit en ook 
geen veranderingen in aantal circulerende tumorcellen. Sunitinib heeft geen invloed op 
ifosfamide farmacokinetiek. Echter ifosfamide verlaagt significant de expositie aan sunitinib 
met daarbij een toegenomen expositie aan de actieve metaboliet (SU12662) als gevolg van 
CYP3A4-inductie. Aangezien de farmacokinetische interactie niet de relatief lage dosering 
van sunitinib in de MTD kan verklaren, is het meer waarschijnlijker dat er een synergie 
in toxiciteit op cellulair niveau is. Of dit ook op gaat voor antikankeractiviteit zal verder 
uitgezocht moeten worden.
 Hoofdstuk 5 is een overzichtsartikel over de relatief nieuwe tyrosine kinase remmer 
pazopanib. Dit medicijn is ontworpen om angiogenese tegen te gaan door het blokkeren 
van de functie van VEGFR2. Pazopanib remt VEGF-geïnduceerde endotheliale proliferatie in 
vitro en angiogenese in vivo en heeft aangetoonde antitumor activiteit in het muismodel. 
Dat de concentratie die in vivo resulteerde in de maximale VEGFR2-fosforylatie overeen 
kwam met de concentratie die nodig is voor het inhiberen van tumorgroei in xenografts, 
suggereert dat pazopanib inderdaad werkt door remming van VEGFR2. In een voorgaande 
studie is de dosering pazopanib geïdentificeerd die zowel goed getolereerd werd als ook 
die in een groot deel van de mensen tot plasmaconcentraties leidt tot boven het niveau 
die in vivo nodig bleek voor maximale VEGFR2-fosforylatie in de preklinische modellen. 
Pazopanib heeft aangetoonde antitumorwerking in onder andere weke delen tumoren als 
ook niercelkanker.
 Een studie gericht ter bepaling van de MTD van de combinatie van pazopanib 
gecombineerd met twee verschillende ifosfamide schema’s is beschreven in hoofdstuk 6. 
Dit is de eerste studie die gebruikt maakte van het eerder beschreven 3 + 3 + 3 ontwerp. 
Patiënten met een gevorderde maligniteit kregen een vaste dosering ifosfamide, als een 
3 dagen continu-infuus dan wel als een 3-uur durende bolus op 3 dagen achter elkaar 
(9 g/m2 per kuur, elke 3 weken). Oraal in te nemen pazopanib werd in opvolgende cohorten 
geëscaleerd. Tijdens continue ifosfamide infusie kon de dosering pazopanib opgehoogd 
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worden tot 1000 mg/dag, terwijl tijdens bolus infusie zelfs de laagste dosering pazopanib te 
schadelijk was op basis van uiteenlopende toxiciteit. De farmacokinetiek gegevens toonde 
een ifosfamide geïnduceerde vermindering van blootstelling aan pazopanib aan. Maar 
desondanks werd na de toevoeging van ifosfamide een toename van placentale groeifactor 
en VEGF-A met een gelijktijdige daling in oplosbaar VEGFR2 gezien, passend bij pazopanib 
gemedieerde VEGFR2-remming. De aanbevolen dosering voor vervolgstudies is 800 mg 
pazopanib per dag gecombineerd met 3-dagen durende continue-infuus van ifosfamide 
van 9 g/m2 per kuur.
 In een volgende fase I studie werd pazopanib gecombineerd met twee verschillende 
schema’s van docetaxel en deze studie staat beschreven in hoofdstuk 7. Patiënten met een 
solide maligniteit kregen naast dagelijks oraal in te nemen pazopanib, docetaxel via het 
infuus toegediend, om de 3 weken dan wel wekelijks met na drie weken een week geen 
toediening. Beide medicijnen werden geëscaleerd in opeenvolgende cohorten, waarbij 
opnieuw gebruik werd gemaakt van het 3 + 3 + 3 model. Deze studie toonde aan dat beide 
infusie schema’s gecombineerd konden worden met een dosis van 400 mg pazopanib 
per dag. De MTD van het 3-wekelijks toegediende docetaxel was 50 mg/m2, terwijl voor 
het andere schema dit 20 mg/m2 was. Beide doseringen zijn lager dan de dosering die 
wordt toegepast als docetaxel als enige antikanker medicijn wordt toegediend, waarbij dit 
grotendeels verklaard wordt door een klinisch relevante toename in docetaxel blootstelling 
als gevolg van een gedaalde docetaxel klaring met circa 33% door de gelijktijdige toediening 
van pazopanib. Meest waarschijnlijk is deze interactie een gevolg van CYP3A4 en OATP1B1 
remming.
 Nadat doseringen van combinaties zijn vastgesteld, moeten fase II studies verricht 
worden die inzicht geven of er een potentiele antikanker werking van een combinatie 
uitgaat, die het waard maakt de combinatie in een grote fase III studie te evalueren. In 
de voorgaande hoofdstukken van dit proefschrift zijn steeds 2 antikanker medicijnen 
tegelijkertijd gebruikt door de patiënten, echter een combinatie kan ook gebruikt worden 
door eerst het ene middel een langere tijd toe te dienen en vervolgens over te stappen op 
een 2e middel indien daar aanleiding toe is. In het algemeen wordt sequentie therapie beter 
verdragen dan combinatie therapie. Als vervolgens de totale overleving met sequentie 
therapie even groot is als met combinatie therapie, dan heeft sequentie therapie de voorkeur, 
zeker als dit resulteert in het uitstel van de introductie van klassieke chemotherapie en er 
mee samenhangende bijwerkingen. Hoofdstuk 8 beschrijft het onderwerp van sequentie 
versus combinatie gebruik makend van een van de eerste doelgerichte antikanker 
middelen in de solide oncologie: trastuzumab; in deze studie in combinatie met docetaxel. 
Beide middelen hebben van zich zelf al bewezen antitumor effect in patiënten met een 
gemetastaseerd Her2Neu-positief mammacarcinoom, echter doorgaans worden beide 
middelen in combinatie gegeven. Aangezien dit gecombineerde schema geassocieerd is 
met relevante toxiciteit, is een sequentiële aanpak met eerst toedienen van trastuzumab 
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en dit wijzigen in docetaxel zodra er tumor progressie is opgetreden, een mogelijk zinnige 
strategie om de kwaliteit van leven te bevorderen. Chemotherapie-naïeve patiënten met 
een Her2Neu-positief gemetastaseerd mammacarcinoom werden gerandomiseerd tussen 
combinatie behandeling trastuzumab plus docetaxel (H+D) versus sequentiële behandeling 
trastuzumab en bij ziekteprogressie alleen docetaxel ( H → D), met als primaire eindpunt 
progressie vrije overleving (PFS). De studie liet zien dat de mediane PFS voor de H+D groep 
en voor de H → D groep 9.4 vs 9.9 maand was met een 1-jaar PFS kans van 44% vs 35%, 
respectievelijk. Echter de kans op respons was 79% en 53% (p=0.016) met een overleving 
van 30.5 vs 19.7 maand in het voordeel van de H+D groep. In de H → D groep was de respons 
op trastuzumab 34% met een kans van 39% op respons tijdens de vervolgbehandeling met 
docetaxel, met een mediane PFS op trastuzumab alleen van 3.9 maand. De incidentie en 
ernst van neuropathie was significant hoger in de H+D groep. Retrospectieve analyse van 
continueren van trastuzumab na progressie, toe gepast in 46% en 37% van de H+D groep en 
de H → D groep, respectievelijk, liet een correlatie zien met een langere overleving in beide 
behandelgroepen (36.0 vs 18.0 maanden en 30.3 versus 18.6 maanden, respectievelijk). 
Op basis van deze studie kan geconcludeerd worden dat 1e lijns behandeling bij patiënten 
met een gemetastaseerd Her2Neu-positief mammacarcinoom met H → D resulteerde in 
een vergelijkbare progressie vrije overleving in vergelijking met H+D, maar dat de kans op 
respons kleiner was en de overleving niet-significant korter.
Toekomst
Gegeven het enorme aantal nieuwe medicamenten in ontwikkeling die toe gepast kunnen 
worden in een vrijwel oneindig aantal aan schema’s, is het onmogelijk om combinatie 
studies te verrichten met elke potentiële combinatie. Het proces van studie ontwerp van 
de studies gericht op het vinden van de MTD is een hoeksteen in de evaluatie richting de 
implementatie van een bewezen effectieve combinatie therapie. Vanaf het allereerste begin 
van de ontwikkeling van een combinatie van antikanker middelen, moet strenge selectie 
op basis van hypotheses worden toe gepast om te komen tot combinaties die een hoge 
mate van waarschijnlijkheid hebben om uiteindelijk te kunnen bij dragen aan de tijd en/
of kwaliteit van leven van de patiënt met kanker. Hypotheses kunnen gegenereerd worden 
op basis van verwachte synergie naar aanleiding van theoretische of preklinische data. 
Voordat een dergelijke studie van start gaat moet een inschatting gemaakt worden of er 
een farmacokinetische interactie te verwachten is. Omdat verhoogde antitumor activiteit 
een farmacodynamische interactie is, moet ook op het gebied van potentiele interactie 
met betrekking tot toxiciteit geanticipeerd worden. Computermodellen, gevoed met data 
van preklinische als ook van vroeg-klinische studies met gegevens over remmende en 
inducerende effecten van de geneesmiddelen op de meest relevante enzymen betrokken 
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bij geneesmiddelmetabolisme, kunnen behulpzaam zijn bij het identificeren van de 
combinaties met relevante farmacokinetische interacties.
 Voorts is het te overwegen de opbrengst per patiënt die bloot gesteld wordt aan een 
bepaalde combinatie van geneesmiddelen te verhogen. Er zou bijvoorbeeld intra-patiënt 
dosis escalatie plaats kunnen vinden. Dit introduceert uiteraard wel een bias, omdat een 
dosis alleen opgehoogd zal kunnen worden als logischerwijs de toegewezen startdosering 
verdragen wordt, maar het geeft wel aanvullende informatie met betrekking tot de 
bovenste doseer limiet. Een valkuil kan zijn dat de toxiciteit zich juist toont nadat de vooraf 
gedefinieerde MTD-observatie termijn verstreken is, echter deze valkuil bestaat ook in de 
huidige fase I modellen. Een andere zwakte is dat cumulatieve toxiciteit toegeschreven 
wordt aan een verkeerd dosis-niveau. Dus, data gegenereerd op basis van intra-patiënt 
dosis escalatie kunnen geen definitief antwoord geven, maar hooguit een signaal over de 
tolerantie afgeven.
 Maar niet alleen de informatie per geïncludeerde patiënt moet toe nemen, ook de 
informatie per fase I studie moet worden geoptimaliseerd. Het zou verplicht moeten worden 
voor fase I combinatie studies om een strategie toe te passen die potentieel tenminste 2 
MTDs voor die combinatie definieert. Tevens zou het aan te raden zijn om veranderingen 
in toedieningsvolgorde te onderzoeken en ook hierbij kan een intra-patiënt vergelijking 
leerzaam zijn.
 Strategieën die de inclusie bevorderen van patiënten die een aangetoond voordeel 
hebben van de toepassing van een van beide middelen, kunnen de studie versnellen. Het 
verrijken van de patiëntpopulatie kan er voor zorgen dat een fase I studie tevens fase II-
achtige informatie oplevert. Het vervlechten van fase I en II studies (net als fase II en III 
studies) kan zorgen voor het eerder beschikbaar komen van relevante informatie voor 
verdere ontwikkeling van de combinatie. Het is dan wel belangrijk dat dit type signalen niet 
gezien wordt als het definitieve antwoord, maar louter dient om een snelle startpositie voor 
de vervolg fase II studie en later de fase III studie te verkrijgen.
 De leiders in het veld van vroeg klinische medicatie ontwikkeling zouden in 
gezamenlijkheid moeten besluiten tot nieuwe modellen zoals bijvoorbeeld bovenstaande 
voorstellen, die het mogelijk maken om fase I studies uit te voeren die snel en adequaat 
resulteren in het definiëren van MTD-curves voor veelbelovende combinaties als mede ook 
in het vast stellen van een minimum set aan kwaliteitseisen voor dergelijk studies.
 Het blijft echter ook bij het toepassen van een combinatie van antikanker middelen zo 
dat, hoe behulpzaam alle nieuwe theoretische modellen ook kunnen zijn in het identificeren 
van veelbelovende combinaties, uiteindelijk de “proof of the pudding is in the eating”.
149Dankwoord | 
Dankwoord
Het boekje is af. Er is weer een mijlpaal bereikt en die heb ik kunnen bereiken door de 
ondersteuning van velen. Allereerst gaat mijn dank uit naar de patiënten en hun naasten 
die hebben deel genomen aan de studies beschreven in dit proefschrift. Door de aard van 
de studies, te weten de begin fase van de ontwikkeling van medicamenteuze therapie, 
was er voor velen geen bewezen effectieve therapie meer beschikbaar. Om uiteenlopende 
redenen is door de patiënten gekozen voor deelname aan deze projecten, waarbij er een 
soms heftige behandeling ondergaan moest worden terwijl er vaak maar een beperkte 
tijd van leven was. Het was indrukwekkend om betrokken te zijn bij de (poli)-klinische 
begeleiding.
 Prof.dr. Verweij, beste Jaap, veel dank ben ik je verschuldigd voor de uitstekende 
begeleiding. Jij bent een meester geweest in het scheppen van de heldere kaders van dit 
project. Het kort en krachtig op inhoud bediscussiëren van de resultaten was zeer nuttig. 
Dat ik eerder een einde aankondigde aan mijn academische carrière dan dat jij in je hoofd 
had, heeft je er niet van weer houden om me vlak daarna te vragen samen met jou een 
JCO-editorial te schrijven . Ik heb dat beschouwd als uiting van waardering.
 Prof.dr. Sleijfer, beste Stefan, hartelijk dank voor de begeleiding waarvan jij initieel als 
co-promotor, en later als promotor, het grootste deel voor je rekening hebt genomen op 
een bijzonder aangename manier. Scherp en vliegensvlug. Verder zou je hier graag zien 
dat ik zeg dat je buitengewoon slim en geestig bent, medisch inhoudelijk sterk, en een 
krachtpatser in netwerken en een goede wijnvoorraad hebt. Veel klopt, maar de wijn was 
echt niet te drinken.
 Op deze plek wil ik ook mijn dank overbrengen aan de staf van de Interne Oncologie 
van het Erasmus MC, die naast betrokkenheid bij mijn studies me ook opgeleid hebben tot 
medisch oncoloog. In het bijzonder wil ik Maja de Jonge en Caroline Seynaeve noemen van 
wie ik enorm veel geleerd heb en ik blij ben dat ik een tijd lang “hun” assistent mocht zijn op 
de polikliniek.
 De ondersteuning door research-verpleegkundigen, nurse practitioners en data-
managers was onontbeerlijk. Velen zijn betrokken geweest bij de projecten in dit proef-
schrift. Vanwege hun enorme inzet wil ik uit deze groep met name noemen Diane van der 
Biessen, Diana de Jong, Patricia de Vos & Désirée Meier.
 Het laboratoriumteam met voor mij als belangrijke aanspreekpunten Ron Mathijssen, 
Walter Loos en Peter de Bruijn verantwoordelijk voor de het farmacokinetiek-gedeelte, ben 
ik dankbaar voor de zeer hulpvaardige inzet in de analyses en interpretaties.
 Dan wat verder van het proefschrift af, een woord van dank richting de maatschap 
Interne Specialismen Rijnmond Noord, voor het opnemen van mij in de gelederen nu 
alweer 4 jaar geleden. Dat de uitkomst van 1+1 niet altijd voorspelbaar is, blijft nog steeds 
wel een grote uitdaging. 
150 | Appendix
In het bijzonder gaat mijn dank uit naar “mijn maten in het gangetje”, Hanneke, Henk & 
Ward. Een groot deel van mijn werkplezier komt door de samenwerking met jullie, waarbij 
we elkaar goed aanvullen met kennis en kunde en elkaar op een plezierige manier scherp 
houden om zo een hoge kwaliteit van zorg te blijven nastreven. Bij mijn komst in het 
SFG heb ik plechtig moeten beloven het eerste half jaar geen onderzoeksprojecten op te 
starten. Sinds ik daar op mijn 183e SFG-dag dan uiteindelijk mee begonnen ben, heb ik me 
steeds door jullie gesteund gevoeld bij het opzetten van studies en het studie-team. Maar 
dat hardlopen, dat kan echt niet gezond zijn. 
 Niet om anderen tekort te doen, maar ik wil nog één iemand uit mijn huidige werkkring 
benoemen en dat is Janny Salomé. Toen ik na de opgelegde periode van rust van start ging 
om het medisch-oncologisch onderzoek in het Sint Franciscus Gasthuis op te gaan zetten, 
kon ik jou snel gemotiveerd krijgen om nog een laatste grote uitdaging aan te gaan. Mede 
dankzij jouw tomeloze inzet is het gelukt om het inmiddels volwaardige studieapparaat 
vorm te geven. Dat we in een aantal landelijke studies in de top 3 van includerende sites 
staan is zeker ook jouw verdienste. Ik snap goed dat patiënten je op handen dragen en net 
zoals zij je gaan missen zo is jouw pensionering een aderlating voor ons studie-team.
 Dan mijn waarde paranimfen Sander en Edward. Wat een eer dat jullie me willen 
ondersteunen op deze bijzondere dag. Beste Sander, 2B or not to be, daar is onze vriendschap 
ooit begonnen. Ik hoop dat er nog vele gedenkwaardige momenten als Salamanca en 
Schotland zullen volgen, aangevuld met “a bad falcon day”. Beste Edward, vanuit de mooie 
tijd die we in het Diak hadden met onder andere de oprichting van “de maligne week” is 
onze vriendschap ontstaan en zijn we tegelijkertijd ook congresmaatjes geworden. Het 
lijstje met aardige restaurantjes waar we inmiddels heerlijk hebben gedineerd, begint al 
een redelijk formaat te krijgen. Ik hoop dat we nog geregeld met onze gezinnen leuke 
dingen blijven doen.
Lieve Mama
Papa en jij hebben me de solide basis gegeven om te komen tot waar ik nu ben. Ook in 
de vele keuzes die gemaakt moesten worden om dokter te worden hebben jullie een 
belangrijke rol gespeeld. Dank voor de onbezorgde jeugd en het veilige nest van waaruit ik 
heb kunnen uitvliegen. Jelly, Bart en Eric: dank voor de prachtjeugd die we samen hebben 
gehad. Hopelijk in rustiger vaarwater weer meer mogelijkheid om gezamenlijk dingen te 
ondernemen met onze families.
Lieve Kasper, Julianne en Justus
Onderzoek doen, is op zoek gaan naar iets dat je nog niet weet. Eigenlijk wat jullie ook 
dagelijks doen: de wereld om je heen steeds verder ontdekken. Ik ben heel blij dat ik jullie 
daarbij mag helpen. En wat ben ik trots op wat jullie allemaal al ontdekt hebben!
Lieve, lieve, lieve Minouche. Als geen ander weet je me zowel uit, maar vooral ook in balans 
te krijgen. Wat maak jij me gelukkig. 1+1 = onmetelijk veel. Dank je!
151Curriculum vitae | 
Curriculum vitae
Aart Paul Hamberg (1971; Erle) started medical school in 1990 after graduating het Christelijk 
Lyceum in Apeldoorn. He qualified as MD at the University of Utrecht in 1999. During the 
medical curriculum he was a board member of the Medical Student Society MSFU “Sams” as 
well as member of het Jonge Heeren Gezelschap “Single Handed” .
 He started his internship in het Antoni Van Leeuwenhoek, (Amsterdam), followed by an 
internship in het Diakonessenhuis (Utrecht) with a subsequent residency in Internal Medicine 
in the same hospital (Supervisor Prof. Dr. JBL Hoekstra and later on Dr. WNM Hustinx). The 
academic phase of his residency was supervised by Prof. Dr. HAP Pols and subsequently 
Prof. Dr. JLCM van Saase (Erasmus Medical Center, Rotterdam). He was trained as medical 
oncologist at the Department of Medical Oncology in the Daniel den Hoed Cancer Center 
(currently the Erasmus MC Cancer Institute) of the Erasmus Medical Center, Rotterdam 
(Supervision Prof. Dr. G Stoter and later on Prof. Dr. J Verweij)
 During the latter training, he started on the scientific work described in this thesis 
coached by Prof. Dr. J Verweij and Prof. Dr. S Sleijfer. After he became a board certified 
medical oncologist, he joined the staff of the Department of Medical Oncology in the Daniel 
den Hoed Cancer Center. Subsequently, he moved for a short period of time to Medisch 
Centrum Haaglanden (The Hague), before finding his current position in 2010 as medical 
oncologist in het Sint Franciscus Gasthuis (Rotterdam).
 He married Minouche ten years ago and they live with their three children, Kasper, 
Julianne & Justus in Scheveningen, The Hague.

153List of publications | 
List of publications
“Serum S100 is suitable for prediction and monitoring of response to chemo-immunotherapy in 
metastatic malignant melanoma”
Hamberg P, Korse CM, Bonfrer JM, de Gast GC.
Melanoma Res 2003; 13(1): 45-49.
“Central nervous system toxicity induced by irinotecan”
Hamberg P, Donders RCJM, ten Bokkel Huinink D
J Natl Cancer Inst 2006; 98: 219.
“Non-islet-cell tumour induced hypoglycaemia in patients with advanced gastrointestinal 
stromal tumour, possibly worsened by imatinib”
Hamberg P, de Jong FA, Boonstra JG, van Doorn J, Verweij J, Sleijfer S
J Clin Oncol 2006; 18: e30-31.
“Cytotoxic therapy for the elderly with metastatic breast cancer: a review on safety, 
pharmacokinetics and efficacy”
Hamberg P, Verweij J, Seynaeve C.
Eur J Cancer 2007; 43: 1514-1528.
“Irinotecan-induced central nervous system toxicity. Report on two cases and review of the 
literature”
Hamberg P, de Jong FA, Brandsma D, Verweij J, Sleijfer S.
Acta Oncol 2008; 47(5): 974-978.
“When to start cytotoxic therapy in asymptomatic patients with hormone refractory prostate 
cancer?”
Hamberg P, Verhagen PCMS, de Wit R.
Eur J Cancer 2008; 44:1193-1197.
“Phase I drug combination trial design: Walking the tightrope”
Hamberg P, Verweij J
J Clin Oncol 2009; 27: 4441-4443.
“Chemotherapy in patients with castration-resistant prostate cancer”
Meulenbeld HJ, Hamberg P, de Wit R
Eur J Cancer 2009; 45 Suppl1: 161-171.
154 | Appendix
“It takes two to tango: combinations of conventional cytotoxics with compounds targeting the 
VEGF-VEGFR pathway in patients with solid malignancies”
Boere IA, Hamberg P, Sleijfer S
Cancer Sci 2010; 101: 7-15.
“Physiological effects of aging on treatment of older women with breast cancer. Impact on 
pharmacokinetics and pharmacodynamics of anticancer treatment”
Hamberg P, de Jonge M, Seynaeve C
In: Management of breast cancer in older women (Reed MW and Audisio RA, editors), Springer Verlag London 
Ltd, 2010; pp 75-99.
“Decreased sunitinib exposure due to concomitant administration of ifosfamide: results of a 
phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients 
with advanced solid malignancies”
Hamberg P, Steeghs N, Loos WJ, van der Biessen D, den Hollander M, Tascilar M, Verweij J, 
Gelderblom H, Sleijfer S.
Br J Cancer 2010; 102: 1699-1706.
“(Pre-)clinical pharmacology and activity of pazopanib, a novel multi-tyrosine kinase inhibitor”
Hamberg P, Verweij J, Sleijfer S. 
The Oncologist 2010; 15: 539-547.
“Dose escalation models for combination phase I trials in oncology”
Hamberg P, Ratain MJ, Lesaffre E, Verweij J.
Eur J Cancer 2010; 46: 2870-2878.
“Phase I safety, pharmacokinetics and inhibition of Src activity study of saracatinib in patients 
with solid tumors”
Baselga J, Martinelli E, Chirivella I, Hoekman K, Hurwitz HI, Jodrell DI, Hamberg P, Casado E, 
Elvin P, Swaisland A, Iacona RB, Tabernero J.
Clin Cancer Res 2010; 16: 1476-1483.
“Randomized phase II study comparing efficacy and safety of trastuzumab/docetaxel 
combination therapy versus sequential therapy trastuzumab followed by docetaxel at 
progression as first line chemotherapy in patients with HER2-overexpressing metastatic breast 
cancer: HerTax trial”
Hamberg P, Bos MMEM, Braun HJJ, Stouthard JML, van Deijk GA, Erdkamp FLG, van der 
Stelt-Frissen IN, Bontenbal M, Creemers GJM, Portielje JEA, Pruijt JFM, Loosveld OJL, Smit 
WM, Muller EW, Schmitz PIM, Seynaeve C, Klijn JGM, on behalf of the Dutch Breast Cancer 
Trialists’ Group (BOOG)
Clin Breast Cancer 2011; 11: 103-113.
155List of publications | 
“Effect of ketoconazole-mediated CYP3A4 inhibition on clinicical pharmacokinetics of 
panobinostat (LBH589), an orally active histone deacetylase inhibitor”
Hamberg P, Woo MM, Chen LC, Verweij J, Porro MG, Zhao L, Li W, van der Biessen D, Sharma 
S, Hengelage T, de Jonge M.
Cancer Chemother Pharmacol 2011; 68: 805-813. 
“Topical psoralenen plus UV-A therapy for Tyrosine kinase inhibitor induced hand foot syndrome”
Bos WE, Nijsten TE, de Jonge MJ, Hamberg AP
Arch Dermatol 2012; 148(4): 546-547. 
“Effects of CYP induction by rifampicin on tamoxifen exposure” 
Binkhorst L, van Gelder T, Loos WJ, de Jongh FE, Hamberg P, Ghobadi Moghaddam-
Helmantel IM, de Jonge E, Jager A, Seynaeve C, van Schaik RHN, Verweij J, Mathijssen RHJ.
Clin Pharmacol Ther 2012; 92(1): 62-62.
“Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in 
patients with advanced solid tumors”
De Jonge MJA, Hamberg P, Verweij J, Savage S, Suttle AB, Hodge J, Arumugham T, Pandite 
LN, Hurwitz HI.
Investigational New Drugs 2013; 31(3): 751-759.
“Sunitinib associated thrombocytopenia: not always what it seems”
Albersen A, Porcelijn L, Schilders J, Zuetenhorst H Njo T, Hamberg P
Platelets 2013; 24(7): 566-570.
“Cyanide intoxication by apricot kernel ingestion as complimentary cancer therapy”
Seghers L, Walenbergh-van Veen, Salome J, Hamberg P
Neth J Med 2013; 71(9): 496-498.
“Clinical activity and Tolerability of Enzalutamide (MDV3100) in Metastatic Castration Resistant 
Prostate Cancer Patients progressing after Docetaxel and Abiraterone Treatment”
Badrising S, van Oort IM, van den Berg HP, Los M, Hamberg P, Coenen JL, van den Eertwegh 
AJM, de Jong IJ, Kerver ED, van Tinteren H, van der Noort V, Bergman AM
Cancer 2014; 120 (7): 968-975.
“Pazopanib exposure decreases as a result of an ifosfamide-dependent drug-drug interaction: 
results of a phase I study”
Hamberg P, Boers-Sonderen M, van der Graaf WTA, de Bruijn P, Suttle AB, Eskens FALM, 
Verweij J, van Herpen CML, Sleijfer S
Br J Cancer 2014; 110 (4): 888-893.
156 | Appendix
“A randomized phase I bayesian dose escalation design for the combination of anti-cancer 
drugs”
Dejardin D, Lesaffre E, Hamberg P, Verweij J
Pharmaceutical Statistics 2014 In press.
Abstracts
“Serum S100 is suitable for prediction and monitoring of response to chemo-immunotherapy in 
metastatic malignant melanoma”
Hamberg P, Korse CM, Bonfrer JM, de Gast GC.
Melanoma Res 2001; 11, suppl 1; S134.
“Serum S100 is suitable for prediction and monitoring of response to chemo-immunotherapy in 
metastatic malignant melanoma”
Hamberg P, Bonfrer JGM, Korse CM, de Gast GC.
The Netherlands Journal of Medicine 2001; 58: A48 (93).
 
“Phase I study of AZD0530, an oral potent inhibitor of Src kinase: first demonstration of inhibition 
of Src activity in human cancers”
Tabernero J, Cervantes A, Hoekman K, Hurwitz HI, Jodrell DI, Hamberg P, Stuart M, Green TP, 
Iacona RB, Baselga J.
Proceedings Annual Meeting Am Soc Clin Oncol 2007; abstract # 3520. 
“Combined trastuzumab (HER)/docetaxel (TAX) versus sequential trastuzumab followed by 
docetaxel at progression as first line chemotherapy for Her2-positive metastatic breast cancer: 
preliminary results (multicenter BOOG-study; 2002-02)”
Hamberg P, Bontenbal M, Vernhout RM, Bos MM, Braun HJ, Erdkamp F, Stouthard JML, van 
Deijk G, Schmitz PIM, Seynaeve C, Klijn JGM.
Breast Cancer Res Treat 2007; 106 suppl 1, abstract # 1077.
“Randomized study comparing efficacy/toxicity of monotherapy trastuzumab followed by 
monotherapy docetaxel at progression and combination trastuzumab/docetaxel as first line 
chemotherapy in HER2-neu positive, metastatic breast cancer (MBC)(HERTAX study)”
Bontenbal M, Seynaeve C, Stouthard JML, Bos MM, Braun HJ, Erdkamp F, van Deijk G, Schmitz 
PIM, van der Stelt-Frissen I, Seynaeve C, Hamberg P, Klijn JGM.
Proceedings Annual Meeting Am Soc Clin Oncol 2008; abstract # 1014. 
157List of publications | 
“Phase I safety and pharmacokinetics study of sunitinib in combination with ifosfamide in 
patients with advanced solid tumors”
Hamberg P, Steeghs N, Loos WJ, van der Biessen AJ, den Hollander M, Tascilar M, Verweij J, 
Gelderblom H, Sleijfer S.
Proceedings Annual Meeting Am Soc Clin Oncol 2009; abstract # E13520.
“A drug interaction study between ketoconazole and panobinostat (LBH589), an orally active 
histone deacetylase inhibitor, in patients with advanced cancer”
de Jonge M, Woo MM, van der Biessen D, Hamberg P, Sharma S, Chen LC, Myke N, Zhao S, 
Hirawat S, Verweij J.
Proceedings Annual Meeting Am Soc Clin Oncol 2009; abstract # E2501.
“Pharmacokinetic interaction between intravenous ifosfamide and oral sunitinib”
Loos WJ, Hamberg P, Steeghs N, Kroep J, Tascilar M, Verweij J, den Hollander M, van der 
Biessen D, Gelderblom H, Sleijfer S.
Clin Pharmacol Ther 2010; 87: S78.
“Predictive and mechanistic factors of tyrosine kinase inhibitor (TKI) induced macrocytosis”
Hamberg P, Dulfer R, Oosten AW, von Lindern MM, Boere IA, van Doorn L, van Meerten E, 
Sleijfer S, Verweij J, Kruit WH
Proceedings Annual Meeting Am Soc Clin Oncol 2010; abstract 42589.
“Incidental pulmonary embolism in oncology patients; a frequent finding with unknown 
prognosis”
van der Veer M, Hamberg P, Hanselaar WEJJ
Proceedings Annual Meeting Netherlands Association of Internal Medicine 2011; abstract 134.
“Bayesian dose escalation in phase I studies of combinations of drugs with control”
Dejardin D, Hamberg P, Verweij J, Lesaffre E.
Proceedings of the 26th International Workshop on Statistical Modelling, (editors: Conesa D, Forte A, Lopers-
Quiles A, Munos F.) page 169-172. 
“Bayesian dose escalation in phase I studies of combinations of drugs with control”
Lesaffre E, Hamberg P, Verweij J, Dejardin D
Proceedings of the 2nd Conference of the Central European Network (CEN2011), 2011; abstract 239. 
158 | Appendix
“Induction of tamoxifen metabolism by rifampicin: a worrying drug-drug interaction” 
Binkhorst L, Loos WJ, de Jongh FE, Hamberg P, Ghobadi Moghaddam-Helmantel IM, Jager 
A, Seynaeve C, Verweij J, van Gelder T, Mathijssen RHJ.
San Antonio Breast Cancer Conference 2011; abstract P2-17-04.
“Thrombotic thrombocytopenic purpura-Haemolytic Uremic syndrome (TTP-HUS) following 
administration of docetaxel and zoledronic acid in a patient with castrate refractory prostate 
cancer (CRPC)”
van Oosten MJM, Schrama YC, Boeve ER, Hamberg P
10th European Congress on Internal Medicine 2011; European Journal of Internal Medicine 2011; 22: S97.
“Sunitinib associated pseudothrombocytopenia: a cause of erroneous platelet transfusion”
Albersen A, Porcelijn L, Schilders J, Hamberg P, Njo T
Ned Tijdschr Klin Chem Labgeneesk 2012; 37: 123 (Abstract nr 60).
“Sunitinib associated pseudothrombocytopenia: a cause of erroneous platelet transfusion”
Albersen A, Porcelijn L, Schilders J, Zuetenhorst H, Hamberg P, Njo T
Int J Lab Hem 2012; 34 S1: 85 abstract nr AM82.
“Sunitinib associated pseudothrombocytopenia: not always what it seems”
Schilders J, Albersen A, Porcelijn L, Zuetenhorst H, Njo T, Hamberg P 
Proceedings Annual Meeting Netherlands Association of Internal Medicine 2012; abstract 52.
“Phase I and pharmacokinetic (PK) study of pazopanib (P) in combination with two schedules of 
ifosfamide (I) in patients (pts) with advanced solid tumors (STs)”
Hamberg P, Boers-Sonderen M, Loos WJ, de Jonge MJA, van der Graaf WT, Eskens FA, Verweij 
J, van Herpen CM, Sleijfer S
Proceedings Annual Meeting Am Soc Clin Oncol 2012; abstract 2593.
“Gene expression profiles of circulating tumor cells in metastatic breast cancer patients”
Mostert B, Sieuwerts AM, Kraan J, Bolt-de Vries J, Peeters D, Dirix LY, Seynaeve CM, Jager 
A, de Jongh FE, Hamberg P, Stouthard JML, Kehrer DFS, Look MP, Smid M, Jiang Y, Wang Y, 
Gratama JW, Foekens JA, Martens JWM, Sleijfer S
Proceedings Annual Meeting Am Soc Clin Oncol 2012; abstract 10504.
159List of publications | 
“Induction of tamoxifen metabolism by rifampicin: a worrying drug-drug interaction” 
Binkhorst L, Loos WJ, de Jongh FE, Hamberg P, Ghobadi Moghaddam-Helmantel IM, Jager 
A, Seynaeve C, Verweij J, van Gelder T, Mathijssen RHJ.
Meeting of the Dutch Society of Clinical Farmacokinetics and biofarmacia 2012. 
“Evaluation of the economic burden and impact on patients’ quality of life of metastatic 
castration resistant prostate cancer: implementation of an observational study in 6 European 
countries”
Dass RN, Hamberg P, Spencer M, Wheatley Price P
Mirrors of Medicine 2012: Proceedings of the Global congress on prostate cancer 2012; page 12, abstract nr 
25.
“Quality of life of patients with metastatic castration-resistant prostate cancer:
Results from an observational study in 6 European countries”
Dass RN, Hamberg P, Spencer M, Wheatley Price P
European Society of Medical Oncology, 2012; abstract e954.
“The evaluation of healthcare resource utilization in patients with metastatic castration resistant 
prostate cancer: Results of a multinational observational study”
Dass RN, Hamberg P, Spencer M, Wheatley Price P
ISPOR 15th Annual European Congress, 2012; abstract PCN 140.
“Mapping FACT-P to EQ-5D in a large cross-sectional study of metastatic castrate-resistant 
prostate cancer patients”
Diels J, Spencer M, Hamberg P, Wheatley Price P, Dass RN
ISPOR 15th Annual European Congress, 2012; abstract PCN116.
“Phase I and pharmacokinetic (PK) study of pazopanib in combination with two schedules of 
docetaxel (D) in patients (pts) with advanced solid tumors”
Hamberg P, Mathijssen RH, de Bruijn P, v/d Biessen D, Loos WJ, Sleijfer S, Verweij J, de Jonge 
MJ. 
24th EORTC-NCI-AACR Symposium on ‘Molecular Targets and Cancer Therapeutics’, 2012; abstract 579.
“mRNA expression profiles in circulating tumor cells (CTCs) of patients with metastatic breast 
cancer (MBC) treated with aromatase inhibitors (AI)”
Reijm E, Sieuwerts AM, Bol-de Vries J, Mostert B, Onstenk W, Peeters D, Dirix LY, Seynaeve 
CM, Jager A, de Jongh FE, Hamberg P, van Galen A, Kraan J, Jansen MPHM, Gratama JW, 
Foekens JA, Martens JM, Berns EMJJ, Sleijfer S.
Proceedings Annual Meeting Am Soc Clin Oncol 2013; abstract 11045.
160 | Appendix
"Baseline bone mineral density in men with prostate cancer commencing with androgen 
deprivation therapy (ADT): Characteristics of Quantitative Ultrasound (QUS) of the heel as triage 
test to measure compared to Dual energy X-ray Absorptiometry (DXA)" 
Van Casteren-Messidoro C, Huisman AM, Bangma CH, Birnie E, van Gelder M, van de Geijn 
FE, Hamberg P
European Cancer Congress 2013 (ECCO-ESMO-ESTRO), abstract 2942. P449.
“Effect of dosing time on sunitinib pharmacokinetics”
Kloth JSL, Binkhorst L, de Bruijn P, Burger H, Hamberg P, Wiemer EAC, van der Horst GTJ, 
Mathijssen RHJ
European Cancer Congress 2013 (ECCO-ESMO-ESTRO), abstract 692. P193.
“Tamoxifen pharmacokinetics influenced by circadian rhythm?”
Binkhorst L, Kloth JSL, de Bruijn P, Burger H, van Alphen RJ, Hamberg P, van Gelder T, Wiemer 
EAC, van der Horst GTJ, Mathijssen RHJ
European Cancer Congress 2013 (ECCO-ESMO-ESTRO), abstract 2095. P268.
“Circulating tumor cells (CTCs) in castration-resistant prostate cancer patients treated with 
cabazitaxel; a Dutch Uro-Oncology Studygroup side-study”
Onstenk W, Nieuweboer AJM, Hamberg P, Creemers GJM, MMEM Bos, Gratama JW, de Wit 
R, Mathijssen AHJ, Sleijfer S.
European Cancer Congress 2013 (ECCO-ESMO-ESTRO), abstract 644. P139.
“Gene expression profiles of circulating tumor cells (CTCs) in patients with metastatic breast 
cancer (MBC) treated with aromatase inhibitors (AI)”
Reijm E, Sieuwerts AM, Bol-de Vries J, Mostert B, Onstenk W, Peeters D, Dirix LY, Seynaeve 
CM, Jager A, de Jongh FE, Hamberg P, van Galen A, Kraan J, Jansen MPHM, Gratama JW, 
Foekens JA, Martens JM, Berns EMJJ, Sleijfer S.
European Cancer Congress 2013 (ECCO-ESMO-ESTRO), abstract 698. P193.
“A retrospective study on cabazitaxel and abiraterone acetate sequential treatment (CAST) in 
docetaxel treated metastatic castrate-resistant prostate cancer patients”
Wissing M, Coenen JLLM, van den Berg P van Ort IM, de Wit R, Bergman AM, Westgeest HM, 
Hamberg P, Los M, Gelderblom H.
European Cancer Congress 2013 (ECCO-ESMO-ESTRO), abstract 2904. P411.
161List of publications | 
“Quantitative Ultrasound (QUS) of the heel as triage test compared to Dual energy X-ray 
Absorptiometry (DXA) in men with prostate cancer commencing with androgen deprivation 
therapy (ADT).”
Van Casteren-Messidoro C, Huisman AM, Birnie E, van Gelder M, van de Geijn FE, Hamberg P
Scientific meeting Dutch Rheumatology Society (NVR) 2013, abstract PV35.
”Estimating prevalence of prostate cancer clinical states using a dynamic patient progression 
model” 
Dass RN, Spencer M, Prutz C, Ahlgren G, Berruti A, Ford D, Hamberg P, Klier J, Ribal MJ, 
Schrijvers D, Wolff JM, Durand A.
ISPOR 16th Annual European Congress 2013, Value in Health 2013; 16(7): A397. 
“Citation analysis of the ‘Big Six’ journals in Internal Medicine”
Van der Veer T, Baars JE, Birnie E, Hamberg P
12th European Congress on Internal Medicine 2013; European Journal of Internal Medicine 2013; 24:e233: 
abstract nr 460.
“Gene expression profiles of primary tumors versus circulating tumor cells in metastatic breast 
cancer”
Onstenk W, Sieuwerts AM, Weekhout M, Mostert B, Reijm EA, van Deurzen CHM, Kraan J, 
Jager A, Seynaeve C, Peeters D, Hamberg P, de Jongh FE, Smid M, van Galen A, Ramirez 
Moreno R, Dirix LY, Gratama J-W, Martens JWM, Foekens JA, Sleijfer S.
Proceedings Annual Meeting Am Soc Clin Oncol 2014; abstract 11017.
“Mannose-binding lectin (MBL) serum level and genotype and risk of chemotherapy induced 
febrile neutropenia (FN) in patients with solid tumors”
Goudzwaard JA, Fiets WE, van de Geijn GJM, Njo TL, Zuetenhorst JM, Birnie E, van Schaik 
RHN, van der Putten MM, Polee MB, Hamberg P
Proceedings Annual Meeting Am Soc Clin Oncol 2014; abstract e20653.

163PhD portfolio | 
PhD Portfolio
Summary of PhD training and teaching
Year Workload
(Hours/
ECTS)
General courses 
 – FECS-AACR-ASCO Workshop: Methods in Clinical Cancer Research
 – BROK (‘Basiscursus Regelgeving Klinisch Onderzoek’)
 – Good Clinical Practise
 – Development of Business plan
2009
2013
2,0 ECTS
1,0ECTS
1,0ECTS
1,0 ECTS
Specific courses (e.g. Research school, Medical Training)
 – Medical Specialist Training 2,0 ECTS
Seminars and workshops
 – OMBO workshops Daniel den Hoed 1,5 ECTS
Presentations
 – BOOG presentation HerTax trial
 – ASCO 2010 poster presentation
 – ASCO 2012 poster presentation
2010
2012
0,5 ECTS
1,5 ECTS
1,5 ECTS
(Inter)national conferences
 – Comprehensive Cancer Network Conferences
 – European Society of Medical Oncology
 – “Oncologie dagen” NVMO
 – Annual meeting of American Society Clinical Oncology
 – Jaar symposium Continum Oncologie
 – “Oncologie dagen” NVMO
 – Post ASCO 
 – WIN-O symposium renal cell cancer
 – Annual meeting of American Society Clinical Oncology
 – “Oncologie dagen” NVMO
 – “Oncologie dagen” NVMO
 – Dutch Uro-oncology Meetings 
2010
2010
2010
2011
2011
2011
2012
2012
2013
1,0 ECTS
0,8 ECTS
0,4 ECTS
1,2 ECTS
0,4 ECTS
0,4 ECTS
0,4 ECTS
0,4 ECTS
1,2 ECTS
0,4 ECTS
0,4 ECTS
0,6 ECTS
2. Teaching
Lecturing
 – Several postgraduate lectures
 – Education AIOS/ANIOS Oncology Erasmus MC
 – Education AIOS/ANIOS Internal Medicine SFG
1,2 ECTS
2,0 ECTS
2,0 ECTS
Supervising practicals and excursions, Tutoring
 – Supervisor phase I unit
 – Mentor Specialist Oncology Nurse
1,0 ECTS
2,0 ECTS
Other
 – EORTC-NCI-AACR meeting, poster preparation
 – Research meetings Oncology SFG
0,5 ECTS
1,5 ECTS

